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Abstract 
Background 
Chronic obstructive pulmonary disease (COPD) is a multimorbidity disease associated 
with increased risk of cardiovascular events, arterial stiffness and changes in body 
composition, potentially features of premature ageing and frailty. The aim of this thesis 
was to assess the change in aortic pulse wave velocity (PWV) over two years and its 
contributing factors in COPD. In addition, this thesis also aimed to examine the 
concept of frailty in patients with COPD and its change over a two-year follow-up. 
Methods 
Aortic stiffness and frailty were assessed cross-sectionally in 500 patients with COPD 
and 150 comparators using aortic PWV and frailty index (FI). Other assessments 
included spirometry, body composition, handgrip strength, Timed Up and Go test 
(TUG) and systemic inflammatory biomarkers. After two years, 143 consecutive 
patients were reassessed to examine the changes in aortic PWV and FI. 
Results 
In the cross-sectional data, patients with COPD had greater aortic PWV than 
comparators similar in age, gender and BMI, independent of traditional risk factors. 
After two years, the patients demonstrated a significant increase in aortic stiffness, 
independent of age, lung function, blood pressure and inflammation. In addition, a 
subset of patients was identified to have an accelerated aortic stiffness by 1.6 m/s. 
At the initial visit, the patients were more frail than comparators similar in age and 
gender. After two years, the patients had an increase in the FI, independent of lung 
function and inflammation. The progression of frailty was related to loss of muscle 
mass and strength, and prolonged TUG time. 
Conclusion 
The longitudinal findings of this thesis suggest that COPD is associated with a rapid 
increase in aortic stiffness, independent of conventional risk factors.  Frailty is a 
clinical feature of COPD and its progression is dependent on loss of musculoskeletal 
mass and strength and prolonged TUG time. 
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1.1 Introduction
Chronic obstructive pulmonary disease (COPD) is a persistent low grade inflammatory 
disease with important extrapulmonary disorders and associated consequences 
(GOLD, 2014). The origin of inflammation is not fully understood, but it is likely to be 
multifactorial and contributes to the development of systemic manifestations (Barnes 
and Celli, 2009). The accepted systemic manifestations include loss of skeletal 
muscle mass and function, physical inactivity, osteoporosis, insulin resistance, 
diabetes mellitus, potential premature vascular ageing and enhanced cardiovascular 
risk and psychological problems including anxiety and depression (Barnes and Celli, 
2009, Hanania et al., 2011). 
Cardiovascular disease (CVD) is of particular importance in patients with COPD as 
several studies have shown increased cardiovascular morbidity and mortality in 
COPD independent of tobacco exposure (Hole et al., 1996, Engstrom et al., 2001). A 
number of studies have found a strong association between impaired lung function 
and CVD. A large cohort study showed reduced lung function is associated with a 3-
fold increased risk of cardiovascular morbidity and mortality (Tockman et al., 1995). 
The mechanism(s) underlying increased cardiovascular risk is unclear, but  there is 
growing evidence, which supports the theory of a chronic low grade inflammation in 
COPD could be potentially implicated the pathogenesis of the lung induced CVD, 
which will be discussed in the literature review (Sin and Man, 2005). Systemic 
inflammation is also involved in the pathogenesis of atherosclerosis and has been 
related to arterial stiffness in patients with COPD (Barr et al., 2012, Sabit et al., 2007). 
Arterial stiffness is an integrated measure of the vasculature, which reflects several 
pathological mechanisms including elastin degradation, endothelial dysfunction, 
increased oxidative stress and atherosclerosis (Maclay et al., 2012, Ives et al., 2013, 
Barr et al., 2012). 
 3 
 
In the general population, increased central arterial stiffness is a major independent 
risk factor for CVD as well as in subjects at increased cardiovascular risk 
(Vlachopoulos et al., 2010). Aortic pulse wave velocity (PWV) is the accepted gold 
standard non-invasive assessment of arterial stiffness and is predictive of adverse 
cardiovascular outcomes (Laurent et al., 2006). In COPD, Sabit et al. (2007) and 
others demonstrated increased aortic stiffness in patients with COPD, which was 
related to the severity of airflow obstruction and systemic inflammation compared with 
controls similar in age and gender. Increased aortic stiffness was associated aortic 
calcification, asymptomatic left ventricle dysfunction, myocardial injury and 
emphysema severity (Bolton et al., 2011, Patel et al., 2013, Sabit et al., 2010a, 
Maclay et al., 2009). Taken together such evidence suggests that increased central 
arterial stiffness may reflect various risk factors that have been implicated in the 
pathology of CVD and could be a mediating factor in the increased cardiovascular risk 
associated with COPD. Therefore, it will be a valuable biomarker of monitoring and 
early recognition of patients with COPD who are at greater risk for cardiovascular 
events.  
The change in arterial stiffness over time has not been evaluated in COPD so far as 
all the studies have only been cross-sectional. Thus, a longitudinal COPD population 
study is important to increase understanding of the rate at which arteries stiffen and 
generate information on possible cause(s) of arterial stiffening and the interaction of 
central arterial stiffness with other cardiovascular risk factors in COPD.  
The presence of co-morbidities in COPD may resemble the accumulation of deficits 
with biological ageing where bodily physiological systems have become frail to resist 
stressors. Such deficits may represent frailty and the presence of multiple deficits in 
COPD be a result of premature ageing. Frailty reflects the impairment in multiple 
interrelated physiological systems, which range from subcellular levels to the 
organismic level (Fulop et al., 2010). Frailty has been established in several chronic 
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diseases including CVD, and the similarities between the accumulation of deficits in 
frailty and multiple comorbidities in COPD suggests that frailty is likely to be common 
in such chronic disorders (Newman et al., 2001). However, frailty is complex and not 
well defined, and may manifest a number of clinical changes indicating abnormal 
homeostasis (Rockwood et al., 2005). Therefore, frailty may quantify the risk of 
morbidity, mortality and healthcare and may be a useful concept to decribe 
heterogeneity and multimorbidity in COPD.  
A number of epidemiological studies have shown that frailty is an independent 
predictor of adverse outcomes, disability, poor health status and death. Therefore, this 
study will examine the concept of frailty and its progression in COPD using the 
Comprehensive Geriatric Assessment short form (Rockwood et al., 2005).  
Healthcare providers frequently, focus on just a single disease and overlook other 
comorbidities, which may have debilitating effects on health status and national 
resources. The management of patients with COPD is usually focused in primary 
care, where other comorbidities and needs are neglected. The traditional approach of 
treating individual components of multimorbidity in isolation is unlikely to produce 
optimal clinical outcomes for patients. However, an assessment of frailty provides a 
simple and holistic overview of multimorbidity that may identify risk factors at an early 
stage and enhance appropriate management decisions with a better health status for 
the patient and enhanced cost effective healthcare. Thus, this study would provide a 
comprehensive assessment of patients with COPD and potentially extend risk 
assessment and early recognition of CVD, which is currently underestimated, and 
may create an opportunity for therapeutic interventions in the future or developing 
preventative strategies.  
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1.2 COPD Definition 
In the past, COPD has been defined as an irreversible disease, but now the optimistic 
accepted definition and most widely used is proposed by the Global Initiative for 
Obstructive Lung Disease (GOLD) for COPD is " a common preventable and treatable 
disease, characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response  in the airways and the 
lung to noxious particles or gases‘‘ (GOLD, 2014). 
1.3 Diagnosis and Classification 
Currently, there is no single diagnostic test for COPD; therefore, diagnosis is based 
on exposure to risk factors, such as cigarette smoke, domestic and occupational 
smoke and clinical symptoms including dyspnoea, chronic cough and sputum 
production. The diagnosis is usually confirmed by spirometry test that shows the 
presence of airflow limitation defined using the following parameters: 
Forced Expired Volume in One Second (FEV1): The volume of air expired in the 
first second of maximal expiration after maximal inspiration. This measures how 
quickly the lungs can be emptied. 
Forced Vital Capacity (FVC): The maximum volume of air that can be exhaled 
during a forced manoeuvre. 
FEV1:FVC: The ratio of FEV1 to FVC gives a clinically useful index of airflow 
obstruction. 
The diagnosis of COPD is made when FEV1:FVC is less than 0.70. Spirometry may 
be used to classify the severity of airflow obstruction based on the predicted value of 
FEV1 as proposed by GOLD (Table 1.1).  Patients with COPD may also be classified 
according to breathlessness (Table 1.2) or by the frequency of chest exacerbations 
per year (GOLD, 2014).  
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Recently, GOLD (2014) produced a new classification diagram to comprehensively 
assess patient‘s illness severity, incorporating patient‘s breathlessness or health 
status, alongside airflow obstruction and the number of exacerbations (Figure 1.1).  
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Table 1.1: Spirometric classification of patients with COPD according to (GOLD) 
 
Stage 
 
Severity of COPD 
 
FEV1:FVC 
 
FEV1 % Predicted 
I Mild <0.7 >80 
II Moderate <0.7 50-80 
III Severe <0.7 30-50 
IV Very Severe <0.7 <30 
Abbreviations: FEV1= forced expired volume in one second; FVC= forced vital capacity. 
Table 1.2: Medical Research Council (MRC) dyspnoea scale (Fletcher et al. 1959) 
Grade Description of Breathlessness 
0 I only get breathless with strenuous exercise. 
1 I get short of breath when hurrying on level ground or walking up 
a slight hill. 
2 On level ground, I walk slower than people of the same age 
because of breathlessness, or have to stop for breath when 
walking at my own pace. 
3 I stop for breath after walking about 100 yards or after a few 
minutes on level ground. 
4 I am too breathless to leave the house, or I am breathless when 
dressing. 
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mMRC 0-1                           mMRC ≥2
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Symptoms (mMRC or CAT score)   
 
 
  
Abbreviations: mMRC= Modified Medical Research Council; CAT= the COPD Assessment 
Test.    
Figure 1.1: New GOLD (2014) classification 
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1.4  Aetiology 
Smoking is the most widely accepted cause of COPD; it is suggested that 
approximately 50% of smokers will develop COPD (Lundback et al., 2003). Smoking 
results in a deterioration in the rate of FEV1, by a factor of three, and an increase in 
mortality related to the total number of cigarettes smoked. It is accepted that reducing 
smoking will gradually diminish the prevalence of COPD (Doll et al., 2004, Xu et al., 
1994). For this reason, the term ‗preventable‘ has been introduced in the definition of 
COPD in the joint ATS/ERS definition. Tobacco smoking causes changes in the 
structure and function of the lungs before clinical signs of airway obstruction become 
apparent. These changes can be detected early in the disease process by body 
plethysmography and diffusing capacity measurement with routine spirometry (Perez-
Padilla et al., 1996). Although, smoking is not the only predisposing factor, the 
contribution of environmental factors is still unknown, their effect is still minimal 
compared to those of smoking (Salvi and Barnes, 2009). In developing countries, a 
major contributor to the prevalence of COPD in non-smoking subjects is the burning of 
biomass fuel in poorly ventilated areas (Salvi and Barnes, 2009). Other risk factors for 
COPD include occupational exposure (noxious fumes, coal and silica dust, etc.), 
airway hyperresponsiveness, poor nutrition, deficiencies in anti-oxidant vitamins, 
childhood infections and socioeconomic class (Yach et al., 2004). 
Airway hyperresponsiveness is considered one of the risk factors that causes an 
accelerated decline in lung function in individuals with non-specific airway 
hyperreactivity and with a smoking history. Non-specific airway hyperreactivity is 
inversely related to FEV1 and may predict a decline in lung function (Lundback et al., 
2003). The possible role of airway hyperresponsiveness as a risk factor for the 
development and progression of COPD in subjects who smoke is still unknown 
(Silverman et al., 1998). Moreover, airways hyperreactivity may be a consequence of 
airway inflammation observed with the development of smoking-related chronic 
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bronchitis. This may contribute to airway remodelling, leading to a more fixed 
obstruction, as seen in patients with COPD. 
While around 50% of smokers develop COPD, this suggests that some individuals 
may have a genetic propensity for the development of COPD (Demeo et al., 2004, 
Lundback et al., 2003). Familial clustering of COPD is well recognised, and 
compromise in lung function in the general population has a heritability of 
approximately 50%. Several genes have been identified that may predispose to the 
development of COPD. The most extensively studied genetic abnormality is α-1 
antitrypsin  deficiency. This is thought to be accountable for less than 2% of cases of 
COPD (Tarjan et al., 1994). AAT decelerates serine proteases and is recognised to 
have a prominent selective action against neutrophil elastase. It is a member of a 
larger family of structurally unique serine protease inhibitors known as serpins, which 
have been implicated in other disease pathogenesis including angioedema, 
neurodegenerative diseases and coagulation abnormalities (Hersh et al., 2004, Stoller 
and Aboussouan, 2005). The AAT gene is located on the long arm of chromosome 
14, and more than 90 different phenotypes have been identified according to their 
electrophoretic properties, giving rise to the phase inhibitor (Pi) nomenclature 
(Sandford and Silverman, 2002). Approximately 24 variants of the AAT molecule have 
been identified and the most widely known allele variant is PiM, found in 90% of the 
people, which regulates the activities of AAT. Conversely, the most abnormal alleles 
are S mutation and Z mutation. They are associated with a reduction in the plasma 
level of AAT and function. PiZ is the most anomalous genotype, accounted for 16% of 
anti-protease activity and patients with this gene have a progressive decline in FEV1 
and unrelated to smoking effect. However, symptoms may vary between individuals, 
ranging from asymptomatic in some, to fatal in others (Hackett et al., 2003). 
Recently, genome-wide association studies (GWAS) make it possible to study people 
without prior knowledge of their disease, which significantly impacts on the 
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understanding of COPD. In GWAS pooled results, three novel genes have been 
identified to be associated with increased susceptibility of COPD. Pillai and colleagues 
(Pillai et al., 2009) found genome-wide significant associations between COPD and 
the cholinergic receptors nicotinic alpha (CHRNA3 and CHRNA5) and iron-responsive 
element binding protein 2 (IREB2) regions on chromosome 15. Although these results 
are interesting and envisage for identifying possible subjects prone to the disease, a 
disease like COPD, a multisystem disorder, could not be linked to just an abnormality 
in one gene, and further work need to be done to comprehensively understand 
pathways that link human tissue and system that are involved in COPD (Barabasi, 
2007, Barabasi et al., 2011). 
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1.5  Epidemiology of COPD 
The prevalence of COPD increases with ageing. Although this disease is preventable 
and treatable, a number of people who experience shortness of breath and limited 
physical function remain undiagnosed (Sutherland and Cherniack, 2004). This is 
attributed to the understanding and interpretation of these symptoms by these 
individuals (i.e. part of the ageing process or common symptoms of smoking). In 
addition, obtaining an estimate of the true prevalence of COPD largely relies on the 
instruments used, the population studied and the spirometric criteria for airway 
obstruction (Halbert et al., 2003). This heterogeneity has contributed to an 
underestimation of the true figure worldwide. The prevalence worldwide varies 
depending on the spirometric criteria for COPD. In an international study, Burden of 
Obstructive Lung Disease, the prevalence of COPD among the population aged over 
40 was estimated at 10±4.8% (Buist et al., 2007). However, this is likely to 
underestimate the actual figure of people having the condition, since most people do 
not seek medical help until the symptoms of COPD have become quite advanced. In 
the UK, it is estimated that the number of people who have been diagnosed with 
COPD is around one million. However, this number is likely to underestimate the true 
prevalence (Halbert et al., 2006). In 2004, COPD was a principal cause of death in 
England and Wales (National Statistic, 2004). Currently, COPD is cited as the fifth 
leading cause of death in the UK and the fourth worldwide (National Statistic, 2004, 
Pauwels et al., 2001). Surprisingly, despite advances in the management of COPD, 
the mortality from COPD continues to increase, while other leading causes of death, 
such as cancer and cardiovascular disease, continue to decline. By 2020, COPD is 
expected to be the third leading cause of death worldwide (GOLD, 2014).  
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1.6  Pathogenesis of COPD  
COPD is associated with an abnormal inflammatory response of the lungs to the 
inhalation of exogenous noxious stimuli. This involves various types of inflammatory 
cells and mediators. The inflammatory response extends to both the lungs and other 
body systems. Although smoking is considered to be the primary trigger to elicit this 
inflammatory response, only a proportion of smokers develop COPD (Gottlieb et al., 
2001). The susceptibility to developing COPD is still unknown, however, other 
contributing factors, such as genetic and immune system abnormalities may play a 
role in the development of COPD (Feghali-Bostwick et al., 2008, Houben et al., 2009). 
The inhalation of toxic particles and gases activates an abnormal inflammatory 
response that is thought to play an integral role in mucous hypersecretion, fibrosis and 
proteolysis, which in consequence leads to chronic bronchitis, emphysema and airway 
obstruction (Gottlieb et al., 2001, He et al., 2010, Lundback et al., 2003). The extent of 
airway inflammation relates to the severity of COPD and exists even many years after 
smoking cessation (Agusti and Faner, 2012, Barnes and Celli, 2009).  
Despite the existence of technology and extensive research on the pathogenesis of 
COPD, the exact mechanism of central and peripheral airway inflammation remains 
unclear. Cigarette smoke, other exogenous noxious gases and infectious organisms 
are believed to activate alveolar macrophages, bronchial epithelial cells and other 
cellular elements in the airways of genetically susceptible individuals (Marin et al., 
2012). Once activated, these cells produce a variety of chemokines and cytokines 
including macrophage chemotactic protein-1, which lead to the pulmonary 
parenchyma and vasculature abnormalities and airway remodelling (Keatings et al., 
1996). Compelling evidence suggests that the neutrophil is the key effector cell in 
COPD (Mannino et al., 2006). Increased neutrophil in the bronchial glands suggests a 
development of mucus hypersecretion and tissue damage (Rovina et al., 2009). In the 
peripheral airways, the inflammatory cell infiltrate consists predominantly of 
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mononuclear cells and macrophages (Tsoumakidou et al., 2009). The macrophages 
count increase in the airways and lung parenchyma, in parallel with the increase in 
severity of the disease (Tsuda et al., 2009).  
Another potential mechanism involved in the pathogenesis of COPD is of 
proteases/antiprotease imbalance. Patients with COPD demonstrated a high 
prevalence of matrix melloproteinase (MMP) 9 in their skin (Maclay et al., 2012). This 
suggests that there is a breakdown of lung connective tissue and parenchyma.  
A further mechanism that involves the pathogenesis of COPD is oxidative stress. 
Oxidative stress has also been attributed a central role in the pathogenesis of COPD, 
because, in addition to causing direct injury to the respiratory tract, oxidative stress 
triggers and exacerbates inflammation, protease/antiprotease imbalance and 
apoptosis (Barnes et al., 2003). 
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1.7 Comorbidity in COPD 
COPD is not just a chest disease, but it is associated with extrapulmonary 
comorbidities. Comorbidities and systemic manifestations are features of COPD and 
commonly used interchangeably. However, they are really two different entities. 
Comorbidities are chronic diseases that associated with COPD, while the systemic 
manifestations are consequences of COPD. Nevertheless, both comorbidities and 
systemic consequences worsen the patient‘s condition. 
A number of comorbidities can present in patients with COPD and recently Divo et al. 
(2012) represented them as a ―Comobidome‖ (Figure 1.2). Comorbidities share 
common pathophysiological mechanisms with COPD and this accelerates the disease 
progression and increases hospitalisation and mortality rate (Divo et al., 2012). A 
number of factors may link these comorbidities to COPD including genetic 
predisposition, physical inactivity and inflammation (Barnes and Celli, 2009). 
Therefore, COPD is currently considered as a complex heterogeneous disease with 
various pulmonary and extrapulmonary comorbidities (Vanfleteren et al., 2013). 
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 Figure 1.1: Comorbidities in COPD 
The‗‗Comorbidome‘‘ is a graphical expression of comorbidities. The area of the circle relates to 
the prevalence of the disease. The colours of the bubbles represent organ systems or disease 
clusters. Red: cardiovascular; pink: female-specific comorbidities; green: pulmonary; blue: 
psychiatric; brown and orange: others. OSA: obstructive sleep apnoea; CVA: cerebrovascular 
accident; HTN: hypertension; RHF: right heart failure; CHF: congestive heart failure; PAD: 
peripheral artery disease; CAD: coronary artery disease; BPH: benign prostatic hypertrophy; 
CRF: chronic renal failure; DJD: degenerative joint disease; GORD: gastro-oesophageal reflux 
disease. Figure was taken from Divo et al. (2012) article. 
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1.7.1 Systemic Inflammation in COPD 
There is a growing evidence to suggest that COPD is not just a pulmonary disease, 
but also a systemic disease with several extrapulmonary manifestations including 
systemic inflammation (Thomsen et al., 2012, Vanfleteren et al., 2013). Patients with 
COPD have evidence of increased systemic inflammation especially at late stage of 
the disease or during exacerbation (Gan et al., 2004). 
A meta-analysis by Gan and colleagues (2004) concluded that individuals with COPD 
had significantly higher levels of many circulating inflammatory mediators, such as C- 
reactive protein (CRP) and fibrinogen in the peripheral blood of COPD compared to 
individuals free from the disease. Persistent systemic inflammation continues even 
after smoking cessation suggesting that COPD is a systemic inflammatory disease 
(Agusti and Faner, 2012, Fabbri et al., 2012). Moreover, patients with a higher level of 
systemic inflammatory markers are more likely to have a progressive deterioration in 
their lung function and have an increased risk of hospitalisation (Valvi et al., 2012, 
Vernooy et al., 2002, Vestbo et al., 2011). 
The association between COPD and systemic inflammation is not fully understood. 
Several hypotheses have been proposed and investigated. The hypothesis that the 
inflammatory process in the airways ―spills over‖ into the systemic circulation has 
been questioned in the literature, since the sputum and plasma levels of important 
inflammatory mediators such as tumor necrosis factor alpha (TNF-α) and interleukin-6 
(IL-6) have no clear relationship (He et al., 2010, Vernooy et al., 2002). Recently, the 
understanding of the mechanism of persistent inflammation in COPD, despite 
smoking cessation has considered another avenue, which is autoimmune system 
deficiency (Nunez et al., 2011). The hypothesis of immune system dysfunction 
addresses a few missing links in the pathogenesis of COPD (Agusti et al., 2003). This 
is evident from the presence of antinuclear antibodies in patients with COPD when 
compared with healthy controls, and these molecules are not related to smoking 
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history or lung function (Agusti et al., 2003). This suggests that the immune system 
adapts with a specific response to the inflammatory process that is driven by the 
repeated proliferation of B- and T- cells, indicating that the autoimmune system is 
involved in the pathogenesis of COPD and activation of systemic inflammation (Cosio 
et al., 2009). Another possible mechanism is that patients with COPD have a common 
genetic susceptibility or epigenetic changes to both systemic and pulmonary 
inflammation (Hackett et al., 2003, Houben et al., 2009). Having excluded sources of 
systemic inflammation not originating from the lung, the increased systemic 
inflammatory markers in patients with COPD may derive from other sources, such as 
circulating leukocytes, skeletal muscle or even cardiac muscle. Systemic hypoxia 
commonly seen in patients with severe stage of COPD, may also contribute to 
systemic inflammation since it has been shown to correlate with both IL-6 and TNF-α, 
and soluble receptors are predominantly higher than in control subjects (Sabit et al., 
2010b, Takabatake et al., 1999). Moreover, local and systemic inflammations do not 
occur concurrently, and there may be more than one pathway involved at a given time 
during the progression of the disease. These mechanisms are regulated differently, 
locally and systemically, in response to inflammation and are dependent on disease 
severity (He et al., 2010). This leads to the possibility that systemic inflammation is a 
primary phenomenon, which itself leads to airway injury and inflammation. 
Finally, due to the complexity of this disease and the involvement of other 
comorbidities which play a role in aggravating systemic inflammatory markers, this 
makes judging the source of systemic inflammation difficult. Additionally, the current 
evidence lacks a well-conducted study. Most studies are cross-sectional which, due to 
their methodological limitations, cannot determine the association between 
inflammatory markers and comorbidities.  
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1.7.2 Hypertension in COPD 
Hypertension is the most common comorbidity occurring in patients with COPD and 
estimated to be between 40-60% (Mannino et al., 2008). This seems to rise with 
severity of the disease with an odds ratio of 1.4 in GOLD II and 1.6 in GOLD III & IV 
compared with control subjects.  Hypertension is a key risk factor for atherosclerosis 
and the leading cause of cardiovascular events including coronary heart disease, 
myocardial infarction and stroke and its presence in COPD increases the risk of 
hospitalisation and mortality (Mannino et al., 2008). The link between increased blood 
pressure and COPD is not fully understood, but accelerated vascular ageing through 
elastin breakdown and deposition of collagen in the arterial wall, which consequently 
leads to arterial stiffness may be a factor (Maclay et al., 2012). 
1.7.3 COPD and Type 2 Diabetes Mellitus 
Several cross-sectional studies have shown a relationship between type 2 diabetes 
and COPD even at early stage of COPD (Carrasco-Garrido et al., 2009, Cazzola et 
al., 2010). The prevalence of diabetes in patients with COPD has been shown to 
range from 1.6% to 16% (Mannino et al., 2008, Rana et al., 2004). In the UK, patients 
with COPD have double the relative risk 1.8 (95%CI: 1.1 to 2.8) of developing type 2 
diabetes compared with non-COPD subjects (Rana et al., 2004). COPD and diabetes 
mellitus share similar risk factors, including smoking. However, stopping smoking for 
more than 5 years can mitigate this risk in diabetes but not in COPD. Several studies 
have found a link between diabetes mellitus and abnormal lung function (Rana et al., 
2004, Walter et al., 2003). A prospective cohort study of diabetes found an 
association between impaired lung function, as measured by FEV1, and FVC, which is 
more pronounced in smoking subjects (Walter et al., 2003). However, in a recent large 
cohort study, diabetes mellitus and decreased FEV1 were found to be related 
regardless of smoking status, and this relationship is more remarkable in people with 
central (abdominal) obesity (Lam et al., 2010). The underlying mechanism of the 
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increased prevalence of type 2 diabetes in COPD remains uncertain. However, both 
COPD and diabetes mellitus share other common risk factors including increased 
obesity, physical inactivity, hypoxia, oxidative stress and inflammation.  
1.7.4 Osteoporosis 
Osteoporosis is common in COPD, and is characterised by loss of bone mineral 
density and microarchitectural changes resulting in an increased risk of fracture 
(Biskobing, 2002). A number of cross sectional studies have shown an increased 
prevalence of osteoporosis and osteopenia in COPD (Bolton et al.,2004, Sabit et al., 
2007). The risk of osteoporosis has been found to increase with declining lung 
function as measured by FEV1, independent of age, BMI and corticosteroid use 
(Graat-Verboom et al., 2009). Osteoporosis also contributes to vascular calcification 
and increased arterial stiffness, which may account for increased cardiovascular risk 
in patients with COPD (Bolton et al., 2011, Sabit et al., 2007). 
The association between osteoporosis and COPD is unknown, but is likely to be multi-
factorial. A number of known risk factors for osteoporosis are associated with COPD 
including increasing age, smoking, low levels of vitamin D, reduced physical activity, 
alteration in body composition and hypogonadism (Barnes and Celli, 2009). Although 
systemic steroid use in COPD has been linked to loss of bone mass and 
osteoporosis, the association with inhaled corticosteroids is still not obvious. Hip and 
vertebral fractures are common in COPD, with the latter reducing intra-thoracic 
volumes and causing compromised lung function and therefore it is prudent to put 
great efforts to diagnose and intervene at an early stage to minimise the complications 
associated with fracture. 
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1.7.5 Physical Activity 
COPD is a heterogeneous disease associated with physical inactivity ( Barnes and 
Celli, 2009). Patients with COPD frequently complain of dyspnea during everyday 
activity and subsequently tend to avoid performing normal daily tasks, which 
eventually leads a downward spiral symptom-induced inactivity (Pitta et al., 2006). 
Reduced physical activity occurs in different patients to different extents, if at all. 
Some patients have severely impaired lung function, yet have well preserved physical 
exercise capacity and maintain their functional status, whereas other patients have 
severely impaired physical and functional capacity, but have only mild or moderate 
disease airway obstruction (Spruit et al., 2010). Part of this variation may be 
attributable to the balance of the underlying aetiology (lung growth impairment in early 
life, smoking and occupational exposures), the underlying predominant 
pathophysiology (airway disease versus emphysema) alongside the patient‘s genetic 
makeup. This emphasises the idea that FEV1 is a poor predictor of exercise capacity 
and cannot reflect patient‘s physical performance (Kapella et al., 2011). 
Physical inactivity plays a key factor in causing morbidity, hospital admission related 
to exacerbation, accelerate the progression of disease severity and health related 
quality of life (Pitta et al., 2006). Patients with low physical activity level have doubled 
the risk of disability (Garcia-Aymerich et al., 2006).  
Although physical inactivity is a modifiable risk factor and reversible, its assessment in 
clinical settings is limited due to limited resources. Regular physical activity has been 
found to reduce the risk of CVD, but also reduced the hospitalisation rate and death 
related to COPD (Watz et al., 2009).  
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1.7.6 Body Composition in COPD 
1.7.6.1 Loss of Muscle Mass 
A common comorbidity of COPD, which is well established, is the loss of 
musculoskeletal mass, which manifests as weight loss (Bolton et al., 2004). This is a 
common clinical manifestation of COPD, and in particular those with emphysema 
(Engelen et al., 2000b). As the severity of the disease increases, the patient is more 
prone to loss of weight and low body mass index (BMI). Several studies have shown 
higher COPD-related mortality rates in underweight and normal weight patients 
compared to overweight and even obese patients (Landbo et al., 1999, Schols et al., 
1998). Such a relationship contrasts with the U-shaped survival curve that is seen for 
BMI in other population studies (Bray, 1987). This discrepancy is attributed to the fact 
that BMI does not reliably reflect metabolic change in muscle mass (Rutten et al., 
2013). 
Fat Free Mass (FFM) has been shown to be a reliable indicator of mortality and 
prognosis in several studies (Schols et al., 2005, Van Den Borst et al., 2011, Vestbo 
et al., 2006). Vestbo and co-authors (2006) demonstrated that patients with COPD 
have some depletion of muscle mass in the presence of a normal or high BMI, and 
this is inversely related to the severity of the lungs' condition, especially in GOLD 
stages III and IV. Interestingly, this subgroup of patients, known as having muscle 
mass loss, are also at increased risk of death, suggesting that FFM is a predictor of 
mortality independent of BMI (Vestbo et al., 2006).    
Loss of FFM adversely affects peripheral and respiratory muscle function, resulting in 
further respiratory compromise, exercise intolerance and reduced health status 
(Engelen et al., 1994, Hopkinson et al., 2007). In addition, loss of FFM increases the 
risk of exacerbation, hospital admission and mortality (Engelen et al., 2000b, Schols 
et al., 2005). Furthermore, Eisner and colleagues (2007) demonstrated that increased 
fat mass was strongly associated with activity limitation. 
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The underlying mechanism of both weight loss and loss of FFM seems to be complex 
and remains poorly understood. Nevertheless, various hypotheses have been 
proposed, which include systemic inflammation, protein metabolism imbalance and 
deregulation of muscle homeostasis. Bolton et al. (2004) demonstrated that the 
urinary pseudouridine (PSU), a marker of cellular protein breakdown, is significantly 
associated with the loss of FFM and particularly in severe and very severe COPD 
patients.  
1.7.6.2 Fat Tissue and Adipokines 
Pathophysiological mechanisms linking COPD and development of comorbidities 
remain largely unknown, but increased systemic inflammation has been suggested to 
play a role (Vanfleteren et al., 2013). Systemic inflammation has been implicated in 
the development of musculoskeletal dysfunction, atherosclerosis, osteoporosis and 
CVD (Eid et al., 2001, Bolton et al., 2004, Sin and Man, 2005). However, the source of 
inflammation is not fully elucidated. Patients with COPD often have altered body 
composition. Previously, great interest was shown in loss of FFM and the link to 
increased mortality. More recently attention has focused on an increased fat mass 
(FM), even in the presence of a normal FFM, because of it‘s relationship to systemic 
inflammation, loss of physical function and cardiovascular risk. Adipose tissue is now 
accepted as an active endocrine organ that produces a variety of pro-inflammatory 
mediators including interleukin-6, which contributes in the development of insulin 
resistance and the increased risk of diabetes mellitus and cardiovascular disease in 
COPD (Barnes and Celli, 2009, Rutten et al., 2010, Watz et a., 2008). Adipose tissue 
also produces a variety of adipokines, which influence a wide range of bodily 
physiological systems (Rutten et al., 2010). COPD is associated with intermittent or 
chronic hypoxemia, which is suggested to lead to adipose tissue hypoxemia and 
consequently adipose tissue inflammation (Agusti et al., 2010). The most studied 
adipokines in COPD are adiponectin and leptin. Adiponectin plays a crucial role in 
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inhibiting inflammation, improving vascular haemostasis and reducing cardiovascular 
morbidity and mortality (Sood, 2010, Breyer et al., 2012, Yoon et al., 2013). In 
contrast, increased levels of leptin are associated with increased local inflammation, 
oxidative stress and development of CVD (Breyer et al., 2011, Sattar et al., 2006).  
Adiponectin has a pleiotropic effect and its regulatory role is not fully understood. In a 
subset of patients from the ECLIPSE study, Breyer and colleagues (2012) have found 
that patients with COPD demonstrated raised levels of serum adiponectin and were 
inversely related to BMI compared with age, gender and BMI matched control 
subjects. They showed the levels of adiponectin were inversely related to CRP and 
independent of gender. Similar findings have been reported in a small sample size of 
Chinese COPD population and serum adiponectin increased with the airways severity 
(Chan et al., 2010). However, unlike the study by Beryer et al. (2012), Chan and 
colleagues (2010) reported a positive relationship between CRP and serum 
adiponectin. Contrary to previous studies, in a fair sample sized COPD study, Breyer 
and co-authors (2011) reported no association between plasma adiponectin and 
inflammatory biomarkers (i.e. CRP or TNFα) and the levels of serum adiponectin were 
similar between patients with COPD and age and gender matched controls.  
Recently, the longitudinal results from the Lung and Health Study showed increased 
levels of serum adiponectin were associated with lower hospitalisations and reduced 
risk of cardiovascular mortality (Yoon et al., 2012). This is supported by a number of 
clinical studies, which have found increased plasma levels of adiponectin has a 
cardioprotective role against coronary heart disease, increased risk of myocardial 
infarction and remodelling of cardiomyocytes after infarction (Sattar et al., 2006).  
Nevertheless, this study showed other debilitating effects of circulating adiponectin on 
the lung, where raised levels of plasma adiponectin were associated with bronchial 
hyperactivity, rapid decline in lung function and doubled the risk of respiratory-related 
mortality (adjusted hazard ratio, 2.09; 95% CI, 1.41-3.11). Consistent with these 
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findings, other studies have reported that increased levels of adiponectin were 
associated with the severity of airway obstruction and increase the risk of 
exacerbations (Kirdar et al., 2009, Chan et al., 2010). 
Another adipokine that has been studied in COPD populations is leptin. Patients with 
COPD showed elevated levels of plasma and pulmonary leptin, which were 
associated with increased inflammation compared with age and gender matched 
control subjects (Broekhuizen et al., 2005, Beryer et al., 2011). A conflicting result has 
also been reported in a study by Kirdar and colleagues (2009) who showed patients 
with COPD and age and gender matched controls had similar levels of serum leptin.  
Plasma leptin has been shown to be gender and BMI dependent (Breyer et al., 2011). 
Female patients demonstrated higher levels of leptin than their male counterparts 
(Breyer et al., 2011). These differences are not fully understood, but may attribute to 
differences in sex hormones and body fat distribution.  
Increased serum and pulmonary leptin and it‘s relationship with other pro-
inflammatory biomarkers suggest a potential role for leptin in the pathogenesis of 
COPD and the increased risk of CVD in this population. 
Nevertheless, the role of adipokines in COPD is still controversial due to limited 
studies and knowledge in this field. Understanding the physiological and 
pathophysiological role of adipokines in local and systemic inflammation is crucial. 
Future studies are needed to explore the role of adipokines and their involvement in 
the disease process. 
1.7.7 Chronic Kidney Disease 
Chronic kidney disease has recently received a great attention in COPD and the 
GOLD guidelines recommended that patients with COPD should be screened for 
renal disease (GOLD, 2014). The prevalence of COPD is reported to be between 6-
11% and is not associated airways severity (Patel and Hurst, 2011). The presence of 
chronic kidney disease in patients with COPD has been associated with a high 
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mortality rate compared to patients without chronic kidney disease (Incalzi et al., 
1997). Association between chronic renal disease and COPD is not fully elucidated, 
but it may be related to inability of the kidney to clear inflammatory biomarkers and 
prothrombotic molecules or presence of other comorbidities such as hypertension and 
type 2 diabetes may amplify the risk. Screening for chronic kidney disease may help 
to understand the link between COPD and CVD. 
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1.7.8 Sarcopenia in COPD 
As part of the ageing human body, body composition experiences several changes 
including loss of muscle mass and strength, which is known as sarcopenia.  Age 
related sarcopenia involves loss of muscle mass and function with a subsequent 
decrease in physical performance and health related quality of life (Cruz-Jentoft et al., 
2010). Skeletal muscles undergo several changes during the ageing process including 
a decrease in their mass and cross-sectional area, and a reduction in the size and 
number of type II fibre. However, the exact underlying pathophysiological mechanism 
of sarcopenia is poorly understood. It is likely to be a multifactorial involvement of 
neuromuscular integrity, neuroendocrine and physical inactivity (Joseph et al., 2005). 
The latter is thought to play an important role in the development of loss of 
musculoskeletal mass and strength in health and disease (Cesari et al., 2006). 
Age related sarcopenia features are frequently seen in patients with COPD at younger 
age, suggesting that COPD has the potential to accelerate these physiological 
changes (Eid et al., 2001). Results from the cross-sectional studies have shown that a 
decline in muscle mass and function is associated with reduced fat oxidation rate and 
increased insulin resistance (Bolton et al., 2004, Eid et al., 2001, Gosker et al., 2007). 
Maintaining muscle mass and function is an integrative process and extremely 
complex. However, physical activity has a strong preventative influence on muscle 
mass loss (Pitta et al., 2006, Watz et al., 2009). Longitudinal studies are needed to 
examine the changes in body composition and physical performance in the natural 
history of COPD. 
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1.8 Cardiovascular Diseases 
Cardiovascular disease (CVD) is the most common comorbidity associated with 
COPD. Over the past three decades, there has been a growing body of 
epidemiological evidence suggesting a strong association between COPD and CVD. 
The association between COPD and CVD has been previously attributed to smoking. 
However, several studies have suggested that smoking may partially contribute but 
cannot entirely explain the increased risk of cardiovascular events in COPD. Other 
contributing factors may explain why COPD induces CVD are likely to be reduced 
lung function, inflammation and increased sympathetic overactivity. 
1.8.1 Lung Function Impairment  
Reduced lung function is another factor that can link COPD to CVD. In the general 
population of Tecumseh (USA), individuals with FEV1 less than 2.0 L had a fivefold 
increase in their relative risk of cardiovascular mortality than those with FEV1 greater 
than or equal to 2.0L (Higgins and Keller, 1970). This relationship was subsequently 
confirmed in other prospective cohort studies (Hole et al., 1996, Schunemann et al., 
2000). Interestingly, in these studies, the risk of cardiovascular death continuously 
decreases as the FEV1 increases suggesting that CVD is lung function dependent.  
In a large UK cohort study; Hole and colleagues (1996) followed 7058 men and 8353 
women aged between 45 and 64 for 15 years and found that reduced FEV1 accounted 
for 26% of all deaths related to ischaemic heart disease in men and 24% in women.  
Although these early studies strongly suggested that reduced pulmonary function is 
responsible for increased cardiovascular mortality, they did not consider other 
comorbidities such as hypertension, hypercholesterolemia and diabetes and 
confounding factors such as sex, tobacco exposure and physical activity. In addition, 
these studies did not classify individuals according to their lung function.  
In the general adult population, the cause of FEV1 reduction is of two types, either 
obstructive or restrictive airway diseases. However, a reduced FEV1/FVC ratio is a 
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hallmark indicator of obstructive airway disease. Engstrom and colleagues (2001) 
prospectively followed a cohort of 621 males for over thirteen years. During this 
period, all cardiovascular events and mortality were documented. They found that 
men in the lowest quintile of FEV1/FVC were more than twice as likely to die of 
coronary events and complex ventricular arrhythmias as those in the highest quintile. 
This remained significant after controlling for important risk factors, such as tobacco 
exposure, alcohol consumption, physical activity and the presence of diabetes 
mellitus. Although the results of this study were interesting, the authors did not 
consider the role of other comorbidities or previous cardiac events on causing cardiac 
mortality. Additionally, the authors considered abnormal systolic blood pressure above 
160 mmHg, which is 20 mmHg above the accepted limit for normal systolic blood 
pressure, which increases the risk factor for cardiovascular events and mortality 
(Lewington et al., 2002). Similarly, the lung health study reported that cardiovascular 
events were responsible for 25% of deaths over 5 years in a large cohort of smokers 
with airways obstruction (Anthonisen et al., 1994). This study also showed that 
cardiovascular events were responsible for 42% of first hospitalisations and 48% of 
second hospitalisations. In general, for every 10% decrease in FEV1, cardiovascular 
mortality was increased by 28%, and non-fatal coronary events increased by 20%, 
after controlling for relevant risk factors (Sin and Man, 2005).  
In two large cohort studies (Atherosclerosis Risk in Communities (ARIC) and the 
Cardiovascular Health Study (CHS)) comprising of 20,296 patients over the age of 45 
years, the cardiovascular mortality in 5 years follow-up was nearly 6% and was airway 
severity dependent (Mannino et al., 2008). Recently, the ―TOwards a revolution in 
COPD health‖ (TORCH) study recruited 6,184 patients with moderate to very severe 
COPD and followed them up for three years. The incidence rate of cardiovascular 
events during this period of time was from 20.8% to 24.3%, and the death rate was 
14% (Calverley et al., 2010). However, considering the effects of bronchodilators, and 
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in particular ipratropium bromide and its probability to increase cardiovascular events, 
this may raise the question of whether these adverse events stem purely from COPD 
or are attributable to drug effects. In addition, the influence of other potentially 
confounding factors, such as diabetes mellitus, hyperlipidaemia, socioeconomic status 
and physical inactivity, were not controlled for in their analysis. Therefore, the 
percentage of cardiovascular deaths in patients with COPD reported in the TORCH 
study may not precisely address or link completely to the effects of COPD. 
In the Baltimore Longitudinal Study of Ageing (BLAS), individuals who had a 
progressive decline in FEV1 during a 16 years follow-up were three to five times more 
likely to die from a cardiovascular event than those who had the slowest decline in 
FEV1 (Tockman et al., 1995). Although these results were adjusted for age, baseline 
FEV1, smoking status, blood pressure, BMI and serum cholesterol, the effects of other 
confounding factors, such as gender, race, dyslipidaemia, socioeconomic status and 
physical inactivity, which are well-recognized risk factors for cardiac mortality, were 
not considered.  
Similarly, a Finnish-based population study found that symptoms of chronic bronchitis 
were associated with a 50% increase in coronary deaths, after correcting for age, 
gender, serum cholesterol, systolic blood pressure and smoking history (Jousilahti et 
al., 1996). However, the diagnosis and severity of chronic bronchitis were based only 
on subjective information obtained from a simple questionnaire, which cannot quantify 
the severity of the disease. In addition, lack of quantification of lung function may 
question the relationship.  
Moreover, the relationship between the decline in FEV1 and cardiovascular disease is 
independent of smoking, though it has also been demonstrated in lifetime non-
smokers (Hole et al., 1996; Tockman et al., 1995). In the BLSA study, the accelerated 
decline in FEV1 amongst lifetime non-smokers was associated with a five- to ten-fold 
increase in the risk of cardiac death. This further adds to the notion that the 
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confounding effects of smoking cannot describe the relationship between reduced 
FEV1 and CVD.  
COPD is also a risk for cardiovascular events. In the UK, the prevalence of angina 
and myocardial infarction (MI) in newly diagnosed patients with COPD was >1% 
within the first year after their diagnosis (Soriano et al., 2005). Recently, from a large 
database of primary care comprising over one million, 29870 patients were identified 
with COPD and were five times more likely to have CVD compared with those without 
COPD (Feary et al., 2010). In the follow-up analyses and after adjustment for 
confounding factors including age, sex and smoking status, the incidence of MI was 
three times greater in patients with COPD than non-COPD individuals. Interestingly, 
the incidence of MI was age dependent. In the ECLIPSE (Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-points) study, ― heart trouble‖ and 
MI were found to be higher in patients with COPD (26% and 9%) than smoking 
controls (11% and 9%), respectively (Hurst et al., 2010). Likewise, the prevalence of 
CVD in the ARIC and CHS studies was between (20% and 22%) in patients with 
COPD compared with 9% in non-COPD group (Barr et al., 2009, Mannino et al., 
2006). In a cross-sectional study involving 405 patients with COPD in primary care 
with unknown heart failure, 83 patients were identified to have heart failure after they 
underwent a thorough clinical investigation (Rutten et al., 2005a). Interestingly, none 
of the patients had a right side heart failure. 
1.8.2 Inflammation 
Systemic inflammation is a feature of extrapulmonary manifestations of COPD, which 
has also been implicated in the pathogenesis of CVD. Although the origin of 
inflammation is poorly understood, COPD is characterised by a persistent lung and 
systemic inflammation, which increased during exacerbation (Van Eeden et al., 2012, 
Patel et al., 2013). Most importantly, inflammation that happens at level of the small 
airways and alveoli, may play a significant role in the lung induced CVD. The 
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mechanism by which inflammation induces CVD is complex and not fully understood. 
However, it is likely that inflammation is involved in the pathogenesis of 
atherosclerosis and formation of plaque, which is thought to be the first phase of CVD 
(Lusis, 2000). Animal studies have shown that chronic exposure of the lung to small 
noxious particles are responsible for increased local and systemic inflammation, 
accelerated atherosclerotic changes in coronary arteries, endothelial dysfunction and 
increased oxidative stress compared with control animals (Suwa et al., 2002, Sun et 
al., 2005). Additionally, although the mechanism/s behind these changes was 
obscure, these studies elucidated a key point, which these abnormal responses were 
directly related to lung inflammation. Similar findings have been demonstrated in a 
double-blind, randomised, crossover study of men with stable ischaemic heart disease 
who had been exposed to either dilute diesel exhaust (induce lung inflammation) or 
filtered air during one hour training (Mills et al., 2007). Men who were exposed to 
dilute diesel exhaust demonstrated impaired fibrinolytic activity and reduced 
myocardial oxygenation compared to filtered air group. Consistent with these findings, 
Smeeth and colleagues (2004) analysed the data of five millions patients using the UK 
General Practice Research Database and showed that the risk of MI was five times 
greater within the first three days from the onset of respiratory infection compared to 
upper tract of urinary infection. The role of inflammation has been recently implicated 
in the pathogenesis of arterial stiffness, which is an independent predictor of adverse 
cardiovascular events. In patients with COPD, the role of systemic inflammation in 
increased arterial stiffness is contentious. This controversy is due to the fact that 
these studies have used non-specific systemic inflammatory biomarkers such as CRP 
and fibrinogen. This is supported by a recent study by Coulson and colleagues (2010) 
who found that increased arterial stiffness in patients with COPD was related to 
increased vascular inflammation, which was independent of systemic inflammation. 
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1.8.3 Autonomic Nervous System Dysfunction 
Recently, the role of increased sympathetic nervous system activity has been 
recognised as a responsible mechanism for increased CVD in COPD (Van Gestel et 
al., 2012). Patients with COPD have a higher resting heart rate and a decrease in 
heart rate variability (Agusti et al., 2003). An increase of 10 beats is associated with 
increased risk of cardiovascular and all cause of mortality in patients with COPD 
compared to COPD free individuals (Agusti et al., 2003). Additionally, concomitant use 
of cardioprotective drugs (statins and angiotensin-converting enzyme inhibitors) may 
increase the risk of arrhythmia, myocardial infarction and cardiovascular death 
(Mancini et al., 2006). Another possible factor worsening heart function in patients 
with COPD risk is autonomic nervous system instability, which may be mediated by 
the use of inhaled anti-cholinergic drugs. These drugs are believed to increase the 
sympathetic drive manifested by reduced heart rate variability and can increase the 
risk of myocardial infarction and coronary heart disease (Anthonisen et al., 2002). 
Physical inactivity and lower socioeconomic status have also been implicated in the 
increased cardiovascular risk in COPD (Watz et al., 2008).  
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1.9 Arterial Stiffness 
There is a growing evidence linking COPD to increased risk of cardiovascular events, 
and the nature of this relationship is proportional to the severity of the disease. 
Although both diseases share common predisposing factors, such as age and 
smoking exposure, the nature of this association still exists after controlling for these 
confounding factors (Sin and Man, 2005, Van Eeden et al., 2012). 
The interaction mechanism linking COPD to CVD is not fully defined. However, 
several proposed mechanisms have been suggested including increased arterial 
stiffness. 
1.9.1 Definition 
Arterial stiffness characterises an artery‘s capacity to expand and contract with 
cardiac pulsation and relaxation. Terms such as arterial compliance, distensibility, 
elastic modulus, augmentation index and pulse wave velocity are all specific 
measures that come under the general term of arterial stiffness (Laurent et al., 2006). 
Stiffening of the larger arteries is a normal part of the ageing process; as the arteries 
lose part of their elasticity and become stiffer (McEniery et al., 2005). This is known as 
arteriosclerosis and is commonly seen in elastic arteries, such as the aorta and 
carotid, and little change is seen in muscular arteries such as the femoral and radial 
(Lee and Oh, 2010).  
Elastin fibres play a major part in determining the mechanical strength of the vessels 
at lower pressures, while collagen fibres provide most of the strength at higher 
pressures. Therefore, elasticity of the arteries is needed to accommodate the flow of 
blood with every cardiac cycle by absorbing the energy during the systole phase and 
releasing it during the diastole phase (Blacher and Safar, 2005). 
1.9.2 Structural Component of Artery Stiffness 
The integrity of the arterial wall is dependent on two prominent components, elastin 
and collagen. The proportion between elastin and collagen is usually regulated by a 
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slow dynamic process of formation and degradation. Disturbance of this balance 
typically results in a reduction of elastin production and accumulation of the collagen 
components in the arterial wall (Zieman et al., 2005). Overproduction of collagen is 
mainly triggered by an inflammation milieu, but also stimulated by high blood 
pressure. Ageing of the arterial system is manifested by a two- to threefold increase in 
intima-media thickness during a normal lifetime (Jani and Rajkumar, 2006). 
Histological examination of the intima of stiffened arteries shows abnormal and 
disorganised endothelial cells, overproduction of collagen content, diminished elastin 
molecules, infiltration of smooth muscle, inflammatory activity and increased matrix 
metalloproteinases (MMP) (Lakatta, 2003).  
The tensile strength of the arterial wall is mainly achieved by cross-linked collagen 
molecules. However, collagen is particularly susceptible to non-enzymatic glycation 
and cross-linking due to its slow turnover rate (Zieman et al., 2005). This leads to 
more misalignment and a dysfunctional collagen fibre structure with less elasticity. 
Elastin fibre plays a key role in providing arterial wall elasticity. However, activated 
metalloproteases stimulate production of frayed elastin fibre, and disruption of the 
cross-links predisposes protein mineralization and an increase in arterial stiffness 
(Zieman et al., 2005). 
Advanced glycation end products (AGEs) play an important role in arterial stiffening 
by forming irreversible cross-links in collagen (Konova et al., 2004). AGEs also 
increase arterial stiffness via impairment of the endothelial function by reducing nitric 
oxide bioavailability and the formation of free oxygen (Zieman et al., 2005). 
Furthermore, AGEs stimulate inflammatory responses via activation of 
metalloproteinases, which are known to promote endothelial dysfunction, increase 
vascular smooth muscle cell (VSMC) tone and accelerate the progression of 
atherosclerosis (Wendt et al., 2002). 
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1.9.3 Assessment of Large Artery Stiffness 
For many decades, the concept of arterial stiffness was only associated with ageing 
and the clinical significance of its waveform and its importance in clinical examination 
of patients was not appreciated until recently. 
Arterial stiffness can be quantified non-invasively using several methods. One of 
these methods is a regional measurement between two arteries, commonly between 
the carotid-femoral arteries.  
1.9.3.1 Pulse Pressure  
Pulse pressure is the difference between systolic and diastolic blood pressure. Pulse 
pressure is a surrogate measure for arterial stiffness, as it is mainly determined by 
cardiac output, aortic and large artery stiffness, and pulse wave reflection (Dart and 
Kingwell, 2001). 
Both systolic and diastolic blood pressures tend to increase with age. However, 
diastolic blood pressure reaches its peak around age 60 and thereafter starts to 
decline, which consequently results in rapidly increasing pulse pressure (Roman, 
2012). 
Pulse pressure is a simple and reproducible marker of arterial stiffness, and it can be 
easily assessed with a standard blood pressure machine (Benetos et al., 1998). 
Despite the simplicity and availability of pulse pressure measurement, unfortunately, it 
can be an inaccurate measure of arterial stiffness as it does not take changes in 
volume into consideration. Moreover, peripheral pulse pressure is taken from the 
brachial artery, which may not reflect a true reading of central pulse pressure as it has 
been noted there is a variation of up to 20 mmHg (Wilkinson and Cockcroft, 2000). 
Pulse pressure has been shown to predict cardiovascular risk in a number of 
populations (Benetos et al., 1998, Cockcroft et al., 2005). Additionally, pulse pressure 
has been shown to be a better predictor of cardiovascular mortality and morbidity than 
mean arterial pressure (Millar et al., 1999). In contrast, a large study on African-
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Americans found no association between pulse pressure and mortality (Pastor-
Barriuso et al., 2003). This suggests that pulse pressure may not be a good measure 
for arterial stiffness. 
1.9.3.2 Pulse wave velocity 
Pulse wave velocity (PWV) is defined as a propagation of the pressure wave within 
the arterial system with every cardiac contraction. PWV is mainly determined by 
arterial wall elasticity and the size of its lumen (Laurent et al., 2006). The regional 
measurement of arterial stiffness using applanation tonometry involves taking 
recordings from two different sites and matching them with simultaneous recording of 
the R wave from a recorded simple electrocardiography (ECG). As the aorta is the 
first artery subjected to left ventricle ejection contraction, it is more likely to be prone 
to stiffness than other arteries. Carotid-femoral pulse wave velocity (cf-PWV), also 
called aortic PWV, is considered as the gold standard for aortic stiffness 
measurement (Laurent et al., 2006). 
The assessment of pulse wave velocity using cf-PWV is a relatively simple technique 
and has been widely used in several populations. By recording ECG gated waveforms 
in the carotid and femoral arteries, wave transit time can be calculated using system 
software. Aortic PWV is then calculated by dividing the distance between the two 
recording sites by the wave transit time (Figure 1.3). A higher aortic PWV suggests 
increased large artery stiffness.  
Pulse wave velocity can be determined throughout the vasculature, but the aorta 
is the main vessel of interest, for two reasons: 
1) Aortic pressure reflects the left ventricular systolic load, relevant to cardiac risk; 
2) The aorta plays a major role in buffering pulse pressure and wave volume. 
When blood is ejected into the aorta, a pressure wave is generated and travels 
throughout the arterial tree. Young healthy arteries are elastic and absorb the 
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pulse pressure from the heart efficiently. With age and pathology, the arteries 
stiffen, which causes the pulse waves to increase in pressure and velocity (Lee 
and Oh, 2010). When a pulse wave meets greater resistance at arterioles, a 
reflected wave is created. In healthy arteries, this reflected wave returns to the 
heart during the diastolic phase, which augments myocardial oxygenation and 
coronary perfusion. If the arteries stiffen, the reflected wave travels at higher 
velocity, returning to the heart late in the systolic phase. The result is an 
increase in systolic blood pressure (SBP), left ventricular afterload and pulse 
pressure (Laurent et al., 2006). There is also a reduction in diastolic pressure, 
which results in reduced coronary perfusion, with increased risk of myocardial 
ischaemia and subsequent myocardial fibrosis and loss of ventricular diastolic 
distensibility (Laurent et al., 2006). 
1.9.3.3 Augmentation Index 
Augmentation index (AIx) is another measure of arterial stiffness obtained from the 
aortic waveform and defined as the difference between the systolic peak and the 
second reflected wave (P2 − P1) expressed as a ratio of the pulse pressure 
(Laurent et al., 2006). Increased AIx results from an early arrival of the reflected 
pulse wave from the periphery and augment systolic blood pressure. Although AIx 
has been used as a measure of arterial stiffness, it is influenced by a number of 
variables including gender and heart rate (Gatzka et al., 2001, Wilkinson et al. 
2000). In the Anglo-Cardiff-Cambridge Collaborative Trial (ACCT) study, McEniery 
and colleagues (2005) found that AIx is not a good measure for arterial stiffness for 
individuals over 50 years of age. 
Other assessment methods include ultrasound scans and magnetic resonance 
imaging (MRI). Ultrasound can be used to measure changes in arterial diameter 
during systole and diastole to determine arterial distensibility and compliance 
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(Laurent et al., 2006). However, ultrasound has a number of limitations; it can only 
be used on larger, easily accessible arteries and requires an operator skilled in 
imaging vessel walls (Laurent et al. 2006). Arterial distensibility and compliance can 
also be determined by MRI. However, its use is limited, given the expense and 
expertise required to assess arterial stiffness (Laurent et al. 2006). 
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Figure 1.2: Measurement of carotid-femoral pulse wave velocity with a foot-to-foot 
method. 
ΔL: distance between both measurement sites, Δt: transit time 
Figure taken from Laurent et al. (2006) 
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1.9.4 Factors Affecting Artery Stiffness  
1.9.4.1 Age 
Inevitably, large artery stiffness occurs as part of the normal human ageing process 
and is consequently considered the most influential determinant of arterial stiffness 
(Lee and Oh, 2010). Several studies have used different techniques and found a 
positive association between arterial stiffness and age (McEniery et al., 2005, Mitchell 
et al., 2004). However, only large central arteries experience structural and 
mechanical changes and progressively stiffen with age, whereas the elastic properties 
of the peripheral arteries exhibit few changes with age (Cecelja and Chowienczyk, 
2009). Data from a large cohort of healthy individuals in the ACCT study showed that 
aortic PWV experience changes after age of 50 (McEniery et al., 2005).  
Increased aortic stiffness was thought to be as part of normal ageing process that 
associated with structural and functional changes in the arterial wall (Lee and Oh, 
2010). However, this concept has changed, as it cannot explain why some elderly 
people have an aortic PWV like someone in his twenties. This largely attributed to the 
fact that normal or healthy ageing mechanism has not fully understood. Therefore, 
further mechanism may be involved and alter the properties of the arterial wall 
(Maclay and MacNee, 2013). 
Disproportion between elastin and collagen proportion within the media layer of the 
arterial wall may contribute to large artery stiffness. As age increases, there is a 
higher collagen to elastin ratio, and this increases the risk of large artery stiffness (Lee 
and Oh, 2010).  
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1.9.4.2 Gender 
Several cross-sectional studies have examined the gender related difference for PWV 
using different methods (Borlaug and Paulus, 2011, Duprez et al., 2009, Rossi et al., 
2011b). 
In the Cardiovascular Abnormalities and Brain Lesions (CABL) cohort study, women 
showed higher arterial stiffness than men as measured by augmentation index, 
independent of body size and heart rate (Russo et al., 2012). However, this 
relationship disappeared after adjustment for other cardiac risk factors. Likewise, the 
Multi-Ethnic Study of Atherosclerosis (MESA) study, women demonstrated lower large 
and small arteries elasticity than men, which was dependent on height and body size 
(Duprez et al., 2009). In contrast, in the BLSA cohort study, men showed more 
pronounced aortic stiffness than women independent of the effect of traditional risk 
factors (Alghatrif et al., 2013). This controversy is attributed to methodological 
variation among these studies of arterial stiffness measurements. In addition, none of 
these studies used the gold standard measure of arterial stiffness, which is aortic 
PWV.   
The gender related difference for increased arterial stiffness in women may be the 
result of variation in sex hormones, obesity, low grade inflammation and endothelial 
dysfunction. Increased arterial stiffness and wave reflections, and changes in central 
haemodynamics increase left ventricle afterload, enhance the left ventricular 
remodelling process and also decrease the coronary blood flow, resulting in 
subendocardial ischemia and myocardial injury (Patel et al., 2013, Roman et al., 2007, 
Sabit et al., 2010a). 
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1.9.4.3 Body Composition 
A number of studies have found an association between global and regional index of 
obesity and aortic stiffness (Mackey et al., 2002, Recio-Rodriguez et al., 2012, Sutton-
Tyrrell et al., 2001). Excessive body fat generates abundant proinflammatory 
biomarkers and adipokines that directly or indirectly are involved in arterial 
pathogenesis and subsequently increase the risk of cardiovascular events (Sutton-
Tyrrell et al., 2001, Recio-Rodriguez et al., 2012). 
Obesity affects the level of testosterone in COPD, which is an independent risk factor 
for CVD (Atlantis et al., 2013, Herring et al., 2013). Testosterone deficiency is 
associated with increased aortic stiffness and enhances the risk of cardiovascular 
morbidity and mortality (Araujo et al., 2011, Dockery et al., 2003). Patients with COPD 
have evidence of both testosterone deficiency and increased aortic stiffness (Laghi, 
2005, Sabit et al., 2007). 
1.9.4.4 Hypertension 
High blood pressure markedly accelerates ageing through elastin breakdown and 
deposition of collagen in the arterial wall, which consequently leads to arterial stiffness 
(Roman et al., 2007). In a large cohort study, Benetos et al. (2002) found that in 
poorly controlled hypertensive patients, age-induced pulse wave velocity acceleration 
was three times greater than in normotensive and well-controlled hypertensive 
patients. A recent study suggests that increased aortic stiffness in COPD may be 
associated with loss of elastic connective tissue (Maclay et al., 2012). Another 
mechanism that may link hypertension to arterial stiffness is low birth weight, which is 
a determinant of hypertension (Te Velde et al., 2004). This could be as a result of 
impaired elastin synthesis in the aorta during intra-uterine growth retardation, which is 
associated with the development of hypertension (Martyn and Greenwald, 1997). 
Interestingly, recent results demonstrate that aortic stiffness is an independent 
predictor of the progression to hypertension in normotensive subjects without clinical 
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signs of CVD (Kaess et al., 2012, Najjar et al., 2008). This suggests that 
measurement of aortic stiffness is a useful measure to predict and identify individuals 
at high risk of developing hypertension. 
1.9.4.5 Diabetes and Metabolic Syndrome 
COPD and diabetes mellitus share a common risk factor for increased CVD, which is 
increased arterial stiffness. The relationship between arterial stiffness, diabetes and 
metabolic syndrome has been established in several studies. In patients with 
metabolic syndrome, increased arterial stiffness is proportional to the degree of 
metabolic derangement (Teoh et al., 2013). Increased arterial stiffness is also shown 
in populations with impaired glucose tolerance and increased insulin resistance 
(Henry et al., 2003, Sengstock et al., 2005). Arterial stiffening, therefore, may precede 
the development of type 2 diabetes, just from the early stages of an insulin-resistant 
state (Sliem and Nasr, 2010). Therefore, increased insulin resistance may contribute 
to increased arterial stiffness in COPD. 
1.9.4.6 Hypercholesterolaemia 
A high level of cholesterol is a major risk factor for CVD. An elevated cholesterol level 
can induce premature arterial stiffness via the deposition of cholesterol in the intimal 
layer of the artery, which increases the risk of coronary heart disease (Wilkinson and 
Cockcroft, 2007). Several studies have evaluated the relationship between 
hypercholestolaemia and arterial stiffness. However, the results of these studies are 
conflicting. Lehmann et al. (1992) found increased aortic distensibility, as measured 
by aortic PWV, in young patients with familial hypercholesterolemia (FH), but in 
contrast; they reported decreases in adults with the same disorder. In a middle-aged 
population with metabolic syndrome, there is a direct relationship between aortic PWV 
and triglyceride and a negative link to high density lipoprotein (HDL), even after 
adjustments for age and sex (Czernichow et al., 2005). 
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1.9.4.7 Vascular Dysfunction 
Aortic stiffness is elevated in patients with COPD in comparison to matched age and 
sex controls (Sabit et al., 2007). Structural components of the arterial wall including 
extracellular matrix, vascular smooth muscle and endothelium are the main 
determinant of arterial stiffness (Zieman et al., 2005). Flow mediated dilatation (FMD) 
is an accepted measure of endothelial function and patients with COPD showed to 
have abnormal endothelial function (Barr et al., 2007, Eickhoff et al., 2008, Ives et al., 
2013). Recently, patients with COPD showed impaired vascular function, measured 
by carotid-radial PWV and FMD, compared with age matched subject controls (Ives et 
al., 2013). Interestingly, this study showed that vascular dysfunction could be reversed 
by an ingestion of antioxidant cocktail, which has an effect on altered redox balance 
and nitric oxide bioavailability. In addition, nitric oxide is an important antiatherogenic 
molecule, which can, therefore, affect large artery stiffness via its augmentation of 
atherosclerosis (Bäck, 2008). Furthermore, damage to small vessels is another risk 
factor for increased CVD (Anavekar et al., 2004, Gibson et al., 2003). Casanova et al 
(2010) measured urinary albumin to creatinine ratio and showed that patients with 
COPD without overt CVD had renal microvascular damage compared with smoking 
controls, independent of traditional cardiovascular risk factors. This finding was 
extended further by John et al. (2013) and found that aortic stiffness was related to 
urinary albumin/creatinine ratio, which may suggest the effect of aortic stiffness on 
vital organs such as the kidney. 
1.9.4.8 Connective Tissue Degradation 
Arterial function is not just limited to the endothelium, but the extracellular matrix is 
also involved in large artery compliance. An increase in vascular smooth muscle tone 
further increases synthesis of structural proteins, including collagen resulting in 
increased arterial stiffness (Maclay et al., 2009). Patients with COPD experience intra 
and extra pulmonary elastin breakdown that contribute to arterial stiffness (Black et 
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al., 2008, Maclay et al., 2012). In a study by Patel and colleagues (2006) showed that 
patients with COPD had more facial skin wrinkles, which is an indicator of elastin 
degradation, compared with non-COPD smoking subjects. Skin elastin degradation 
has been found in patients with COPD, which related aortic stiffness (Maclay et al., 
2012). In addition, the authors also found an increased MMP-9 expression in the skin 
of the patients, which was associated with aortic stiffness. A similar relationship has 
also been reported in a healthy population (Yasmin et al., 2006). 
1.9.4.9 Systemic Inflammation 
A number of studies have shown a relationship between low-grade chronic 
inflammation and aortic stiffness in COPD. However, the exact mechanism underlying 
the association between systemic inflammation and arterial stiffness is still unclear. 
Systemic inflammation is strongly implicated in the pathogenesis of atherosclerosis, 
which may increase large artery stiffness (Hansson, 2005, Herrington et al., 2004). In 
addition, systemic inflammation has been associated with endothelial dysfunction, 
which may cause arterial stiffening through reduced nitric oxide bioavailability and 
increased activity of endothelin-1 (Eickhoff et al., 2008, Ives et al., 2013). Recently, 
aortic wall calcification, elastin degradation and production of MMP-9 have been found 
in patients with COPD, which are associated with arterial stiffness (Bolton et al., 2011, 
Maclay et al., 2012). Vascular inflammation is lately recognised to play a crucial role in 
increased aortic stiffness and developing CVD (Coulson et al., 2010, Figueroa et al., 
2013). 
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1.9.4.10 Smoking 
Smoking is a common and important risk factor for both CVD and COPD. A number of 
studies have investigated the effects of smoking on arterial stiffness; however, the 
results of these studies are controversial. Mahmud and Feely (2003) demonstrated 
that smoking a single cigarette produces a transient effect in aortic PWV in both 
smokers and non-smokers. A similar finding between smoking and arterial stiffness 
was reported by other researchers (Jatoi et al., 2007, Vlachopoulos et al., 2004). 
These results were supported by an improvement in PWV after stopping smoking, and 
this relationship was proportional to the duration of smoking cessation. However, this 
is not the case in COPD, as arterial stiffness still exists even after smoking cessation 
(Sabit et al., 2007). Smoking may increase arterial stiffness in some individuals, but 
not in others, which may suggest the involvement of a genetic component (Doonan et 
al., 2010). 
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1.10 Arterial Stiffness and COPD 
Increased arterial stiffness is associated with a higher risk of cardiovascular events, 
due to the physiological consequences of stiffened arteries (Mitchell et al., 2010). A 
number of consequences of arterial stiffness are associated with increased 
cardiovascular risk in COPD, including increased inflammation, left ventricular 
dysfunction, endothelial dysfunction and connective tissue degradation (Coulson et 
al., 2010, Ives et al., 2013, Maclay et al., 2012, Sabit et al., 2010a). Several 
longitudinal epidemiological studies have found that aortic PWV is an independent 
predictor of cardiovascular morbidity and mortality in a variety of different diseased 
and healthy populations. These include patients with essential hypertension, type II 
diabetes, renal failure, elderly subjects and the general population (Blacher et al., 
1999, Boutouyrie et al., 2002, Cruickshank et al., 2002, Sutton-Tyrrell et al., 2005, 
Willum-Hansen et al., 2006). Moreover, in a cross-sectional study of 194 middle-aged 
males free of coronary heart disease, Zureik and colleagues (2001) reported an 
inverse relationship between FEV1, FVC and their ratio, and aortic PWV. Although this 
study did find an association between airway obstruction and arterial stiffness, these 
results cannot be extrapolated to patients with COPD. In addition, the severity of 
airway obstruction in this population was not classified, and it is unclear what 
proportion of their participants had restrictive or normal lung function. Additionally, this 
study was limited to men; thus its results cannot be generalised to women.  
The first well designed study, which highlighted the relationship between arterial 
stiffness and COPD was by Sabit and co-authors (2007) in 74 patients with COPD 
and 42 controls similar in age and gender proportion. In this cross-sectional study, the 
authors found that patients with COPD, when compared with healthy controls, had an 
increase in arterial stiffness as measured by aortic PWV. The degree of arterial 
stiffness was proportional to the severity of airway obstruction even after adjustment 
for other confounding factors, such as diabetes, smoking, physical inactivity, high 
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cholesterol and blood pressure. Additionally, patients with COPD and osteoporosis 
showed greater aortic PWV than those without osteoporosis. Interestingly, this 
relationship remained significant even after controlling for other confounding factors, 
including age, sex, level of physical activity, smoking history, lung function and mean 
arterial pressure. However, there was no relationship between inflammatory 
biomarkers and osteoporosis. Nevertheless, IL-6 was found to be related to aortic 
PWV and was severity dependent. Although this study reported a significant 
relationship between arterial stiffness and COPD, the cross-sectional nature of the 
study cannot infer a causal relationship. Documentation of physical activity using a 
questionnaire may be subjected to recall bias, which may underestimate the effect of 
physical activity on arterial stiffness measurement. Additionally, the contribution of 
other confounding factors, including controls and patients with high blood pressure, 
who are on antihypertensive medications, which has an impact on arterial stiffness; 
may have affected the readings of aortic PWV. 
Another study by McAllister et al. (2007) examined the relationship between 
emphysema and carotid-radial PWV in 157 patients. The authors found that PWV was 
high in patients with severe and very severe airway obstruction, and men 
demonstrated to have higher significant readings than women. The carotid-radial 
PWV did not differ between patients with ischemic heart disease more than those 
without ischemic heart disease. In this study, there was no association found between 
circulating CRP and carotid-radial PWV. A limitation of this study was the use of 
carotid-radial PWV as a measure of aortic stiffness, which is less robust than carotid-
femoral PWV. The radial artery experiences less changes in the functional and 
structural features and therefore does not mirror what exactly happens in the aorta 
(Laurent et al., 2006). Given that, unlike the aortic artery, the radial artery is more 
muscular and not subjected to atherosclerotic changes and pressure variability of the 
cardiac cycle. In addition, the radial artery has less elastin and is barely affected by 
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the ageing process and other cardiovascular risk factors such as hypertension, this 
measure may not be suitable to predict cardiovascular risk. Furthermore, this study 
lacked controls and included patients with cardiac disease, which has an adverse 
effect on the arterial system. Given the fact that both COPD and heart disease share 
common risk factors, this makes it difficult to differentiate the source of origin.  
In another large cross-sectional study from the same research group, the association 
between COPD and arterial stiffness was also confirmed. Mills and colleagues (2008) 
measured arterial stiffness in 102 patients and 103 controls similar in age and sex 
using the AIx. In this study, the authors found that patients with COPD had increased 
arterial stiffness, compared with the controls. This difference was maintained between 
patients with COPD, free from CVD, and control subjects. In addition, the authors 
found that arterial stiffness was associated with inflammatory biomarkers (i.e. CRP) in 
patients but not in controls. Although this study found a significant relationship 
between arterial stiffness as measured by AIx and COPD, Mills and co-authors (2008) 
failed to adjust for sex and heart rate in their analysis, which have a great influence on 
AIx (Gatzka et al., 2001, Wilkinson et al., 2000). In addition, lung function was not 
measured in the control subjects, which may raise the possibility of undiagnosed 
airway obstruction among current or past smokers. Cigarette smoking plays a crucial 
role in aggravating the abnormal inflammatory response inside the lungs and is a 
central part in the pathogenesis of COPD. Furthermore, although AIx increased in the 
patients compared with the controls, a number of factors may limit the ability of AIx to 
predict arterial stiffness and cardiovascular events in a COPD population. Firstly, 
unlike aortic PWV, which is the gold standard measure of arterial stiffness, AIx is a 
less robust and indirect measure of stiffness and is dependent on multiple 
components of the arterial pressure wave (Laurent et al., 2006). The AIx also exhibits 
different age-related changes to aortic PWV. This was highlighted in the Anglo-
Cardiff-Cambridge Collaborative trial, which found that age-related changes in AIx and 
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aortic PWV follow different patterns (McEniery et al., 2005). Whereas changes in AIx 
were found to be more prominent in younger individuals (<50 years), aortic PWV 
changes were found to be more marked in older individuals (>50 years).  
Moreover, in a prospective cross-sectional study, Janner et al. (2012) studied arterial 
stiffness in 494 (246 males) patients with COPD. The authors found a significant 
difference between patients with COPD and non-COPD controls in both sexes. 
However, AIx was independent of the degree of airway obstruction. Nevertheless, 
when the authors limited the analysis to patients less than 60 years old and adjusted 
the analysis for confounding factors that contribute to CVD (i.e. age, blood pressure, 
heart rate, smoking history, physical activity, CRP and education), they found no 
association between AIx and COPD. Therefore, Janner and co-workers (2012) 
concluded that COPD is not an independent factor of arterial stiffness after controlling 
for confounding factors. In the aforementioned study, the authors based the diagnosis 
of COPD on just pre-bronchodilator spirometry results, which is not the standard 
method of diagnosing COPD. The diagnosis of COPD should be based on post-
bronchodilator results to eliminate the possibility of any reversibility element (GOLD, 
2014). This may have led to include some patients with asthma, which has a different 
pathophysiology. Additionally, the characteristics of patients with COPD and non-
COPD controls were not obvious, as the authors referenced demographic data that 
was published in 2001; however, the data collection for this study was carried out 
between 2001 and 2003. This raises a question about the general health of the 
subjects, who may, during this period, have developed some comorbidities that trigger 
changes in the arterial system. Furthermore, the authors limited their analysis to 
patients younger than 60 and with FEV1 <80; this led to the inclusion of only 63 
patients in their analysis, which may have led to underestimation of the link between 
COPD and arterial stiffness. 
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The conflicting results may be related to the outcome measure used to quantify 
arterial stiffness. In this study, AIx was used as a marker of arterial stiffness; however, 
this index is less rigorous than the gold standard of arterial stiffness for several 
reasons. These include the fact that an elevated heart rate causes the early return of 
the pulse wave to the aorta during the cardiac cycle, and this is affected by increased 
peripheral vascular resistance and is age-dependent (Wilkinson et al., 2000, McEniery 
et al., 2005). 
Recently, in a prospective cross-sectional study, aortic PWV was measured in 62 
patients with stable COPD, free from CVD, and 22 controls (Cinarka et al., 2013).  
The authors extended the previous research findings and found that even patients 
free from hypertension, type 2 diabetes and hypercholesterolemia had greater aortic 
PWV compared with control subjects, independent of age and smoking. Similar to 
Sabit et al. (2007) study, patients with an FEV1% <50 had greater aortic stiffness than 
those with an FEV1% >50. In this study, aortic PWV was negatively related to partial 
pressure of arterial oxygen. In contrast to Sabit et al. (2007) study, in this study, aortic 
PWV was not associated with CRP or tobacco exposure. The limitation of this study, 
in addition to its nature, was the majority of patients (96%) were male and therefore 
these results cannot be generalised to the female population. 
The results of these studies have clearly demonstrated that COPD has an adverse 
effect on the arterial system and accelerates the features of premature vascular 
ageing and could be a potential factor in developing CVD. However, although some of 
the used aortic PWV as an outcome measure in their studies, none of them has 
examined the reliability of aortic PWV in COPD, which limits the generalisibility of their 
findings. As far these studies have been cross-sectional in nature, which limits their 
findings, therefore, further longitudinal studies are needed to evaluate the effect of 
COPD on arterial system over time and its contributing factors.  
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The change in aortic stiffness over time has been evaluated in different populations, 
but none of them was in a COPD population (Benetos et al., 2002, Briet et al., 2011, 
Utescu et al., 2013). In a hypertensive population, Benetos et al. (2002) found that 
aortic PWV increased by 0.17 m/s per year compared with 0.07 m/s in normotensive 
subjects, independent of blood pressure. A similar finding has been reported in 109 
renal failure patients with chronic haemodialysis (Utescu et al., 2013). In this study, 
the adjusted progression of aortic stiffness, 0.84 m/s, was independent of age, blood 
pressure, systemic inflammation, diabetes and atherosclerotic CVD. In contrast, Briet 
et al. (2011) studied 180 patients with chronic kidney disease for four years and found 
no annual significant change in aortic PWV.  
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1.11 Frailty in COPD 
COPD is a respiratory disease associated with a multisystem impairment including an 
increased risk of cardiovascular disease, systemic inflammation, osteoporosis, loss of 
skeletal muscle mass and function, hypertension and type 2 diabetes that 
consequently impact on health related quality of life (HRQoL) (Barnes and Celli, 2009, 
Divo et al., 2012, Vanfleteren et al., 2013). These co-morbidities are usually seen in 
natural ageing and may be regarded as deficits in physiological systems. With 
advance ageing, subjects are increasingly more susceptible to chronic diseases that 
weaken the normal physiological response to internal and external stressors (Fried et 
al., 2001, Rockwood, 2005). These features are mistakenly confused with disability 
associated with COPD. However, it is not really understood how COPD leads to 
disability. It is evident that COPD could lead to loss of function in the sense of failed 
physical function, such as a reduction in exercise tolerance. However, it seems likely 
that the systemic manifestations of COPD may be important factors in functional 
limitation and disability both of which lead to frailty. Disability, comorbidity and frailty 
are frequently used interchangeably because both are seen in old populations and 
share most common risk factors (Fried et al., 2004). Disability may lead to frailty and 
worsen comorbidity, and frailty could contribute to the progression of chronic diseases 
(Fried et al., 2004).  
Frailty is a separate clinical entity and not necessarily to be associated with the 
elderly. The frailty concept has been around for nearly three decades, but, 
unfortunately, there is no operational definition for it (Morley et al., 2013). Recently, a 
group of experts agreed to acknowledge that frailty is not like disability and is a clinical 
syndrome that presents some individuals that could be reversible in some cases and 
progressive in others (Rodriguez-Manas et al., 2013). However, these experts failed 
to agree on one operational definition for frailty. Rockwood has previously defined 
frailty as an accumulation of deficits (Rockwood et al., 2005). This definition has been 
 55 
 
embraced by several studies that found its utility in predicting adverse outcomes and 
mortality (Mitnitski et al., 2002, Song et al., 2010). 
Frailty is a complex mechanism and the exact pathophysiology is still unclear. 
However, it was hypothesised that inability of one or multiple physiological systems to 
return to normal homeostasis after the perturbation, provokes a cascade of 
dysregulation that influence many clinical features and comorbidities (Fulop et al., 
2010, Rockwood and Mitnitski, 2007). Failure to resume equilibrium status with the 
loss of the complexity of physiological systems increases the vulnerability to further 
poor prognosis that is frequently associated with frailty (Morley et al., 2006, Puts et al., 
2005a, Rockwood et al., 2006, Walston et al., 2006).  
There are two different clinical models to assess and quantify frailty (Fried et al., 2001, 
Rockwood et al., 2005). The frailty phenotype model was derived from the 
Cardiovascular Health Study in the United States, which defined frailty by the 
presence of at least three of the following five deficits in an individual: slow walking 
speed, weak handgrip strength, a self-reported decline in activity levels, unintentional 
weight loss, or exhaustion (Fried et al., 2001). Although this phenotypic approach is 
valid and useful in detecting frailty, it is mainly based on physical frailty and ignored 
other potentially important factors such as comorbidities, psychosocial and cognitive 
capacity, which is highly associated with functional impairment and disability 
(Rothman et al., 2008). Additionally, this approach is limited to identify the frailty, but 
not to classify or determine the degrees of frailty and heavily relies on patient 
recollection for much of the data (Rockwood and Mitnitski, 2011). Another approach to 
define frailty is by quantifying the number of deficits including cognitive, psychosocial 
status, comorbidities, and disabilities (Rockwood et al., 2005). The Comprehensive 
Geriatric Assessment is a questionnaire based tool that measures impairments, the 
level of frailty and predict outcomes in older individuals (Rockwood et al., 2006). The 
number of deficits relative to the total number of potential deficits sought can be used 
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to calculate a Frailty Index (FI) ranging from 0 to 1 (Rockwood and Mitnitski, 2007). 
This model supports the idea that FI increases with the number of deficits 
independent of the nature of this deficit. Consequently, this validates the concept of 
frailty, which is a progressive accumulation of deficits due to integral loss of 
homeostasis mechanism. On top of that, the FI may be used clinically to stratify risk or 
predict adverse outcomes and a good candidate to express biological age (Rockwood 
et al., 2006). Moreover, the value of 0.67 can be used as a warning sign, which 
beyond the incidence of mortality is highly likely (Scheffer, 2010). 
Ageing and COPD share similar systemic manifestations and probably share an 
underlying mechanism. In the elderly, frailty predicts adverse outcomes independent 
of co-existing medical conditions and is associated with an increased risk of falls, 
hospitalisation, residential care, reduced HRQoL, progression to disability and 
increased mortality (Rockwood and Mitnitski, 2006, Rockwood et al., 2006, Song et 
al., 2010). The similarities between the accumulation of deficits in ageing and multiple 
co-morbidities in COPD suggest that COPD may accelerate the features of premature 
ageing and the patients could present with early signs of premature ageing and are 
likely to have high levels of frailty.  
However, frailty in COPD has not been well studied, and the literature has only two 
studies on frailty in COPD. A study by Galizia et al. (2011) who examined the 
predictive role of frailty on long-term mortality in patients with and without COPD, 
reported that frail patients with COPD had higher rates of mortality compared to non-
frail patients after 12 years follow-up. However, this study was not intended to 
examine the relationship between COPD and frailty. Moreover, diagnosis of COPD 
was based on patient‘s level of symptoms and report, which may have led to inclusion 
of patients with a wide spectrum of respiratory diseases such as asthma. A recent 
secondary cross-sectional study, using survey data from the National Health and 
Nutrition Evaluation Survey, which included only 70 patients with confirmed COPD, 
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suggested the prevalence of frailty was 57.8% based on a nine-item self-reported 
questionnaire. This study was not limited to only COPD, but included patients with 
known cancer and kidney diseases, which the prevalence of frailty is high (Balducci, 
2013, Dalrymple et al., 2013). Additionally, the lack of a specific comparator group 
and validation of the frailty questionnaire limits the interpretation of this data. 
COPD and frailty are both progressive with increased risk of adverse outcomes and 
poor health status. Therefore, emerging the assessment of frailty in routine clinical 
practice in patients with COPD would yield an early identification of those who are at 
high risk and subsequently implementing appropriate management to tackle this 
problem and improve the quality of life. 
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1.12 Summary 
Several epidemiological studies have confirmed the association between COPD and 
CVD, however, this intimate relationship is not fully understood. Recently, increased 
aortic stiffness has been identified as an attributing factor. A number of cross-
sectional studies have found that patients with COPD have increased aortic stiffness 
and associated with different risk factors including local and systemic inflammation 
and increased fat mass, which overall are likely to be factors in causing other co-
morbidities such as increased insulin resistance and changes in body composition 
with loss of bone mineral density.  
The presence of co-morbidities in COPD is similar to a multisystem deficit that is 
frequently seen in natural ageing or prematurely of what so called frailty. Frailty is 
considered to represent weakness or failure of physiological systems to sustain 
further an internal or external insult, and COPD may cause premature physiological 
changes or is itself an outcome of adverse outcomes.  
Therefore, the aim of this thesis is to examine the progression of cardiovascular risk in 
COPD as measured by change in aortic stiffness and its interaction with other risk 
factors such as inflammation and other co-morbidities in COPD over a two-year 
follow-up. Additionally, this thesis aimed to explore the concept of frailty and the role 
of physical activity in the development and progression of frailty in COPD. Prior to 
that, the reliability of non-invasive outcome measures, including arterial stiffness, 
cardiac haemodynamics and bone density need to be established for use in patients 
with COPD. 
 
  
 59 
 
1.13 Hypotheses 
1. Aortic PWV will be a reliable outcome measure for assessing aortic stiffness in 
COPD using the SphygmoCor machine.  
2. Assessment of cardiac haemodynamics in COPD (i.e. stroke volume and cardiac 
output) will be reliable using the Cheetah machine. 
3. Calcaneal Ultrasound Bone Analyser will be a reliable and valid machine for 
assessment of heel bone density in COPD. 
4. Timed Up and Go would be a simple test for physical performance in COPD. 
5. Patients with COPD would have elevated aortic stiffness compared with similar 
age and sex comparator group. 
6. COPD would cause an increase in aortic PWV independent of traditional risk 
factors after two years follow-up. 
7. Patients with COPD will be more frail compared with similar age and sex 
comparator subjects. 
8. Patients with COPD would have an increase in the frailty index and more 
impairment after two years follow-up.  
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1.14 Study Objectives 
1.  Assess the reliability of aortic stiffness in COPD using the SphygmoCor machine.  
2. Assess the reliability of cardiac haemodynamics in COPD (i.e. stroke volume and 
cardiac output) using the Cheetah machine. 
3. Examine the reliability and validity of Calcaneal Ultrasound Bone Analyser in 
COPD. 
4. Examine the feasibility of using Timed Up and Go test as a rapid physical 
performance test in COPD. 
5. Evaluate aortic stiffness in a large population with COPD and compare them with 
similar age and sex non-COPD subjects.  
6. Evaluate the change in aortic stiffness in COPD and its contributing factors over a 
period of two years follow-up. 
7. Assess the concept of frailty in patients with COPD and compare them with similar 
age and sex comparator subjects.  
8. Assess the rate of frailty progression in COPD and its predicting factors after two 
years follow-up.  
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Chapter Two 
Methods 
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2.1 Study Protocols 
This chapter describes the assessment methods undertaken in this thesis. 
Part I 
In this part, the reliability of physiological measures including aortic stiffness, 
cardiac haemodynamics (i.e. cardiac output and stroke volume), broadband 
ultrasound attenuation and the validity of calcaneal ultrasound bone analyser 
(CUBA) (Chapter 3). 
Part II 
This part described a large cross-sectional study from an ongoing longitudinal 
cohort that assesses the risk factors in patients with COPD. The study evaluated 
the use of a simple test to measure physical performance in COPD (Chapter 4).  
Patients with COPD were compared with non-COPD subjects similar in age and 
sex. Physical performance, body composition, inflammatory markers and health-
related quality of life were assessed during the initial assessment. 
Part III 
This part evaluated aortic stiffness cross-sectionally in patients with COPD 
compared with similar in age and sex non-COPD subjects. Then a group of patients 
with COPD was followed up for two years to examine the change in aortic PWV and 
its contributing factors (Chapter 5).  Aortic PWV, spirometry, body composition, 
central and peripheral blood pressure (systolic and diastolic blood pressure, pulse 
pressure and mean arterial pressure), cardiac haemodynamics, heart rate, tissue 
oxygen saturation, kidney function, inflammatory biomarkers and health-related 
quality of life were assessed at the initial assessment and at the two years follow-up 
visit. 
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Part IV 
This part assessed the concept of frailty cross-sectionally in COPD and similar age 
and sex comparators. Then a group of patients with COPD were followed up to 
examine the change in frailty over a period of two years (Chapter 6). The 
comprehensive geriatric assessment questionnaire was administered from which the 
frailty index was calculated. Other assessment including spirometry, body 
composition, cardiac haemodynamics, heart rate, tissue oxygen saturation, physical 
performance, inflammatory biomarkers and health-related quality of life were 
assessed at the initial assessment and at the two years follow-up visit. 
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2.2 Participants Recruitment 
2.2.1 Patient Recruitment 
Patients with COPD who were suitable for the study were identified through the 
respiratory outpatient clinics including Professor Shale‘s clinic and general practice 
databases. Inclusion and exclusion criteria for recruitment were described (Table 2.1).  
2.2.2 Comparator Recruitment 
Comparator subjects were recruited into the study using two methods. The first 
method was to invite participants of previous research projects at Wales Heart 
Research Institute free from respiratory disease. The second method was to recruit 
participant‘s relatives who were current smokers or ex-smokers with a minimum of 10 
pack-years of smoking. All comparator participants underwent a full medical history 
check and spirometry to rule out any cardiorespiratory disease, airflow obstruction or 
other exclusion criteria (Table 2.1). 
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Table 2.1: Inclusion and Exclusion Criteria 
 COPD Comparators 
Inclusion Age 35-80 years 
Previously diagnosed with COPD 
Clinically stability for at least 4 
weeks 
Age 35-80 years  
Current or ex-smokers with minimum 
of 10 pack-years 
 
Exclusion Long-term oxygen therapy 
Malignancy in the last 5 years 
Hepatic or renal failure 
Inflammatory or metabolic disease 
Pregnancy 
Diseases affecting mobility e.g. 
Parkinson‘s disease 
Maintenance oral steroids 
Respiratory disease and COPD 
Malignancy in the last 5 years 
Hepatic or renal failure 
Inflammatory or metabolic disease 
Pregnancy 
Diseases affecting mobility e.g. 
Parkinson‘s disease 
Maintenance oral steroids  
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2.3 Study Investigations 
Subjects interested and eligible were provided with an information sheet to read 
through at their leisure or discuss with their family or friends (Appendices A & B). After 
one week, the patients were contacted again by a member of the research team and 
asked if they were happy to take part in the study. The individuals who agreed were 
asked about their general health, medical history and current medication (including 
inhaled therapy) or the presence of any other medical conditions. In particular, every 
attempt was made to rule out those who did not meet the inclusion criteria for the 
study or met any of the exclusion criteria (Table 2.1). All participants completed health 
questionnaires about their general health (Appendix C). On arrival, patients were 
welcomed and asked to sign a consent form (Appendix D). Participants were asked if 
they had any questions about the study; and if there were any questions, these were 
answered and were told to feel free to ask any further questions during the study, or 
even after they went back home.  
Patients were examined during their clinical stability and those who suffered any 
exacerbation prior to their visit, their test postponed for at least four weeks until they 
felt their pulmonary symptoms had returned to baseline. In addition, comparators 
assessments were postponed if they had influenza or cold symptoms in the previous 
two weeks.  
  
 67 
 
Definition of Clinical Stability 
Clinical stability was defined according to the following criteria: 
● No chest exacerbation four weeks prior to recruitment; 
● No change in pulmonary symptoms four weeks prior to recruitment; 
● No reduction in FEV1>10% compared to patients‘ normal values within daily 
variation during the previous 6 months; 
● No change in medication four weeks prior to assessment; 
● An exacerbation was defined as: 
● Increased or new respiratory symptoms (cough, sputum volume, colour, 
dyspnoea); 
● Increased new systemic symptoms, including any of the following: fever, 
loss of appetite, weight loss, tiredness; 
● Reduced FEV1 >10% compared to usual clinical stability in the previous 6 
months. 
Smoking History 
A history of exposure to cigarette smoke was calculated as pack year exposure. 
This can be calculated by multiplying the number of packs of cigarettes smoked per 
day, by the number of years a person has smoked. For example, smoking 1 pack of 
20 cigarettes per day for 1 year is equal to 1 pack year. 
Number of pack years = (packs smoked per day) x (years as a smoker). 
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2.3.1 Height and Body Composition 
Subjects had their height measured barefoot, with their back straight against a wall 
using a stadiometer (Seca; Vogel & Halke, Hamburg, Germany). Weight and body 
composition were recorded with subjects wearing lightweight clothing and barefoot 
using a single frequency segmental bioelectrical impedance analyser (BC-418 MA, 
Tanita Corp., Tokyo, Japan), operating at 50 kHz, with eight-point contact electrodes 
(Figure 2.1). This system consists of a platform with stainless-steel footpads and two 
handgrips with stainless-steel contacts. The four contacts on the platform are 
arranged in pairs with two contacts for each foot. Each handgrip has one pair of 
contacts. Measurements were taken in a standing position with the arms slightly 
abducted. The electrode arrangement allows separate measurements for each arm 
and leg, the trunk and the whole body. The muscle mass and fat mass of limbs and 
trunk were calculated from the measured resistance values, height, body weight, sex, 
age and training condition. 
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Figure 2.1: Body Composition Analyser (TANITA, BC-418) 
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2.3.2 Heel Bone Density Measurement 
The heel bone density of the patients was examined by the researcher using the 
Clinical CUBA machine (McCue Ultrasonics, Winchester) (Figure 2.2). The CUBA 
machine produces ultrasound waves from two distinct piezoelectric probes in the form 
of a sinusoid impulse. These waves are detected once they have passed through the 
calcaneus. The participants sat on a chair and inserted their right foot into the footwell 
to assess its size prior to measurement. The assessment was performed by using 
lines marked in the footwell and by assessment of the position of the tip of the big toe 
in relation to the lines, which indicates which of the inserts is required. The patient‘s 
foot was removed from the device, and the insert positioned if required. The foot insert 
was designed to raise the foot by a set distance from the base of the footwell, so that 
the patient‘s calcaneus is positioned between the transducers. 
Ultrasound gel was applied to both the transducers and the patient‘s heel. The foot 
was repositioned between the two probes, emitting and receiving, and the leg was 
supported with velcro straps that pass around the calf and prevent excessive 
movement of the heel during measurement. The patient‘s details, such as age, sex 
and which foot was inserted into the machine were entered. The transducers were 
then closed so that they apply light pressure to either side of the calcaneus. 
The measurement took approximately one minute, including an initial 30-second 
settling period to allow for any air bubbles in the gel to dissipate and for some 
compression of the surrounding soft tissue. The measurement was then taken, and 
the transducers dis-attached, releasing the heel. Calibration was checked every 
morning using a quality assured phantom model prior to examinations to ensure 
correct functioning of the transducers in terms of the ultrasound signal emitted and a 
determination of the speed of propagation of the impulse emitted by the probes. 
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 Figure 2.2: Calcaneal Ultrasound Bone Analyser (CUBA) machine 
(Picture taken from: http://www.medical-supplies-and-equipment.com/mccue-
cubaclinical.html) 
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2.3.3 Pulse Wave Analysis and Measurement of Pulse Wave Velocity 
Prior to the assessment of arterial stiffness, participants were requested to abstain 
from caffeine, tobacco and their inhalers (short-acting β2 agonists for six hours and 
long-acting β2 agonists for twelve hours) before testing.  
Arterial stiffness was assessed by an experienced operator using a measurement of 
pulse wave velocity (PWV) using a SphygmoCor device (AtCor medical) (Figures 2.3) 
connected to a laptop computer. Both these methods rely on the principle of 
applanation tonometry, where the curved surface of an artery is flattened by pencil-
shaped probe, known as a tonometer (SPC-301, Millar instruments, Houston, Texas). 
Incorporated into the tip of the tonometer is a high-fidelity micro-manometer, 
consisting of a 0.5 × 1.0 mm piezoelectric crystal with a frequency response greater 
than 2 kHz. By flattening the curved surface of an artery, circumferential pressures are 
equalised and intraluminal pressures can be recorded accurately in the form of arterial 
pressure waveforms.  
Pulse wave analysis was derived by placement of a tonometer on the radial artery of 
the right arm. A pulse trace was recorded for a minimum of 10 consecutive beats and 
an average waveform was processed by the in-built software package. A generalised 
transfer function, based on Fourier analysis, was then used to generate a 
corresponding central aortic waveform (Figure 2.4). The generalised transfer function 
has been prospectively validated for the assessment of ascending aortic blood 
pressure and showed good repeatability of measurements (Wilkinson et al., 1998). 
With the integral software, augmentation pressure (AP) was calculated as the 
difference between the second and first systolic peaks of the central waveform, and 
the AIx was calculated as AP expressed as a percentage of pulse pressure (PP) 
(Figure 2.4).  
Measurement of aortic PWV was performed using the principle of applanation 
tonometry using a high-fidelity micro-manometer with the participant in the supine 
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position. Electrocardiographic-gated carotid and femoral artery waveforms were 
measured. Distances from the carotid pulse site to the manubrium sternum and to the 
femoral artery were measured as straight lines between points on the body surface 
using a tape measure. The time (t) between the onset of femoral and carotid 
waveforms was determined as the mean of 10 consecutive cardiac cycles. The PWV 
(m/sec) was calculated by dividing the distance between measurement points (D) to 
the measured time delay (t) (Figure 2.5). All measurements were duplicated, unless 
they differed by more than 0.5 m/sec, in which case a third reading was taken, with 
the mean values being used in subsequent analysis. 
Calibration of the SphygmoCor device was undertaken using average brachial blood 
pressure in the dominant arm using a validated oscillometric method (HEM-750CP; 
OMRON Corporation, Japan) after 10 minutes of seated rest (O'brien et al., 1996). 
Three independent measurements of systolic and diastolic blood pressure were taken, 
and the average of the last two measurements was used. Blood pressure was 
classified according to the British Hypertension Society (Table 2.2) (Williams et al., 
2004). 
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  Figure ‎2.3: Picture of SphygmoCor Machine (AtCor, Sydney) 
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  Figure 2.4: Central arterial pressure waveform and its derivatives 
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  Figure 2.5: Carotid and femoral arterial waveforms and aortic PWV 
   
 
 
 
Table 2.2: Classification of blood pressure levels by the British Hypertension Society 
(Williams et al., 2004) 
 Systole (mmHg) Diastole (mmHg) 
 
Normotensive <120 <80 
Hypertension ≥140 ≥90 
Isolated systolic hypertension            140-159 <90 
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2.3.4 Cardiac Output Measurement 
With the participant lying supine, the researcher entered participant‘s personal data 
into the machine (identity, sex, height and weight). Cardiac haemodynamics were 
measured non-invasively using a bioreactance technology (NICOM, Cheetah, Medical 
Inc., Indianapolis, IN) (Figure 2.6). This system is based on the discovery that 
changes in aortic blood flow induce small changes in the frequency of electrical 
signals propagating across the thorax. Changing the frequency across the chest 
cavity causes this system to be less affected by body movement, location of the 
electrodes, or the filtering of electrical interference. The NICOM system consists of 
four disposable pairs of double electrodes, which were attached to the patient‘s 
chest—two on either side of the lower thorax (positioned marginally below the ribs) 
and two just below the clavicle (Figure 2.7). Each pair of electrodes delivers a low 
alternating current, and its propagation characteristics are sensed along the thorax by 
the other electrode pairs. Therefore, cardiac haemodynamics are measured 
separately from each side; then, the average of two measurements is calculated. 
These measurements took about one minute to complete. 
The signal-processing unit of the NICOM system determines the relative phase shift 
(ΔΦ,) of the input signal relative to the output signal. The relative phase shift is in turn 
due to changes in blood flow in the aorta with every beat. It has been shown that 
stroke volume can be estimated by: 
SV = C · VET · dΦ/dtmax 
Where C is a constant of proportionality and VET is the ventricular ejection time, 
which is determined from the NICOM and electrocardiogram signal. The value of C is 
optimized with regard to participant age, sex and body size. The cardiac output is then 
calculated using the equation: 
Cardiac output = Stroke volume X Heart rate 
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  Figure 2.6: NICOM device 
 (Picture taken from: http://www.cheetah-medical.com) 
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Figure 2.7: The NICOM system and its connection to the body 
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2.3.5 Pulmonary Function Tests 
All pulmonary function tests were performed and interpreted according to the GOLD 
guidelines (GOLD, 2014). The subjects underwent spirometric evaluation (forced vital 
capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio) using a 
Vitalograph Alpha (Bucks, UK) spirometer. The spirometer was annually calibrated by 
vitalograph technician. Patients were asked to refrain from using their inhalers for 6 
hours for short acting bronchodilators and 12 hours for long acting bronchodilators 
prior to their visit. The tests were performed with the subject in a sitting position and 
with nose clips in place. Participants were instructed to take the deepest possible 
breath, place their lips around the mouthpiece of the spirometer, and breathe out as 
fast as possible, as hard as possible and for as long as possible. All participants were 
given a demonstration of the procedure prior to the test. The FEV1, FVC, FEV1/FVC 
were recorded along with percentage predicted values based on reference values for 
age, sex, height, race and smoking status. Each subject performed at least three 
spirometric tests with at least two reproducible and acceptable manoeuvres. Reliability 
was considered satisfactory when the second highest values of FEV1 and FVC were 
within 5% of the highest value.  
Subjects with obstructive spirometry (FEV1/FVC <70%) underwent reversibility testing, 
where 400µg of salbutamol is given via a spacer device using the tidal breath 
technique. After a ten minute wait, spirometry was repeated a further three times. 
Reversibility was defined as an increase in FEV1 of 12% and 200 ml (GOLD, 2014). 
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2.3.6 Timed Up and Go  
Timed Up and Go (TUG) measurement was obtained by the researcher using an 
armchair (45 cm high) and a stopwatch (accurate to 0.1 s). Subjects were seated with 
their back supported against the chair back. They were instructed to stand up, walk 
three metres (to a mark on the floor), cross the mark, turn around, walk back to the 
chair and sit down (Podsiadlo and Richardson, 1991). The task was to be performed 
at a normal comfortable pace. The stopwatch was started on the word "go" and 
stopped as the subject sat down. The TUG time was documented in seconds. 
2.3.7 Six–Minute Walk Distance (6MWD) 
Blood pressure, heart rate, oxygen saturation and breathlessness score using a Borg 
scale were taken by the researcher before the test, while the participant was sitting 
comfortably on a chair with arms. Resting heart rate and oxygen saturation were 
measured using a pulse oximeter (Pulsox-3iA, Konica-Minolta, Japan). The probe was 
placed on the index finger of each participant until the heart rate and oxygen 
saturation stabilised. The subjects were asked to rate their breathlessness using the 
Modified Borg Scale at the start and end of the walk; this is constructed as a category 
scale with ratio properties (Borg, 1982). A score of 0 would indicate nothing at all; 0.5 
would indicate very, very slight (just noticeable) breathlessness, followed by whole 
numbers 1 through to 10 (Table 2.3). Particular care was taken to check for absolute 
contraindications prior to performing the test, as the American Thoracic Society 
guidelines (2002).  
All 6MWD were performed in the Wales Heart Research Institute by the researcher 
certified in cardiopulmonary resuscitation. Oxygen, sublingual nitroglycerin, a short-
acting inhaled bronchodilator and crash cart were in the immediate vicinity of the test 
area, and a protocol was in place to call for immediate medical assistance if required. 
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Subjects were instructed to wear light clothing and footwear suitable for walking. The 
patients were given 400µg of salbutamol via a spacer device 30 minutes prior to the 
test, after they had rested for at least 15 minutes.  
The 6MWD was carried out in accordance with a protocol adapted from the American 
Thoracic Society's (ATS) guidelines (2002) using a 30-m straight level course in an 
enclosed corridor. The course was marked with cones at either end. Chairs were 
placed at each end and at the midway point to allow resting points if required. 
Standardised instructions were read aloud to the subjects before the test. Patients 
were told to stop walking and inform the researcher if they experienced any chest pain 
or dizziness. At the end of each minute, patients were notified of the elapsed time and 
given standard encouragement.  
If a subject rested during the 6MWD, the following encouragement was given at 15 s 
intervals: 'begin walking as soon as you feel able‘. In the event that profound oxygen 
desaturation occurred (defined as SpO2 <88%), the researcher instructed the patient 
to stop walking immediately and to recommence walking if SpO2 recovered to >88%. 
Patients remained in the clinical area for a minimum of 10 min. following an 
uncomplicated 6MWD. During this time, they were closely observed and any 
abnormal signs and symptoms recorded. 
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                Table 2.3: Modified Borg Scale (Borg, 1982) 
SCALE SEVERITY 
0 No breathlessness at all 
0.5 Very very slight (just noticeable) 
1 Very slight 
2 Slight breathlessness 
3 Moderate 
4 Somewhat severe 
5 Severe breathlessness 
6  
7 Very severe breathlessness 
8  
9 Very very severe (almost Maximum) 
10 Maximum 
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2.3.8 Handgrip Strength 
Maximal right and left handgrip strength (HGS) was determined twice in each hand 
using a hand dynamometer (T.K.K. 5401 grip-D, Takei, Japan) (Roberts et al., 2011). 
In a standing position, with arms by the sides, participants were asked to perform two 
maximum contractions alternating between left and right, each lasting 3-5 seconds 
and at least 15 seconds apart. The maximum handgrip was determined as the 
average of four measurements. 
2.3.9 Health Related Quality of Life Measurement 
Patients completed the St George‘s Respiratory Questionnaire (SGRQ), a 50-item 
status questionnaire designed to measure health impairment (quality of life) in patients 
with COPD (Jones et al., 1992). The questionnaire consists of three domains; 
symptoms, activity and impact (Appendix E). The first part asks about the patient's 
symptoms over the last twelve months, and the questions should be answered based 
on the patient‘s perception of their recent respiratory problems. The second part of the 
questionnaire focuses on the patient‘s activity in daily living and the impact of COPD 
on their psycho-functional activity. The questionnaire was completed to the best of the 
patient‘s knowledge. If the patient had a query regarding a question on the 
questionnaire, an explanation was given without answering the question. After 
completion of the questionnaire, the researcher went through it to check if there were 
any missing answers. 
Each domain of the questionnaire was scored from 0 to 100, where 0 represents the 
best possible health status and 100 represents the worst possible. A total score was 
calculated which summarises the effect of the disease on health status and is 
expressed as a percentage.  
Patients also completed a questionnaire about the impact of COPD on their health 
status. The COPD Assessment Test (CAT) is a simple, reliable and validated 
designed to assess the impact of COPD on health status (Jones et al., 2009). It is a 
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scoring questionnaire consists of eight domains that cover the effect of COPD on daily 
life and health (Appendix F).  
2.3.10 Comprehensive Geriatric Assessment  
Each participant was interviewed to complete a comprehensive geriatric assessment 
(Rockwood et al., 2005). It is a one-page form to assess the effect of ageing on 
general health and identify the number of deficits. This questionnaire consists of 16 
standard domains (Appendix G). The patient scored 1 if he/she had a deficit and 0 if 
did not. The total score for this questionnaire is out of 61 points. Frailty index (FI) was 
then calculated by dividing the number of deficits that the patient had by the 
maximum, 61. 
2.3.11 Dual Energy X-ray Absorptiometry (DXA)  
Data from a sub-set of patients who had been diagnosed with osteoporosis and had a 
dual energy X-ray absorptiometry (DXA) scan as part of their normal medical care 
within a twelve month period from the initial visit was accessed and the results of the 
DXA scan were used to examine the validity of the CUBA scan. The DXA scan was 
performed using a Hologic Discovery bone densitometer (Hologic Inc, Waltham, MA, 
USA) using the whole body protocol and the fan beam array method. The scan was 
performed by a radiographer with the patient lying in a supine position with total 
effective radiation dose of 5.2 µSv (Blake and Fogelman, 1998). Calibration was 
performed daily using a phantom spine to check bone mineral density (BMD). 
The BMD at individual lumbar spine (L1-L4) and hip (neck, trochanter and 
intertrochanteric regions) sites were measured, along with a mean BMD at the lumbar 
spine and hip. The BMD at all sites was recorded as an absolute figure (g/cm2) and as 
a standardised T and Z score. The T score standardises the BMD by relating the 
results as a standard deviation from the mean of a young healthy population of the 
same gender, while the Z score relates the BMD as an SD from the mean of an age 
and gender matched population (WHO, 1994). 
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2.3.12 Blood 
Peripheral blood samples were collected by a research nurse from all subjects from 
the ante-cubital fossa following haemodynamic measurements. Serum creatinine, 
estimated glomerular filtration rate, high sensitivity protein and fibrinogen were 
measured using standard enzymatic methods in the department of Biochemistry, 
University Hospital of Wales. 
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Figure 2.8: Research Flow Chart 
 
500 Patients Recruited at 
initial visit 
30 patients included in 
the reliability studies 
48 patients included in 
the validity study 
143 completed two 
years assessment 
150 Comparators Recruited 
at initial visit 
No comparators 
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Chapter Three 
Methodological Studies 
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3.1 Methodological Consideration 
The reliability of an outcome measure reflects how reproducible or repeatable the 
measurement is under a given set of circumstances. This chapter of the thesis 
examined the reliability of outcome measures to be of use in the longitudinal studies 
and its feasibility in routine clinical practice. 
3.1.1 Reliability 
For an outcome measurement to be useful, it must provide stable or reproducible 
values with small errors of measurement when no variable is influencing the attribute 
that the measurement is quantifying (Rankin and Stokes, 1998). Measurement errors 
are of two types: one is systematic errors, which may constantly under-predict or over-
predict values. Systematic error does not pose problems to the reliability of the 
outcome measure. However, it creates problems of validity since the measured value 
is not the true representation of the quantity measured. The second type of the 
measurement error is a random error. Random error does pose a problem to 
reliability, as they occur due to unpredictable factors such as mechanical inaccuracy, 
lack of experience and fatigue. Inevitability, the unpredictability of the working 
environment and subjects involved cannot be avoided, even if the sources of the 
errors are anticipated. Random errors can be diminished by taking several 
measurements then calculating the average score as a good estimate of the true 
value (Portney and Watkins, 2009). Since measurement error is inevitable and true 
reliability or a true value can never be calculated, reliability is estimated based on the 
statistical concept of variance. Variance is ‗the measure of variability or the difference 
among scores within a sample‘ (Portney and Watkins, 2009:64). It helps to find out the 
true difference among the values measured by yielding a ratio called the reliability 
coefficient that has a coefficient of 1.0 for maximum reliability. Reliability coefficients 
are based on a measure of correlation such as Pearson‘s product moment correlation 
or the intraclass Correlation Coefficient and range between 0.00 and 1.00. The more 
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reliable the measurement response, the less error variability there will be around the 
mean (Bruton et al., 2000). The ICC is one appropriate approach that can be used to 
assess relative reliability among two or more trials. It is based on measures of 
variance from the analysis of variance (ANOVA) (Portney and Watkins, 2009). There 
are different types of ICCs that are available, equation ICC (3, 1), a two-way mixed 
model/absolute agreement, was used to assess the reliability of a fixed rater for 
repeated measurements (Rankin and Stokes, 1998). A coefficient below 0.50 is 
considered as indicating poor reliability, between 0.50 and 0.75 is considered as 
moderate reliability and above 0.75 suggest good reliability (Portney and Watkins, 
2009). As reliability cannot rely solely on ICC, since it measures only the strength of 
association between the two variables not extent of agreement between them. An 
assessment of agreement, as in Bland and Altman should be used in conjunction with 
correlation in any reliability study.  
There are two types of reliability, intra-rater (test-retest) and inter-rater reliability. The 
intra-rater reliability also called test-retest reliability. Intra-rater reliability is the 
reliability of measurement taken by the same researcher on different occasions. It is 
mainly used to establish the consistency of the measurement tool and, for the 
outcome measure to be reliable, the values obtained in a multiple trial should be 
similar. The interval between test and retest should remain stable to avoid random 
error (Portney and Watkins, 2009). Additionally, proper instruction and settings 
should be provided to maintain the uniformity of a study. The second type of the 
reliability is inter-rater reliability. The inter-rater reliability is the reliability of the 
measurement taken by multiple researchers (Bruton et al., 2000).  
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3.1.2 Validity 
Validity refers to the extent to which an instrument measures what it claims and 
intends to measure accurately (Portney and Watkins, 2009). It implies that the 
measurements are free from error and emphasises the ability to make inferences 
from the values measured in the study (Portney and Watkins, 2009). Validity can be 
subdivided into four categories: 
I) Construct Validity 
This is the degree to which a test identifies the concept or variable of that which is 
being measured (Brink et al., 2006). To establish the construct validity of a method, 
the researcher must determine the degree to which the measure accords with other 
measures designed to measure the same thing and whether the new test behaves as 
expected. In addition, the tool should demonstrate appropriateness in measurement 
(convergent validity) and avoid extraneous information (divergent validity). 
II) Criterion Validity 
This is further subcategorised into concurrent validity and predictive validity. 
Concurrent validity is related to which measurement tool is being examined against a 
previously validated measure, often a gold standard measurement. This is 
considered as a common method of examining the validity of a new tool or 
instrument (Portney and Watkins, 2009). Concurrent validity can be performed when 
a new or unexamined equipment is easy and feasible to administer and potentially 
more efficient. Predictive validity refers to a tool‘s capability to predict and make 
inferences about the future. 
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III) Content Validity 
This refers to what extent a tool adequately measures what it asserts to be 
measuring. The content validity employs a reference standard, also called a ‗gold 
standard‘. It is a measure accepted by a consensus of content experts as the best 
available for determining the presence or absence of a particular phenomenon 
(Portney and Watkins, 2009). 
IV) Face Validity 
This refers to a measure‘s appropriateness and relevance to measure what it is 
supposed to measure as assessed by a group of experts (Brink et al., 2006). In other 
words, it is to examine whether the future measure seems to provide a reasonable 
measure of the concept it is intended to measure.  
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3.2 Reliability of Arterial Stiffness Measurement in COPD 
3.2.1 Background 
Chronic obstructive pulmonary disease (COPD) is a systemic disorder associated with 
an increased risk of cardiovascular disease (CVD) (Sin and Man, 2005). A number of 
studies have examined the mechanism that links COPD with CVD; however, the 
precise pathological process is still uncertain. Recently, the role of inflammation has 
been recognised in the pathogenesis of COPD (Thomsen et al., 2012). One of the 
most commonly used indicators of inflammation is CRP. CRP is one of the modulating 
factors of the pathogenesis in atherosclerosis (Barr et al., 2012, Iwamoto et al., 2009). 
In patients with COPD, the level of CRP is increased and, therefore, may contribute or 
accelerate aortic stiffness and calcification, which are risk factors for atherosclerosis 
(Bolton et al., 2011, Man et al., 2008). 
Like COPD, atherosclerosis is a chronic progressive disorder affecting the elasticity of 
the medium and large arteries (Lusis, 2000). With increasing age, the loss of vascular 
properties of the arterial wall in the presence of cardiovascular risk factors contributes 
to stiffness of the large arteries in healthy elderly as well as in individuals with COPD 
(McEniery et al., 2005, Sabit et al., 2007). Several cross-sectional studies have found 
a relationship between arterial stiffness and COPD, suggesting that arterial stiffness 
could be a driving mechanism that increases the CVD risk in patients with COPD 
(Sabit et al., 2007, Cinarka et al., 2013). Stiffness of the large central arteries puts a 
great burden on cardiac function by decreasing diastolic time, which in turn leads to 
insufficient blood supply to myocardial tissue and the coronary arteries, and this may 
increase the risk of cardiovascular events (Sabit et al., 2010a, Patel et al., 2013). 
Changes in vessel wall structure and function composition may be determined by 
measuring arterial stiffness. Aortic PWV is the gold standard for measuring arterial 
stiffness (Laurent et al., 2006). Several studies have reported that aortic PWV is an 
independent predictor of cardiovascular risk in various populations (Boutouyrie et al., 
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2002, Cruickshank et al., 2002, Blacher et al., 1999, Sutton-Tyrrell et al., 2005, 
Willum-Hansen et al., 2006).  
However, few studies have evaluated the repeatability of aortic PWV in COPD. Stone 
and colleagues (2013) examined the reproducibility of aortic PWV measure using a 
Vicorder machine in 23 stable patients with hyperinflation, with two weeks in-between 
the measurements. In this study, the authors found this machine had a reproducibility 
coefficient of 4.02% and limit of agreement between -0.68 and 0.75 m/s. Although the 
Vicorder machine showed to be feasible for measuring aortic PWV, use of 
reproducibility coefficients and small sample size limits the generalisibility. The title of 
the study indicates that this is an inter-rater study, but it is unclear from the 
methodological section whether it is a reproducibility or reliability study.  
A number of studies have examined the reliability of PWV in healthy individuals and 
in those in diseased states. A frequently cited paper is that of Wilkinson et al. (1998), 
which demonstrates within-day intra and inter-rater reproducibility in healthy subjects 
and patients with hypertension and Hypercholesterolaemia. This paper showed no 
difference in aortic PWV within and between operators, (p>0.05). The Bland-Altman 
plots confirmed that there was no systematic bias and that 95% of data fell within the 
limits of agreement (Bland and Altman, 1986). More recently, Frimodt-Moller and 
colleagues (2006) confirmed the within-day reliability of aortic PWV in 23 healthy 
middle-aged participants, but they found that there were differences following acute 
cigarette smoking (within four hours after last cigarette). 
Whilst within-day reliability is important, interventional research requires that outcome 
measures are stable from day to day (Bland and Altman, 1986). The between-day 
reliability of PWV has been investigated for a number of populations. 
As part of a larger study, Tanaka et al. (1998) investigated between-day reliability in 
eight men and women. Aortic PWV was measured and the results were pooled for 
analysis, with no difference in mean PWV between days. However, in this study, the 
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time interval was not stated, so it is difficult to extrapolate the findings; and pooling of 
aortic PWV may not be valid as the variation may be obscured when central and 
peripheral velocities are combined (Laurent et al., 2006). Furthermore, a larger study 
showed no difference in aortic PWV when measurements were repeated over a time 
interval of 2.5 weeks with a coefficient of variation of 3.2% and acceptable Bland-
Altman plots (Liang et al., 1998). Similarly, ter Avest et al. (2005) demonstrated good 
reliability between days and between afternoon and morning assessment in 19 
healthy subjects using the SphygmoCor device. Using the same device, Frimodt-
Moller et al. (2008) assessed the intra- and inter-observer reliability of aortic PWV in 
19 patients with chronic kidney disease. They showed good reliability within a week in 
this population. Good reliability has also been reported in a large sample of patients 
with kidney disease who were assessed twice, with a time interval ranging between 
two and 16 weeks (Savage et al., 2002).  
To evaluate aortic PWV in a long-term study, reliability is critical. In healthy 
individuals, intra and inter-operator reliability has been established and shown to be 
high, as mentioned in the above studies. Although arterial stiffness has been used as 
a measure of cardiovascular risk in patients with COPD in a number of studies, the 
reliability of this measure has not been established in this population using the 
SphygmoCor device. Therefore, the aim of this study was to examine the reliability of 
aortic PWV over one week. 
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3.3 Reliability of Cardiac Haemodynamics Measurement 
3.3.1 Background 
Increased cardiovascular risk is one feature of COPD (Sin and Man, 2005). Several 
studies support the relationship between COPD and CVD. Cardiovascular death 
related to COPD is under-diagnosed and under-recognised in this population. A 
recent well-conducted study TOwards a Revolution in COPD Health (TORCH) found 
that cardiovascular causes were involved in 27% of COPD deaths (McGarvey et al., 
2007). Additionally, CVD increases the risk of hospitalisation by 42% with COPD 
(Anthonisen et al., 2002). The exact mechanism linking COPD to CVD remains 
unknown. Yet, there are several contributing factors that increase cardiovascular 
injury and the load on the heart function including systemic inflammation, hypoxia, 
aortic stiffness, autonomic nervous system dysfunction and oxidative stress (Maclay 
et al., 2012, Sabit et al., 2010a, Sin and Man, 2005, Skwarski et al., 1998, Van Gestel 
et al., 2012). The existence of one or more of these factors, beside COPD, can 
increase the burden on the heart, which will lead to left ventricular dysfunction or heart 
failure, even in the mild stages of COPD (Barnes and Celli, 2009, Rutten et al., 
2005b). In a study of 405 patients with COPD, almost 21% of patients were diagnosed 
with hidden heart failure (Rutten et al., 2005b). Moreover, in a large multi-ethnic 
prospective cohort study of patients with emphysema and unknown cardiovascular 
disease, cardiac haemodynamics and left ventricle changes were present, even in 
mild stages (Barr et al., 2010).  
Furthermore, hyperinflation is a feature of COPD that is associated with abnormal 
lung function (Ferguson, 2006). The effect of hyperinflation on the heart has not been 
studied extensively in patients with COPD. Jorgensen et al. (2007) found that in 
severe emphysema patients, there was a reduction in right and left heart size 
compared with non-emphysematous patients. More recently, Watz et al. (2010) found 
that hyperinflation was associated with reduced heart size and function across the 
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whole spectrum of COPD severity. Increased pulmonary vascular resistance and 
pulmonary arterial pressure, as consequences of hyperinflation, will lead the heart 
chambers to adapt to these changes by changing preload filling (Holverda et al., 
2009).  
There is a close relationship between heart size and cardiac function. Reduced heart 
chambers size leads to changes in cardiac output and stroke volume, which are 
measures of cardiac performance (Boussuges et al., 2000). 
Cardiac output (CO) is one of the fundamental measures of heart function and the 
main determinant of global oxygen transport from the heart to the body. Additionally, 
the primary function of the cardiovascular system is to supply sufficient amounts of 
oxygen to meet the metabolic demands of the tissues; therefore, it appears sensible 
to measure CO to obtain information about the efficiency of the cardiovascular 
system. Given that patients with COPD are at high risk of CVD, and especially heart 
failure, quantifying CO in routine clinical practice may provide insights into the 
presence and degree of heart failure (Williams et al., 2001). 
A study by Barr et al. (2010) found that CO decreases by 100 ml/minute for every 
10% decline in FEV1/FVC, independent of smoking.  
Moreover, stroke volume (SV) is another determinant of cardiac performance. 
Boussuges et al. (2000) studied 34 stable patients with COPD, without hypoxemia, 
hypertension or overt cardiovascular disease, and found that the patients had reduced 
left ventricle stroke volume, in the absence of hypertrophy. This finding is supported 
by another study on a small group of 25 patients with severe COPD, and with 
unknown high blood pressure, CVD or heart failure. In this study, patients had lower 
right and left ventricle stroke volumes than healthy controls, which was concomitant 
with right ventricle hypertrophy (Vonk-Noordegraaf et al., 2005). In a large prospective 
cohort study, Barr et al. (2010) confirmed the negative impact of COPD on cardiac 
haemodynamics. They reported that a greater extent of emphysema and airway 
 98 
 
obstruction was associated with a decline in SV. There was a decrement of 15 ml in 
SV for every 10% reduction in FEV1/FVC.  
Taking the aforementioned studies together, it appears that the assessment of cardiac 
haemodynamics in patients with COPD is sensible, and will provide good insights into 
cardiac performance. Additionally, this will allow clinicians to detect the presence of 
heart dysfunction at an early stage and offer accurate management. The 
aforementioned studies have confirmed the changes in cardiac haemodynamics in 
patients with COPD, even at early stages, using Doppler ultrasound, 
echocardiography or cardiac magnetic resonance imaging. However, the application 
of these techniques in routine clinical settings is difficult due to their limited availability, 
the time needed, and the skills and knowledge of the operator.  
Recently, a new method of measuring CO and SV based on a bioreactance technique 
has been developed to overcome the limitations associated with previous techniques 
such as bioimpedance technology. This non-invasive cardiac output measurement 
(NICOM) system is based on phase shift in the high frequency current delivered to the 
thoracic cavity as a result of changes in aortic blood volume. The accuracy, precision 
and responsiveness of this technique have been validated in several populations 
(Keren et al., 2007, Kossari et al., 2009, Rich et al., 2012, Squara et al., 2007). 
The ideal technology for estimating CO and SV should be non-invasive, continuous 
and reproducible, and have a limit of agreement as assessed by a Bland and Altman 
plot (Bland and Altman, 1986). Furthermore, it should be convenient for both patient 
and health professional, and precise, and have minimum side effects. To date, the 
reliability of this system has been established in several patient populations, and one 
study demonstrated excellent reliability in healthy adults (Elliott et al., 2010). With 
regard to COPD, this technique should take into consideration the pathophysiology of 
COPD, hyperinflation and the ventilation-perfusion mismatches that are associated 
with COPD. To date, none of the available techniques satisfies all these criteria; 
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therefore, the aim of this study was to examine the reliability of measuring CO and SV 
non-invasively using the Cheetah machine. 
Hypotheses 
Aortic PWV will be a reliable outcome measure for assessing aortic stiffness in COPD 
after one week using the SphygmoCor machine. 
Assessment of cardiac haemodynamics in COPD (i.e. CO and SV) will be reliable 
after one week using the Cheetah machine. 
Aims 
The aim of this study was to examine the reliability of aortic PWV in COPD over one 
week using the SphygmoCor machine. In addition, this study aimed to assess the 
reliability of cardiac haemodynamics (i.e. CO and SV) using the Cheetah machine. 
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3.3.2 Methods 
A sub-group of patients were recruited from a large cross-sectional study of the 
Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE), which had 
gained ethical approval from South East Wales ethic committee (REC reference 
number 11/WSE02/7). Patients gave written informed consent. Inclusion criteria were: 
aged 40-80; clinically stable with no exacerbation in the preceding four weeks. An 
exacerbation is defined as ―an event in the natural course of the disease 
characterised by a change in the patient‘s baseline dyspnoea, cough and/or sputum 
beyond day to day variability sufficient to warrant a change in management‖ (GOLD, 
2014). 
Full inclusion and exclusion criteria were detailed (Chapter 2: Table 2.1, p 65).  
The sample size was based on data from a published study on COPD from South 
Wales: mean (SD) aortic PWV was 11.4 (2.7) (Sabit et al. 2007). This equates to an 
effect size of 0.24. The G power software was used to calculate the sample size, with 
80% of power at p=0.05 and an effect size of 0.24 for repeated measures ANOVA, 
and found to require 30 patients. 
Anthropometric Measurements 
Subjects had their height measured barefoot with their back straight against a wall 
using a stadiometer (Seca; Vogel & Halke, Hamburg, Germany) and their weight 
using an electronic scale (Chapter 2:2.3.1, p 68). 
Measurement of Pulse Wave Velocity 
Carotid-femoral PWV was assessed non-invasively using the SphygmoCor device 
connected to a laptop computer (Chapter 2:2.3.3, p 72).  
Cardiac Haemodynamics Measurement 
Cardiac haemodynamics were measured non-invasively using a new bioreactance 
technology (NICOM, Cheetah, Medical Inc., Indianapolis, IN) (Chapter 2:2.3.4, p 77).  
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Second Measurement 
The patients came back after a week to repeat the same measurements, when the 
same protocol was followed. 
Statistical Analyses 
Descriptive statistics, repeated measures analysis of variance (ANOVA), intra-
correlation coefficient and Bland and Altman plots were used to assess reliability. All 
analyses were carried out using SPSS software (version 18.0; SPSS Inc, Chicago, 
IL). The p value was set at <0.05 and ICC > 0.75. Data normality was checked prior to 
analysis using a Kolmogorov-Smirnov test. 
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3.3.3 Results 
Thirty patients (17 male), mean (SD) age 67 (7), height 165 (10), weight 74.8 (18.2) 
and FEV1% predicted 57 (18). The time between the two measurements was mean 
(SD) 7 (1) days. 
A normality test showed that the variable was normally distributed as the p value 
showed no significant difference between the patients (p>0.05). The repeated 
measures ANOVA showed no variability between subject measurements of cf-PWV, 
as demonstrated by the F=0.002 and p=0.965. Similar findings were for CO 
measurements, F=0.002, p=0.965 and SV measurements, F=0.001, p=0.976. This 
suggests that there were no significant differences between the patients (Table 3.1).  
Intra-rater test-retest reliability was analysed using the ICC (3, 1) equation. Between 
days reliability for cf-PWV was 0.96 (95% CI: 0.93- 0.98). Similarly for CO (0.93, 95% 
CI: 0.89- 0.97) and similar SV, 0.94 (0.94, 95% CI: 0.89-97). The relationship between 
the first and second visits cf-PWV was examined using a scatter plot with an R² of 
0.87 (Figure 3.1). The relationship between the two occasions of CO and SV was 
plotted using a scatter plot (Figures 3.3) and (Figure 3.5), respectively. The R² 
between CO and SV measurements was 0.91 and 0.88. This means that 90% and 
88% of the variance was shared between the first and second measurements of CO 
and SV, respectively.  
For all the outcome measures, the majority of the points were also close to the line of 
best fit. 
The Bland and Altman plot was calculated between the first and second cf-PWV, CO 
and SV. The mean difference and standard deviation with 95%CI of the mean for 
each outcome measure is tabulated (Table 3.2). Their difference was plotted on a Y-
axis against their mean on an X-axis. The cf-PWV plot showed that all but two 
patients fell within the 95%CI limit of agreement (Figure 3.2). The plot also revealed 
that there was no systematic bias in the differences between visits, as the zero value 
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was included in the 95%CI. The plot for CO (Figure 3.4) and SV (Figure 3.6) showed 
no systematic bias, as the zero value was included in the 95%CI and the points were 
distributed evenly around the mean, with minimal random error. The plot showed two 
clear outliers for each outcome measure. 
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Table 3.1: Physiological characteristics of patients at both visits 
 First Visit 
Mean (SD) 
Second Visit 
Mean (SD) 
p value 
Aortic PWV (m/sec) 9.7 (2.2) 9.7 (2.2) 0.965 
Cardiac Output (L/min) 5.7 (1.1) 5.6 (1.1) 0.965 
Stroke Volume (ml) 84 (20) 82 (20) 0.976 
Peripheral SBP (mmHg) 138 (18) 135 (16) 0.347 
Peripheral DBP (mmHg) 76 (8) 74 (9) 0.135 
Central SBP (mmHg) 127 (17) 125 (13) 0.331 
Central DBP (mmHg) 77 (9) 76 (8) 0.255 
Heart Rate (bpm) 70 (16) 72 (14) 0.696 
Abbreviations: PWV= pulse wave velocity; SBP= systolic blood pressure;  
  DBP= diastolic blood pressure. 
 
Table ‎3.2: Limit of Agreement Calculation of Outcome Measures 
Outcome Measure Mean Difference (SD) Limit of Agreement 
Aortic PWV (m/s) 0.01 (0.83) -1.62_1.62 
Stroke Volume (ml) 2.07 (7.34) -12.32_16.46 
Cardiac Output (L/min) 0.061 (0.35) -0.75_0.62 
Data presented as mean difference (SD) and 95%CI. 
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Figure ‎3.1: The relationship between the first and second measurement of carotid- 
femoral pulse wave velocity 
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Figure 3.2: Bland and Altman plot showing between day differences in carotid-femoral 
pulse wave velocity 
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Figure ‎3.3: Relationship between first and second visits of Cardiac Output 
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Figure 3.4: Bland and Altman plot showing between day differences in Cardiac Output 
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Figure ‎3.5: Relationship between first and second visits for Stroke Volume 
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Figure 3.6: Bland and Altman plot showing between day differences in Stroke Volume 
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3.3.4 Discussion 
Reliability of Carotid-femoral Pulse Wave Velocity 
Patients with COPD are known to have elevated aortic stiffness and this may have a 
bearing on repeatability (Sabit et al., 2007). However, in this study, the measurement 
of aortic PWV showed excellent repeatability. The results obtained from the repeated 
measurements of ANOVA indicate that there was no significant difference in carotid-
femoral PWV measurements between a week interval. This may have been as a 
result of the standardisation protocol used in this research.  
The present study was designed to evaluate the stability (day-to-day) and reliability of 
carotid-femoral PWV measurements. There were two types of variability associated 
with this measure: systematic bias and random error. A systematic pattern in the data 
is characterised by data spreading in either a positive or a negative direction, and this 
can indicate whether a learning effect exists. Random error reflects the biological and 
mechanical variation inherent in the measurements and is characterised by the 
magnitude of the spread around the mean difference. Close examination of the Bland 
and Altman plot indicates no evidence of any learning effect and minimal error for 
carotid-femoral PWV. The mean difference between intra-operator test-retest is 
approximately zero (i.e. 0.01m/s). Relating this to normal clinical practice, this 
difference is practically non-significant in terms of making changes to clinical decision-
making.  
The repeatability of carotid-femoral PWV in patients with COPD using the 
SphygmoCor device is similar to that recently reported by Stone and co-authors 
(2013) using the Vicorder device. However, the present study was power calculated 
and used the most robust statistical test to examine the reliability. Using the same 
device, Wilkinson et al. (1998) showed a large variation between the two 
measurements taken by the same operator demonstrated by the large standard 
deviation of the mean difference, which is reflected in the limits of agreement. This 
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variability was even maintained between operators. The inconsistency between 
readings could be related to an inexperienced operator, who may have had difficulty 
palpating and positioning the probe on the femoral artery. Similarly, in ter Avest et al. 
(2005) study, variability was observed between morning and afternoon 
measurements. Owing to a discrepancy between the measurement sides (i.e. right 
carotid artery and left femoral artery) and method of distance measurement, this may 
explain the variability. The results of this study are consistent with those obtained by 
Frimodt-Moller et al. (2008), who investigated the repeatability of aortic stiffness in 
patients with renal failure on two different occasions within a week between the 
measurements. Despite the bias of 0.7m/s that they found in their measurements, 
they showed good repeatability. 
Although COPD is a heterogeneous disease with day-to-day variability in patients' 
physiological status, this study has demonstrated high intra-operator test-retest 
repeatability of carotid-femoral PWV using a well controlled standard protocol. Since 
carotid-femoral PWV is a reproducible measure in patients with COPD, it appears to 
be a useful measure to assess and monitor cardiovascular risk in this study. However, 
blood pressure should be taken into consideration when analysing the results. Hence, 
increases in distending pressure, increases carotid-femoral PWV and therefore PWV 
should be adjusted for changes in blood pressure (Laurent et al., 2006).  
 
  
 110 
 
Reliability of Cardiac Haemodynamics 
Cardiac haemodynamics are primary parameters for the evaluation and monitoring of 
cardiac performance; their measurement in clinical settings helps to quantify the 
presence and degree of CVD. The results of this study showed the ability of the 
NICOM system to measure the CO and SV accurately and non-invasively in patients 
with COPD over time. Adoption of any measurement technique for clinical use 
must show adequate between-day stability, since chronic disease management relies 
on repeated test paradigm analyses. Considering the heterogeneity of COPD, the 
NICOM system showed excellent stability over time. As no previous study has 
examined the repeatability of this device in patients with COPD, so no comparison 
could be made. However, the reliability results for the current study are consistent with 
the findings of a previous study of young healthy individuals (Elliott et al., 2010). In 
this study, Elliott and colleagues (2010) reported a high ICC of 0.94 for triple 
measurements of CO during the same visit. However, they did not report the amount 
of variability between the measurements. 
Patients with COPD are at increased risk of heart failure and CVD (Rutten et al., 
2005b). Increasing evidence suggests that CO and SV can be reduced in patients 
with COPD, even in the mild stage of airway obstruction. Similarly, patients with heart 
failure share the same features (Williams et al., 2001). Manifestations of cardiac 
damage and dysfunction may not be obvious in the early stages during routine clinical 
assessment in primary care settings; therefore, the progression of subclinical cardiac 
damage can eventually lead to heart failure (Barr et al., 2010, Sabit et al., 2010a, 
Watz et al., 2008). Clinically, early detection of these changes plays a vital role in 
providing accurate management of these patients by reducing their rate of morbidity 
and mortality-related CVD (Sin and Man, 2005). 
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Furthermore, augmentation of cardiac haemodynamics with other clinical 
measurements, such as aortic stiffness in routine clinical practice may provide good 
insights into left ventricle function and cardiac subclinical abnormalities. Patients with 
COPD and suspected heart failure are at high risk of left ventricle dysfunction (Rutten 
et al., 2005b). Therefore, the NICOM system makes it possible to quantify cardiac 
performance in primary care settings and to stratify patients who are at risk of 
developing CVD or heart failure, and thus to enhance management. 
Given that the NICOM system is independent of the operator and does not need the 
patient‘s participation, and also because of its rapidity, simplicity and accuracy, this 
system can provide the physician with clear information about heart performance in 
patients with COPD.  
Study Limitation 
The reliability results of arterial stiffness and cardiac haemodynamics were based on 
a single operator measurements, therefore, these results could not extrapolated to 
inter-rater reproducibility.  
Conclusion 
Measurement of aortic PWV and cardiac haemodynamics are simple and non-
invasive and provide valuable information about vascular wall properties and cardiac 
performance, respectively. Given the increased cardiovascular risk in COPD 
population, using such assessment tools in routine clinical practice could yield to early 
identification of patients who are high risk of developing CVD and implement 
appropriate management. The assessment of these outcome measures is also useful 
for monitoring patient‘s condition and treatment.  
  
 112 
 
3.4 Assessment of Repeatability and Validity of Quantitative Ultrasound Scan 
in COPD 
3.4.1 Background 
Osteoporosis defined as  a systemic skeletal disease characterised by diminished 
bone mineral density (BMD) and/or deterioration of the microarchitecture, leading to 
increased bone vulnerability to fractures (Biskobing, 2002). It is common in COPD 
estimated to be two to five times more prevalent than controls similar in age and sex 
(Bolton et al., 2004, Sabit et al., 2007).   
The mechanistic links between osteoporosis to COPD is poorly understood. However, 
both diseases share similar risk factors, including use of corticosteroids, systemic 
inflammation, physical inactivity and weight loss (Barnes and Celli, 2009). In addition, 
a decline in FEV1 is associated with an increased risk for osteoporosis and fracture 
(Graat-Verboom et al., 2009, Jorgensen and Schwarz, 2008). As osteoporosis 
develops insidiously, it often remains undiagnosed until a fracture occurs, with 
significant morbidity and mortality. Developing a prevention strategy that involves 
early detection and aggressive management to reduce the risk for osteoporotic 
fracture could benefit patients and reduce healthcare cost. This is of particular 
importance in patients with COPD, who are at greater risk of compromised lung 
function or adverse events with surgery (Bapoje et al., 2007, Schlaich et al., 1998). 
Currently, the gold standard to assess osteoporosis non-invasively is a dual-energy x-
ray absorptiometry (DXA) scan, which measures bone mineral density (BMD) at the 
lumbar spine and hip to monitor the efficacy of the treatment and predict the fracture 
(Blake and Fogelman, 1998). Nevertheless, the DXA only measures BMD, which is 
only one feature of bone structure, and may fail to detect deterioration of the 
microarchitecture of bone and the presence of osteoporosis (Siris et al., 2004). In 
addition, access to the DXA scan is limited and requires considerable time and 
expertise and therefore is not cost effective for screening. An alternative, which does 
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not emit radiation and has potential to identify individuals at high risk of fracture is the 
use of quantitative ultrasound (QUS) measurement of the calcaneus (Pluijm et al., 
1999). Unlike the DXA scan which measures the BMD, the calcaneus ultrasound bone 
analyser (CUBA) measures the microstructure of the bone by broadband ultrasound 
attenuation (BUA). Osteoporosis is predominantly observed in cancellous bones, 
which are metabolically active tissue and affected by age and disease. The calcaneal 
and hip bones share similar bone structure and mechanical loading during daily 
activity. In addition, the calcaneal bone is relatively free from the soft tissue and easily 
accessible. The precision and potential diagnostic ability of the CUBA ClinicalTM 
scanner has been demonstrated in several studies (Cook et al., 2005, Cryer et al., 
2007, Greenspan et al., 1997, Stewart and Reid, 2000). Additionally, the CUBA 
scanner has shown the ability to predict hip and osteoporotic fracture (Khaw et al., 
2004, Pluijm et al., 1999). Although the CUBA scanner has shown promising results to 
identify patients with osteoporosis or predict fractures, its reliability and validity has not 
been established in the COPD population.  
Hypothesis 
As patients with COPD are at high risk of developing osteoporosis and due limited 
resources and high cost of the DXA scan, the CUBA scanner would provide a reliable 
and valid measurement of heel bone density. 
Aim 
This study aimed to examine the repeatability of the CUBA scanner for measuring 
heel bone density and its sensitivity and specificity when compared to the hip DXA 
scan results. 
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3.4.2 Methods 
Subjects 
A sub-group of patients were recruited from the ARACDE study when they were 
clinically stable with no exacerbation in the preceding four weeks. An exacerbation 
was defined as ―an event in the natural course of the disease characterised by a 
change in the patient‘s baseline dyspnoea, cough and/or sputum beyond day to day 
variability sufficient to warrant a change in management‖ (GOLD, 2014). Exclusion 
and inclusion criteria were detailed previously (Chapter 2, Table 2.1, p 59). Patients 
gave written informed consent and the study had approval from the South East Wales 
Research Ethics Committee. 
Anthropometry Measurement 
All patients had their height measured barefoot using a stadiometer (Seca; Vogel & 
Halke, Hamburg, Germany). Weight and body composition were recorded with 
patients wearing lightweight clothing and barefoot using a single frequency segmental 
bioelectrical impedance analyser (BC-418 MA, Tanita Corp., Tokyo, Japan) (Chapter 
2:2.3.1, p 68). 
Heel Bone Density Measurement 
The heel bone density was assessed using the CUBA ClinicalTM (McCue Ultrasonics, 
Winchester) (Chapter 2:2.3.2, p 68).  
Bone Mineral Density Measurement 
Patients with a diagnosis of osteoporosis who were recruited into the ARCADE study 
and had the DXA scan within one year from the initial visit was taken and included in 
the analysis. The mean BMD at the lumbar spine and hip sites were recorded 
according to standard clinical practise by DXA scan at UHW Cardiff (Chapter 2:2.3.11, 
p 83). The BMD at all sites was recorded as an absolute figure (g/cm2) and as a 
standardised T and Z score.  
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Pulmonary Function Tests 
All patients completed post-bronchodilator spirometry and the forced expiratory 
volume in 1 second (FEV1), the forced vital capacity (FVC) and FEV1/FVC ratio were 
recorded (Vitalograph alpha, Bucks, UK) (Chapter 2:2.3.5, p 80).  
Statistical Analyses 
All analyses were carried out using SPSS software (version 18.0; SPSS Inc, Chicago, 
IL). Data was checked for normality using a Kolmogorov-Smirnov test.  
Reliability 
Normally distributed data was presented as mean (SD). Reliability was examined 
using repeated measures analysis of variance (ANOVA), intra-correlation coefficient 
and Bland-Altman plot. The p value was set at <0.05 and ICC > 0.75.   
Validity 
The sensitivity (proportion of patients correctly identified as having osteoporosis) and 
specificity (proportion of patients correctly identified without osteoporosis) of the 
CUBA scan was determined and compared with the gold standard DXA scan. The 
positive predictive value (the proportion of patients with positive CUBA scan findings 
who had osteoporosis) and negative predictive value (proportion of participants with 
negative CUBA scan findings who did not have osteoporosis) were expressed as 
percentages. The cut-off points were determined by 90% of sensitivity as an upper 
limit and 90% specificity as a lower limit by the receiver operating characteristics 
(ROC) curve.  
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3.4.3 Results 
Reliability 
The between-day repeatability study included 30 (17 male) patients, mean (SD) age 
67 (7), height 165 (10), weight 74.8 (18.2) and FEV1% predicted 57 (18). The period 
between measurements was mean (SD) of 7 (1) days. 
The repeated measures ANOVA indicated no variability between patient‘s 
measurements as demonstrated by F-value (0.282) and P-value (0.599). The 
between-day ICC was 0.81 (95%CI: 0.63-0.90). The Bland-Altman plot mean 
difference between repeated measures was 1.36 (14) dB/MHz and the 95%CI was 
between -28.92 and +26.32 dB/MHz. All except two patients fell between the 95%CI 
limits of agreement and there was no systematic bias as the points distributed evenly 
around the mean (Figure 3.7).  
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Figure ‎3.7: Bland and Altman plot showing between day differences in Broadband 
Ultrasound Attenuation Measurement 
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Validity 
Of the 48 patients who underwent the CUBA and DXA scans, 8 had a normal scan, 28 
had osteopenia and 12 had osteoporosis according to DXA scan. Mean age was 68 
(7), FEV1% 57 (18), BUA 49 (17) dB/MHz, heel T-score -2.44 (1.02), hip BMD 0.72 
(0.11) g/cm2 and hip T-score -1.84 (0.80). The BUA correlated with hip BMD (r=0.38, 
p=0.01) and hip T score (r=0.35 p= 0.02), and CUBA T score related to hip BMD (r= 
0.39, p= 0.01) and hip T score (r=0.35, p= 0.01). 
In the first analysis, those patients who had a left hip DXA T- score of <-1 were 
classified as positive bone mass loss, while those who had a normal bone 
densiometry were considered as negative cases. Using the manufacture cut- off point 
of  T score between -2 and -1 as a positive indication of loss of bone density, the 
CUBA scan identified 38 out of 40 patients as having bone mineral density loss with 
95% sensitivity and 13 % specificity (Table 3.3).  
Using the receiver-operating characteristic curve to determine the best sensitivity and 
specificity values for the CUBA clinical machine to identify bone mass loss in this 
population, the cut-off value was -2.66 and the area under the curve was 0.752 
(95%CI: 0.580 to 0.923) (Figure 3.8). According to this value, out of 40 patients with 
bone mass loss, only 15 patients were identified, with 38% sensitivity and 100% 
specificity (Table 3.4).The accuracy of this machine based on the sensitivity and 
specificity analysis was 48%. 
The second analysis, the ROC curve was used to determine the best sensitivity and 
specificity for the CUBA scanner to identify patients with osteoporosis (Figure 3.9). 
Patients who were classified as ―osteopenic‖ were excluded from the analysis. From 
this analysis, the cut-off T-score for the CUBA scanner based on 90% sensitivity and 
90% specificity was -2.74. The area under the curve was 0.750 (95%CI: 0.522 to 
0.968). Based on this cut-off point, the CUBA detected 7 out of 12 patients with 
osteoporosis; however, it did not misclassify any patient as osteoporotic (Table 3.5). 
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In comparison to the ROC curve cut-off, the recommended cut-off value set by the 
manufacture to diagnose osteoporosis revealed that this machine had a sensitivity 
and specificity of 75% and 63%, respectively. The positive predictive value was 75% 
where the negative predictive value was 63%. The percentages of incorrect diagnosis 
(i.e. false negative and false positive values) were equal 15%. 
Combining the two analyses, a T-score between -2.73 to -1 indicated loss of bone 
mass in patients with COPD where a T-score of -2.74 or below suggested 
osteoporosis.  
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Table ‎3.3: Sensitivity and Specificity calculation for bone mass loss based on the 
manufacture recommendation 
CUBA scanner DXA scanner  
 Normal Bone Mass loss Total PPV NPV 
Normal 1 2 3  33% 
Bone Mass Loss 7 38 45 84%  
Total 8 40 48   
 Specificity=13% Sensitivity =95%  FP=15% FN=4% 
  Abbreviations: CUBA= Calcaneal Ultrasound Bone Analyser; DXA= Dual-energy X-ray 
Absorptiometry; PPV= positive predictive value; NPPB= negative predictive value. 
 
Table ‎3.4: Sensitivity and Specificity calculation for bone loss based on the ROC curve 
CUBA scanner DXA scanner  
 Normal Bone Mass loss Total PPV NPV 
Normal 8 25 33  24% 
Bone Mass Loss 0 15 15 100%  
Total 8 40 48   
 Specificity=100% Sensitivity =38%  FP=0% FN=52
% 
  Abbreviations: CUBA= Calcaneal Ultrasound Bone Analyser; DXA= Dual-energy X-ray   
Absorptiometry; PPV= positive predictive value; NPP= negative predictive value. 
Table ‎3.5: Sensitivity and Specificity calculation for osteoporosis based on the ROC 
curve 
CUBA scanner DXA scanner  
 Normal Osteoporosis Total PPV NPV 
Normal 8 5 13  62% 
Bone Mass Loss 0 7 7 100%  
Total 8 12 20   
 Specificity =100 Sensitivity =58%  FP=0% FN=25
% 
Abbreviations: CUBA= Calcaneal Ultrasound Bone Analyser; DXA= Dual-energy X-ray 
Absorptiometry; PPV= positive predictive value; NPP= negative predictive value. 
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Figure ‎3.8: Receiver Operating Characteristics Curve for determining cut-off values for 
bone mass loss 
 
Figure ‎3.9: Receiver Operating Characteristics Curve for determining cut-off values for 
osteoporosis 
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3.4.4 Discussion 
The CUBA ClinicalTM scanner demonstrated an excellent between-day repeatability of 
heel bone density in patients with COPD, with a slight variability between the 
measurements. It also showed the ability to identify patients with loss of bone mass 
and excluded those who do not have osteoporosis. 
Adoption of any measurement tool for use in clinical practice must show adequate 
between days repeatability to identify changes in chronic disease. The Bland-Altman 
plot showed some variability between the measurements of the patients, though 
consistency was optimised, as it should be according to the manufacture 
recommendations. However, previous studies have suggested that results may be 
influenced by the size and width of the foot as well as the position of the ankle (Cheng 
et al., 2002, Greenspan et al., 1997). As no previous study has examined the 
repeatability of this device in patients with COPD, no comparison could be made. Two 
previous studies examined inter-operator measurements precision of the CUBA 
scanner and found this scanner has less variability between the measurements. 
Although, these studies used the coefficient of variation, which can underestimate 
repeatability, the results of the current study are still comparable with their findings 
(Greenspan et al., 1997, Stewart and Reid, 2000).  
The correlation between the CUBA clinical scan and DXA scan is similar to other 
previous studies with consideration of different anatomical sites (Naganathan et al., 
1999, Stewart and Reid, 2000, Cook et al., 2005, Cryer et al., 2007). The 
discriminatory ability of the CUBA scanner to identify patients with bone loss showed 
a good correlation between the CUBA clinical scan and DXA scan. For a useful 
clinical diagnostic test in case of a common comorbidity in COPD such as 
osteoporosis, obtaining high sensitivity is usually recommended. Thus, the results of 
this study showed that this machine had a sensitivity of 95% and specificity of 13%. 
This means if bone mass loss is diagnosed by the CUBA scanner, it is likely to be true 
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(84%). However, only 33% will be classified as a disease free if the results are 
negative. This has changed notably when the cut-off values were set by the ROC 
curve values. The ability to diagnose loss of bone mass decreased to an 
unacceptable value of 38%, but the specificity increased markedly to 100%. 
Therefore, the 8 patients with normal bone density were identified by both the DXA 
and the CUBA scanner. 
For clinical use, a screening test should demonstrate a good sensitivity to rule out any 
patient who does not have the disease. Balancing between the false positive and 
false negative obtained from both cut-off levels, the identification of patients with early 
stage of bone mass loss using the CUBA scan could be based on a T score of -1 or 
below as proposed by manufacture and international osteoporosis foundation (IOF) 
recommendations (Vasikaran et al., 2011). Using this value, the clinician can be 84% 
confident that the patient has some degree of bone weakness and worthy of further 
investigation. The data produced by the ROC curve analysis, to determine the ability 
of the CUBA clinical scanner to identify osteoporosis, showed that the CUBA scanner 
can exclude patients without osteoporosis. Nevertheless, to keep the incorrect 
diagnosis of osteoporosis to a minimum, both cut-off values set by the ROC analysis 
and manufacture maintain the false negative results to its minimum (25%). Even a 
false positive value, should not be ignored, as the CUBA scanner may give different 
information about trabecular bone mass and its density and early changes in bone 
microstructures could be demonstrated in the heel bone before it can be detected by 
the DXA scan at the hip region. Several studies have found that low BUA is an 
independent risk factor for hip and osteoporotic fracture. 
The current study findings are in agreement with Stewart and Reid (2000) study, who 
found that the CUBA scanner has the ability to discriminate between those with loss of 
bone mass and who have apparently healthy bone. In contrast, Naganathan et al. 
(1999) found the CUBA scanner was unable to identify people with bone mass loss.  
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Measuring the BUA at the heel area appears to predict the loss of bone mass at the 
hip region and this is because these bones share similar anatomical and 
biomechanical characteristics. The sensitivity and specificity of the CUBA scanner has 
been examined by several studies to identify subjects with osteoporosis, but 
conflicting results have been reported. The results of this study are consistent with 
Stewart and Reid (2000) and Cryer et al. (2007) studies who found a high sensitivity 
(94% and 90%, respectively) of the CUBA scanner to identify subjects with 
osteoporosis. In contrast to the present findings and previous two studies, 
Naganathan et al. (1999) found this machine had a limited sensitivity to diagnose 
osteoporosis (33%) in postmenopausal women. However, the authors based the 
diagnosis of osteoporosis upon multiple sites and did not specify what area was most 
related to the CUBA clinical scanner; and recent guidelines suggest the hip region as 
the best estimate of osteoporosis (Qaseem et al., 2008). Nevertheless, the certainty, 
i.e. true positive, of this machine to diagnosis osteoporosis is controversial. The 
results of this research are consistent with Stewart and Reid (2000) findings but not 
with Naganathan et al. (1999) and Cryer et al. (2007) studies. Although Naganathan 
et al. (1999) and Stewart and Reid (2000) used the same method as the present 
study, Naganathan and colleagues (1999) did not specify which region was 
osteoporotic. However, Cryer and co-authors (2007) based the diagnosis of 
osteoporosis upon the ulnar BMD results, which is not the recommended site for 
diagnosing osteoporosis. 
The threshold of the CUBA scanner for identifying osteoporosis in patients with COPD 
is similar to Cook et al. (2005) and that recommended by the manufacturer, whereas 
Langton et al. (1997) recommended a slightly lower cut-off value of -1.58 to -1.64. In 
contrast, Naganathan et al. (1999) used a lower cut-off between -2.5 to -1 to diagnose 
osteoporosis.  This discrepancy in the threshold values between the studies is partly 
explained by measuring different sites to diagnose osteoporosis. 
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The CUBA scanner is a useful device to measure the changes in bone mass and 
microstructure of patients with COPD. Although it had moderate ability to identify 
patients with osteoporosis, it was precise to exclude those who did not have 
osteoporosis. Putting this in a clinical context, this machine could be used as a 
screening tool to identify patients who have some degree of bone mass weakness 
when the T-score falls between -2.73 and -1. However, if the T-score is below -2.74, 
the patient is more likely to have osteoporosis and worth further investigation. The 
CUBA scanner could be used for a case finding approach to identify patients at low or 
high risk and need further investigation. This will move the strategy from identification 
to prevention of osteoporosis and its complications, as osteoporosis is common in 
patients with COPD, yet often not diagnosed until a fracture occurs. Furthermore, due 
to limited resources, the DXA scan is not accessible in primary care settings, making 
this simple and portable device feasible to screen patients for changes in bone 
architecture and excludes the possibility of osteoporosis.  
Study Limitations 
Although the DXA and CUBA scans were not undertaken on the same day, they were 
within one year, where appreciable change of BMD is unlikely. The measurement of 
the BUA was obtained using the ankle whereas the BMD was measured over the top 
part of the hip, which may differ in the presence of osteoporosis. However, as an 
easily accessible weight bearing bone, the heel may be a useful surrogate of BMD.  
Conclusion 
The BUA is a reproducible measure of calcaneal bone density and structure in COPD. 
Given the prevalence of osteoporosis in COPD is high and often undiagnosed, a 
cheap and simple device such as the CUBA ClinicalTM could be useful in primary care 
for screening patients with increased risk of loss of bone density and reducing the 
number of referral to the hospital for the DXA scan. Such a device could be feasible in 
promoting prevention strategy, treatment and management of osteoporosis in COPD. 
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4 Chapter Four 
A Simple and Rapid Test of Physical 
Performance in Chronic Obstructive 
Pulmonary Disease. 
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4.1 Background 
A major impact of chronic obstructive airway disease (COPD) is the progressive loss 
of physical performance, which may lead to disability with loss of the ability to perform 
routine activities of daily living (Eisner et al., 2008). Reduced physical activity occurs 
even in mild severity airflow obstruction and continuous activity monitoring has 
demonstrated that patients spend less time walking and standing than healthy 
controls (Gouzi et al., 2011, Watz et al., 2009).  In addition to the impact on functional 
status, physical inactivity is associated with a reduced health related quality of life 
(HR-QoL), and contributes to loss of muscle mass, osteoporosis and cardiovascular 
disease, all co-morbidities of COPD (Barnes and Celli, 2009). Consequently, it 
becomes part of a vicious cycle of physical inactivity and changes in body composition 
that affect physical performance (Barnes and Celli, 2009). 
The assessment of physical performance in patients with COPD in routine clinical 
practice is challenging and often poorly quantified, and the progressive loss of airways 
function, particularly the forced expiratory volume in one second (FEV1) is a poor 
predictor of physical impairment (Kapella et al., 2011). Breaking the cycle of physical 
inactivity and detrimental changes in body composition could have major impacts on 
HR-QoL and earlier life-style interventions may maintain physical activity and normal 
body composition. 
Physical performance in COPD has been assessed by various methods including 
questionnaires, which may have limited reproducibility and validity due to their 
dependence on patient recall. Quantitative measures of physical performance include 
the six minute walking distance (6MWD), the incremental shuttle walk test and cycle 
ergometry (Palange et al., 2007, Revill et al., 1999). The 6MWD is commonly used in 
clinical research and provides a measure of sub-maximal physical performance. 
Although, the 6MWD is a validated measure and reflects daily activity, it is not widely 
used in clinical practice owing to the requirement for substantial time, space and
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expertise (Glaab et al., 2010). The Timed Up and Go (TUG) test has been used to 
assess physical function in the elderly (Savva et al., 2013). It is a relatively simple and 
reproducible test that assesses balance, gait speed and physical performance and 
can predict the risk of falls, functional activity and frailty in the older population 
(Podsiadlo and Richardson, 1991, Viccaro et al., 2011). The TUG test is also 
responsive to a rehabilitation intervention (Brooks et al., 2006). It has not been applied 
widely in COPD, but it has demonstrated to identify patients with COPD with reduced 
balance, co-ordination and an increased risk of falls similar to findings in the elderly 
(Beauchamp et al., 2009). Thus, the TUG may reflect routine daily activities, which 
require the integration of strength and balance.  
Hypothesis 
The TUG test would be prolonged in patients with COPD, compared with a non-COPD 
comparator population. Additionally, the TUG would be a predictor of the 6MWD. 
Aim  
This study aimed to assess the feasibility of using TUG test as an integrated measure 
of physical mobility in patients with COPD when compared to 6MWD.  
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4.2 Methods 
Subjects 
Five-hundred patients with COPD confirmed with spirometry and 150 comparators 
either current or ex-smokers free from respiratory disease were recruited from the 
Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE) study. Patients 
and comparators were recruited following the inclusion and exclusion criteria detailed 
previously (Chapter 2: Table 2.1, p 65). All subjects gave written informed consent 
and the study had approval from the South East Wales Research Ethics Committee. 
Anthropometry and Body Composition Measurement 
All subjects had their height measured barefoot using a stadiometer (Seca; Vogel & 
Halke, Hamburg, Germany). Weight and body composition were recorded with 
subjects wearing lightweight clothing and barefoot using a single frequency segmental 
bioelectrical impedance analyser (BC-418 MA, Tanita Corp., Tokyo, Japan) (Chapter 
2:2.3.1, p 68). Body mass index (BMI), fat free mass (FFM) and fat mass (FM) were 
also determined. Waist and Hip circumferences were measured with a stretch 
resistance tape.  
Pulmonary Function Tests 
All subjects completed spirometry and the forced expiratory volume in 1 second 
(FEV1), the forced vital capacity (FVC) and FEV1/FVC ratio were recorded 
(Vitalograph alpha, Bucks, UK) (Chapter 2:2.3.5, p 80).  
The level of breathlessness was scored using the modified Medical Research Council 
(MRC) dyspnoea scale.   
In the patients, the number of exacerbations, defined as an acute worsening of 
respiratory symptoms characterised by the increase of any combination of three key 
symptoms, which necessitate a change in regular medication, in the last year was 
recorded (Rabe et al., 2007). 
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Six Minute Walk Distance 
The 6MWD was carried out in accordance with a protocol adapted from the American 
Thoracic Society (ATS) guideline (2002) using a 30-m level, straight indoor track 
(Chapter 2:2.3.7, p 81).  
Timed Up and Go  
All subjects undertook the TUG test using a standard chair and standardised 
instructions (Chapter 2:2.3.6, p 79). The task was to be performed at their normal 
comfortable pace and the time recorded in seconds. 
Handgrip Strength Measurement 
Maximal right and left handgrip strength (HGS) was determined twice in each hand 
using a hand dynamometer (T.K.K. 5401 grip-D, Takei, Japan) (Chapter 2:2.3.8, p 
84). 
Health Related Questionnaire 
Patients completed the St George‘s Respiratory Questionnaire (SGRQ) and the 
COPD assessment test (CAT), both validated questionnaires to assess the impact of 
COPD on their health status (Chapter 2:2.3.9, p 82).  
Inflammatory Biomarkers 
A blood sample was obtained for determination of C-reactive protein (CRP, high 
sensitivity) and fibrinogen by standard assays (Dept. Biochemistry, University Hospital 
of Wales). 
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Statistical Analysis 
The statistical software package SPSS 18.0 (Chicago, Illinois, U.S.A.) was used for all 
analysis. Data were checked for normality prior to analysis using a Kolmogorov-
Smirnov test. Results are presented as arithmetic or geometric (for non-normally 
distributed) and standard deviation (SD). Comparisons between patients and 
comparators were performed using analysis of variance (ANOVA). Categorical data 
was analysed using the Chi-square test. Relationships between variables were 
explored using Pearson‘s and Spearman correlation coefficients. Multivariate analysis 
was performed using a stepwise multiple regression model. For all analysis p<0.05 
was considered significant. Receiver operating characteristics (ROC) curve was 
performed to determine the diagnostic ability of the TUG test for discrimination 
between stable patients with COPD and community population.  
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4.3 Results 
The patients and comparators were similar in age, gender ratio and BMI. The patients 
had a greater tobacco exposure, lower mean FEV1, FVC and resting oxygen 
saturation than the comparator group, all p<0.001 (Table 4.1). The severity of airflow 
obstruction by GOLD stratification was: GOLD 1 n=73, GOLD 2 n=251, GOLD 3 
n=144 and GOLD 4 n=32 and the distribution of the modified MRC breathlessness 
score was: mMRC 0 n=65, mMRC 1 n= 172, mMRC 2= 97, mMRC 3 n=121 and 
mMRC 4 n= 44.  
Measures of Physical Performance  
The patients had a greater TUG, 11.1 (3.7) s than comparators 8.2 (1.2) s, p<0.001, 
however, there was no difference in the TUG for males and females in either group, 
p>0.05. The TUG in the patients was weakly related to the FEV1% predicted (r= -0.14, 
p<0.01), oxygen saturation (r= -0.12, p<0.03) and mMRC dyspnoea score (r= 0.28, p< 
0.001). 
The TUG was related to age in patients (r=0.13, p=0.003) and comparators (r=0.21, 
p=0.01). The patients had greater TUG than the comparators across all the age 
decades <50-80, all p<0.001 (Figure 4.1). Using the upper 95%CI (8.5) s for the 
comparator as a cut-off value for the non-COPD range demonstrated that only 101 of 
the 500 patients had a TUG within the comparator reference range. 
The 6MWD and HGS were less in patients than comparators, both p<0.001 (Table 
4.1). In the patients, the TUG was inversely related to the 6MWD (r=-0.71, p<0.001) 
and HGS (r=-0.24, p<0.001), but only to the 6MWD in comparator subjects (r=-0.38, 
p<0.001). The 6MWD, HGS and TUG were all related to each other in the patients, all 
p<0.001. 
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Table 4.1: The characteristics of patients with COPD and comparator subjects 
 COPD (n=500) 
(n= 500) 
Comparator (n=150) 
(n= 150) 
p value 
Gender Male:Female 255:245 75:75 0.451 
Age (years) 66 (7) 65 (8) 0.125 
Smoking (pack-years) 40.6 (25.5) 21.4 (17.9) 0.001 
FEV1 (L) 1.64 (0.84) 2.73 (0.67) 0.001 
FVC (L) 2.50 (0.98) 3.50 (0.90) 0.001 
FEV1/FVC (L) 0.53 (0.11) 0.78 (0.05) 0.001 
FEV1 (%) 59 (21) 105 (13) 0.001 
FVC (%) 87 (21) 110 (15) 0.001 
BMI (kg/m
2
) 28.1 (5.5) 28.3 (4.2) 0.664 
Waist circumference (cm) 100 (15.0) 95 (13) 0.001 
Waist:Hip ratio 1.0 (0.1) 0.9 (0.1) 0.001 
Handgrip (kg) 27.1 (9.9) 31.0 (10.2) 0.001 
FFM (kg) 49.6 (11.0) 52.2 (9.5) 0.011 
FFMI (kg/m
2
) 18.1 (2.6) 18.5 (2.3) 0.088 
Fat mass (kg) 26.9 (11.1) 26.9 (8.6) 0.985 
6MWD (m) 324 (124) 502 (86) 0.001 
TUG (s) 11.1 (3.7) 8.2 (1.2) 0.001 
Resting O2 saturation (%) 97 (2) 98 (1) 0.001 
Fibrinogen (g/L)# 3.51 (1.31) 3.08 (1.25) 0.001 
CRP (mg/L)# 3.49 (2.89) 1.76 (3.18) 0.001 
All data mean (SD) unless otherwise indicated, # Geometric mean  
Abbreviations: FEV1= forced expiratory volume in 1 second; FVC= forced vital capacity;  
BMI = body mass index; HGS= handgrip strength; FFM= fat free mass;   FFMI = fat free mass 
index; 6MWD= six minute walk distance; TUG= Timed Up and Go; CRP= C - reactive protein. 
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Figure 4.1: TUG test across age categories in COPD and comparator subjects 
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Body Composition and TUG Test 
The TUG was related to BMI (r=0.24, p<0.001), FM (r=0.22, p< 0.001), FMI (r=0.21, 
p<0.001) and the waist to hip ratio (r= 0.13, p=0.01), in the patients group, but there 
was no relationships between these variables and TUG in the comparator group. Both 
TUG and 6MWD were related to FFM:FM ratio, r=-0.13, p=0.01, r=0.11, p=0.04, 
respectively, in the patients, but only with 6MWD in comparators (r=0.34, p<0.001). 
Health Related Questionnaires and TUG Test  
The TUG and the SGRQ total score were related (r=0.35, p<0.001), as were the 
domains of activity (r=0.35, p<0.001), symptoms (r=0.24, p<0.001) and impact 
(r=0.32, p<0.001). The CAT score was also related to the TUG (r=0.34, p=0.001). 
Both the 6MWD and HGS were also related to the total SGRQ score, r=-0.59, 
p<0.001 and r=-0.26, p=0.001, respectively, and similarly to the CAT score r=-0.53, 
p<0.001 and r=-0.27, p<0.001, respectively. 
Systemic Inflammation 
Circulating CRP and fibrinogen were greater in patients than comparators, p<0.001, 
and both were related to the TUG, CRP (rs=0.19, p=0.001) and fibrinogen, (rs=0.17, 
p<0.001), but were unrelated to TUG in the comparator group, p>0.05. In the patients, 
6MWD was also related to both CRP (rs=0.19, p=0.001) and fibrinogen (rs=-0.24, 
p=0.001), while neither biomarker was related to HGS.  
Frequency of Exacerbation 
Of the patients, 207 reported 0-1 exacerbations/ year and 293 reported two or more 
exacerbations/ year. The TUG was related to the frequency of exacerbations (r=0.24, 
p<0.001), and frequent exacerbators had greater TUG, 11.5 (3.5) s, than infrequent 
exacerbators, 10.5 (4.1) s, and both were greater than the comparator group TUG, 
p<0.01 (Figure 4.2).  
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Figure 4.2: The TUG difference between infrequent and frequent exacerbators and 
comparator subjects at initial visit 
  
Data presented as mean with SD  
ANOVA, Bonferonni post-hoc, p<0.01 
  
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
Comparator Infrequent Exacerbator Frequent Exacerbator
Ti
m
e
d
 U
p
 a
n
d
 G
o
 (
s)
 
_____*_____ 
___________________*_____________________ 
_____*_____ 
 137 
 
Predictive Factors for the 6MWD 
In the patients, stepwise multivariate regression analysis after controlling for age and 
BMI showed that TUG, mMRC and CAT score explained 55% of the variability in 
6MWD with FEV1% predicted excluded from the analysis (Adjusted R
2=0.54,F= 
182.80,p<0.001). The TUG explained 41% of the reduction in 6MWD, and mMRC and 
total CAT score explained 27% and 25% of the variability, respectively, all p<0.001.  
Predictive Factors for the TUG 
In the patients, stepwise multivariate regression analysis after correcting for age and 
BMI showed that 6MWD, waist:Hip ratio and HGS explained 45% of the variability in 
TUG with FEV1% predicted, FM and inflammatory biomarkers excluded from the 
analysis (Adjusted R2=0.45,F= 61.39,p<0.001). The 6MWD explained 59% of 
prolonged TUG, p<0.001 and waist:Hip ratio and HGS explained 14% and 12% of the 
variability in the TUG, respectively, all p<0.05. 
Diagnostic Ability of TUG Test against 6MWD 
Using the upper 95%CI (8.5 s) of the TUG for the comparator as a cut-off value for 
normal mobility, the TUG test showed an excellent diagnostic ability to predict the 
6MWD as demonstrated by the area under the curve of 0.826 (95%CI: 0.783 to 0.870) 
(Figure 4.3). With 90% sensitivity and 80% specificity, this cut-off value corresponds 
to 360 m on the 6MWD. 
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Figure 4.3: The ROC curve for the TUG test. Diagnostic ability of TUG test in patients 
with COPD 
 
  
 139 
 
4.4 Discussion  
The TUG test is an integrated assessment of physical performance which 
incorporates balance, gait speed and functional capacity (Podsiadlo and Richardson, 
1991). In the present study, the TUG was greater in patients with COPD than a non-
COPD comparator group and age stratified ranges reported in a meta-analysis of 21 
studies in the elderly (Bohannon, 2006). Therefore, by comparing 95%CI of both 
groups, a cut-off point at 8.5 seconds or less is suggested for normal TUG test 
performance in this population. This threshold showed discriminative ability to identify 
patients with less physical performance with an area under the curve of 0.826. 
Similarly, the TUG test was found to predict mobility status and reflect physical 
performance with an area under the curve of 0.969 in community-dwelling elderly 
women (Bischoff et al., 2003). Therefore, in clinical practice, patients who perform the 
TUG test in > 8.5 seconds should receive a further evaluation of their physical status 
and early intervention to avoid subsequent complications related to physical inactivity. 
A prolonged TUG identifies patients with COPD at risk of falls, a status likely to be 
dependent on loss of physical performance, and in the elderly at risk of disability and 
increased mortality (Beauchamp et al., 2009, Idland et al., 2012). The TUG test 
reflects various movements frequently used in everyday activities and its prolongation 
in COPD is a consequence of physical inactivity, skeletal muscle weakness and de-
conditioning in a similar manner to that seen in the elderly. Thus in COPD, the TUG 
test is likely to reflect the presence of co-morbidities affecting body composition and 
similar to other measures of physical performance, independent of the severity of 
airflow obstruction (Watz et al., 2009). This is consistent with a previous study in 
elderly women which found that the TUG test is a measure of the interaction of body 
composition, muscle strength and comorbidities on the physical performance (Bischoff 
et al., 2003). In this study, the TUG was inversely related to the 6MWD, a measure of 
sub-maximal exercise capacity, and HGS as a surrogate marker for muscle strength 
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(Ling et al., 2010). Hence both measures were related to TUG, particularly the 6MWD, 
suggesting that the TUG in COPD similarly assesses impaired functional mobility. 
This interpretation of the longer TUG in the patients is supported by the lower HGS, 
which was associated with reduced physical activity in COPD and in healthy elderly 
populations where it is associated with reduced lower extremity strength, less daily 
activity and predicts future disability (Rittweger et al., 2000). The relationship between 
the increased TUG and SGRQ and CAT score indicates that the TUG reflects the 
impact of physical impairment and inactivity on patients‘ perceptions of their health 
and quality of life (Jones et al., 2009, Jones et al., 1992).   
Altered body composition is an accepted co-morbidity in COPD and interest has 
centred on the importance the loss of skeletal muscle mass and function as a cause 
of impaired physical performance, similar to the sarcopenia and loss of physical 
performance that occurs in healthy ageing (Walston et al., 2002). However, in the 
studied populations, FFM was not related to deficits in physical performance, while 
changes in FM and its distribution were linked in both the patients and comparators. 
The TUG was related to abdominal obesity and FM, which supports the finding that an 
increased FM was the best predictor of functional limitation in COPD (Eisner et al., 
2007, Kapella et al., 2011). Similarly, there is an association between functional 
limitation and FM in the elderly in the UK, in particular abdominal obesity determined 
as waist circumference was a major predictor of disability in similar aged subjects to 
our patients and comparators (Angleman et al., 2006).  
In the present study, the TUG was related to FM and abdominal obesity only in the 
patients. The mechanisms linking FM and abdominal obesity to functional limitation 
may relate to the increased circulating levels of CRP and fibrinogen, which have been 
associated with reduced exercise capacity and impaired left heart function in patients 
with COPD (Watz et al., 2008). The association of the TUG with regional obesity in 
the patients suggests that the components of physical performance measured by the 
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TUG test have a similar relationship to systemic inflammation as other assessments 
used in COPD. Circulating biomarkers, including CRP and fibrinogen, have been 
associated with physical performance decline and cardiovascular risk in older subjects 
(Geffken et al., 2001). Fat produces a variety of pro-inflammatory mediators including 
interleukin-6, a regulator of CRP production and secretion, and is overall likely to be a 
factor in the development of insulin resistance and the increased risk of diabetes 
mellitus and cardiovascular disease in COPD (Barnes and Celli, 2009, Rutten et al., 
2010). Systemic inflammatory biomarkers may also be a factor linking the TUG to the 
frequency of exacerbation when they are likely to increase.   
The finding that the patients‘ TUG was independent of age and was greater than in 
the comparator group when stratified by decades, and published age ranges could be 
interpreted as the loss of physical performance in COPD being further evidence of 
premature ageing and is in keeping with evidence of premature vascular ageing (Sabit 
et al., 2007). Such an interpretation is further supported by the finding that 80% of the 
patient group had a greater TUG than the upper 95%CI of the comparator group. The 
development of co-morbidities in COPD resembles the pattern of accumulating 
deficits, which interrupt normal physiological homeostasis in various systems, a 
feature of ageing (Walston et al., 2002). In the elderly, over 85 years, a TUG in the 
upper 10% of a study population was associated with an increased risk of disability, 
odds ratio 9.02, and mortality confirming that the TUG is a valid indicator of disability 
in natural ageing (Martin-Ruiz et al., 2011).  
The development of co-morbidities is a factor in impaired physical function and 
consequent disability and is clinically important in the management of COPD. Ideally, 
an assessment of physical performance should be part of the assessment of the 
disorder, but most measures of physical performance are difficult to apply in routine 
clinical practice. They often require substantial space, equipment, staff time and some 
patients may not be able to maintain activity long enough to complete an assessment. 
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The rapidity and simplicity of the TUG test suggest that it could be used to assess 
physical performance in the routine clinical settings. Furthermore, in elderly, the TUG 
test has been found to be a responsive measure to a rehabilitation exercise program 
(Brooks et al., 2006, Lihavainen et al., 2012). Combining the TUG test with an easily 
completed validated questionnaire, such as the CAT, as demonstrated here, could 
provide important information about a patient‘s physical performance and functional 
status that is not currently collected.  
Study Limitations 
A key limitation of this study is its cross-sectional nature, which limits understanding of 
the potential of this test in clinical practice. However, a limitation of physical function 
measures is that not all patients are able to complete them, but the short duration of 
TUG removes the endurance issue that limits application of some assessments in 
COPD and experience in the elderly suggests it is a widely applicable assessment.  
Conclusions 
The TUG test is a useful measure to identify limitations of physical performance and 
early signs of disability in the elderly and in COPD. It clearly discriminates between 
patients with COPD and comparators. Implementing the TUG test and simple 
questionnaires in clinical practice may enable clinicians to identify a patient‘s 
functional deficit and facilitate early intervention to improve the patient‘s health status. 
In addition, the TUG test could useful in monitoring adverse effects of 
pharmacological treatment on the musculoskeletal system.  
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Chapter Five 
Cross-sectional and Longitudinal 
Evaluation of Aortic Stiffness in COPD 
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Introduction 
This chapter of the thesis evaluated the aortic stiffness in patients with COPD and 
was divided into two parts: 
The first part was a cross-sectional study to examine aortic stiffness in COPD and 
included all the participants recruited into the ARCADE study at initial visit. 
The second part of this study was a longitudinal study of a group of patients who 
returned for a repeated assessment after they had completed two years from their 
initial visit. 
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5.1 Background 
COPD is a multicomorbidity disease associated with cardiovascular disease (Barnes 
and Celli, 2009). Compelling evidence from large epidemiological studies has found 
that COPD is an independent risk factor for CVD. However, the exact mechanism 
linking COPD to CVD remains poorly understood. Recently, several studies have 
demonstrated that COPD is associated with increased arterial stiffness, which is an 
independent predictor of fatal and non-fatal cardiovascular events (Laurent et al., 
2006, Sabit et al., 2007). 
Although arterial stiffness is increased in COPD, it is unclear how COPD is involved in 
the developing arterial stiffness. Previous mechanistic research in COPD has shown 
inconsistent results and this is not surprising due to methodological variations (Barr et 
al., 2007, Ives et al., 2013, Maclay et al., 2009, Maclay et al., 2012). Nevertheless, all 
these studies support the idea of vascular dysfunction in COPD. Alteration of 
vasculature that is normally associated with ageing has been suggested to happen 
prematurely in patients with COPD, independent of age (Maclay et al., 2009, Maclay 
et al., 2012). Therefore, patients with COPD may demonstrate signs of premature 
ageing either driven genetically or acquired through several mechanisms including 
elastin degradation, oxidative stress or inflammation, which subsequently leads 
premature cardiovascular events, independent of smoking exposure and severity of 
airway obstruction (Barr et al., 2012, Ives et al., 2013).   
Identification of early vascular ageing in COPD may be clinically useful as it reflects 
subclinical features of arterial wall disorder (i.e. sub-atherosclerotic change or pre-
hypertension) that has not been clinically manifested (Alghatrif et al., 2013, Bolton et 
al., 2011, Patel et al., 2013, Sabit et al., 2010a). Aortic pulse wave velocity is an 
accepted measure for vascular function and useful to identify patients with COPD who 
are at increased of cardiovascular risk. Previous cross-sectional studies have linked 
elevated aortic stiffness in COPD to lung function impairment, abnormal body 
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composition and inflammation. However, due to the limitations of these studies, these 
relationships are still questionable. Additionally, as the studies so far have been cross-
sectional in nature, a longitudinal study is needed to confirm these relationships.   
Hypothesis 
Patients with COPD would have greater aortic stiffness than comparators similar in 
age and gender proportion at initial visit. Additionally, the patients would have a rapid 
increase in aortic stiffness after two years from the initial assessment. 
Aim 
This study aimed to prospectively evaluate the effect of COPD on the arterial wall over 
a period of two years, and the rate of change and its contributing factors.  
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5.2 Method 
Part I: 
This was a cross-sectional study of patients with stable COPD confirmed, with 
spirometry, and comparators from the Assessment of Risk in Chronic Airways 
Disease Evaluation (ARCADE) study. Comparators were current or ex-smokers free 
from respiratory disease.  All subjects were clinically stable and free of inflammatory 
disease such as rheumatoid arthritis, oral maintenance corticosteroids and long-term 
oxygen therapy (full inclusion and exclusion criteria in Chapter 2: Table 2.1, p 65). All 
subjects gave written informed consent and the study had approval from the South 
East Wales Research Ethics Committee. 
Lung Function 
All subjects performed spirometry (Vitalograph), to measure forced expiratory volume 
in one second (FEV1), forced vital capacity (FVC) and the FEV1/FVC ratio (Chapter 2: 
2.3.5, p 78). A diagnosis of COPD was confirmed as post bronchodilator spirometry 
FEV1:FVC <0.70, and the number of exacerbations per year were recorded. 
Body Composition  
Weight and body composition were measured barefoot in lightweight indoor clothing, 
fat free mass (FFM), fat mass (FM) and the percentage fat were determined using a 
Bioelectrical impedance device (Tanita BC-418). The FFM was expressed as a 
height-squared ratio, FFMI, and the body mass index (BMI kg/m2) was calculated (see 
Chapter 2: 2.3.1, p 66). A stretch resistant tape measure was used to measure waist 
and hip circumference.  
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Measurement of Pulse Wave Velocity 
Aortic PWV was assessed non-invasively using the SphygmoCor device connected to 
a laptop computer (Chapter 2: 2.3.3, p 70).  
Cardiac Haemodynamics Measurement 
Cardiac haemodynamics were measured non-invasively using a new bioreactance 
technology (NICOM, Cheetah, Medical Inc., Indianapolis, IN) (Chapter 2: 2.3.4, p 75).  
Inflammatory Biomarkers 
High sensitivity C-reactive protein (CRP) and fibrinogen were determined from a blood 
sample according to standard procedures (University Hospital of Wales, 
Biochemistry). 
Data Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences 
(SPSS, Chicago, IL), version 18.0. Results are presented as arithmetic or geometric 
for non-normally distributed data and standard deviation (SD). Analyses included 
One-way Analysis of Variance (ANOVA), Pearson‘s correlations and hierarchical 
multiple regression analysis. Difference between visits was performed using paired t- 
test. Categorical data was analysed using the Chi-square test. A p<0.05 was 
considered significant. Subjects aged less than 50 years were added to age category 
of 50-59. 
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5.3 Result 
Subject Characteristics 
The baseline characteristics of patients and comparators are presented in table 5.1. 
Patients with COPD and comparators were similar in age, gender and BMI, but the 
patients had greater pack-year smoking history (Table 5.1). The severity of airflow 
obstruction in the patients was GOLD 1 n=73, GOLD 2 n=251, GOLD 3 n=144 and 
GOLD 4 n=32. Furthermore, patients were categorised into an FEV1>50% predicted 
(n=318) (GOLD I&II) and an FEV1 <50% predicted (n=182) (GOLD III & IV). Of the 
500 patients, 207 reported infrequent exacerbations, less than two per year, while 293 
patients reported two or more per year.  
Following the classification used by Landbo et al. (1999), of the 500 patients, (26) 5% 
had a low BMI (<19.9 kg/m2), (196) 39% had an elevated BMI (>25 kg/m2), (163) 33% 
were classified as obese (BMI>30 kg/m2), while (115) 23% were within the normal 
limit for BMI (20-25 kg/m2). Among comparator subjects, (34) 23% had an optimal BMI 
and (116) 77% had an elevated BMI, 28% of these subjects were obese (BMI >30 
kg/m2). Patients with COPD had greater waist circumference and waist: hip ratio, and 
lower fat free mass and oxygen saturation, all p<0.001. However, both groups had 
similar fat mass (Table 5.1).  
Patients with COPD and comparator subjects were similar in kidney function indices, 
p>0.05 (Table 5.1). Circulating CRP and fibrinogen were greater in patients with 
COPD compared to non-COPD subjects, all p<0.001 (Table 5.1). 
The proportion of subjects with a prior diagnosis of comorbidities was greater in the 
patients (Table 5.2). Details of medications in both groups are also given (Table 5.2). 
Most of the patients (64%) and comparators (82%) were ex-smokers and had a 
different pack year exposure.  
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Table 5.1: Baseline characteristics of patients with COPD and comparator subjects at 
initial visit 
 COPD (n= 500) Comparator (n= 150) p value 
Gender Male:Female 255:245 75:75 0.451 
Age (years) 66 (7) 65 (8) 0.125 
Smoking (pack-years) 40.6 (25.5) 21.4 (17.9) 0.001 
FEV1 (L) 1.64 (0.84) 2.73 (0.67) 0.001 
FVC (L) 2.50 (0.98) 3.50 (0.90) 0.001 
FEV1/FVC (L) 0.53 (0.11) 0.78 (0.05) 0.001 
FEV1 (%) 59 (21) 105 (13) 0.001 
FVC (%) 87 (21) 110 (15) 0.001 
BMI (kg/m
2
) 28.1 (5.5) 28.3 (4.2) 0.664 
Waist circumference (cm) 100 (15) 95 (13) 0.001 
Waist:Hip ratio 1.0 (0.1) 0.9 (0.1) 0.001 
FFM (kg) 49.6 (11.0) 52.2 (9.5) 0.011 
FFMI (kg/m
2
) 18.1 (2.6) 18.5 (2.3) 0.110 
Fat mass (kg) 26.9 (11.1) 26.9 (8.6) 0.985 
Resting O2 saturation (%) 97 (2) 98 (1) 0.001 
Fibrinogen (g/L)# 3.5 (1.3) 3.1 (1.3) 0.001 
CRP (mg/L)# 3.5 (2.9) 1.76 (3.2) 0.001 
Serum Creatinine (µmol/l) 70 (15) 70 (12) 0.389 
eGFR  (mls/min/1.73m
2
) 94 (20) 93 (14) 0.786 
Data presented as mean (SD) or mean (%) unless otherwise stated. #Geometric mean 
Abbreviations: BMI= body mass index; FVC= forced expiratory volume; FEV1= forced 
expiratory volume in 1 second; FFM= fat free mass; FFMI= fat free mass index; CRP= C-
reactive protein; eGFR= estimated glomerular filtration rate. 
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Table 5.2: Reported comorbidities and medications in patients with COPD and 
comparator subjects at initial visit 
  COPD (n=500) Comparator (n=150) p value 
Hypertension 229 (46%) 33 (22%) 0.001 
High Cholesterol  222 (44%) 40 (27%) 0.001  
Peripheral vascular disease 17 (3%) 3 (3%) 0.304 
Angina 54 (11%) - 0.001 
Heart Attack 44 (8%) - 0.001 
Transit Ischemic Attack 35 (7%) - 0.001 
Atrial Fibrillation 39 (8%) - 0.001 
Other heart problem 46 (9%) - 0.005 
Diabetes Mellitus 63 (13%) - 0.001 
Osteoporosis 87 (%) 8 (5%) 0.001 
Osteoarthritis 174 (35) 40 (26) 0.001 
ACE inhibitors 113 (23%) 8 (5%) 0.001  
Beta Blocker 39 (%8) 5 (%3) 0.420  
Calcium Channel Blocker 109 (22%) 8 (%5) 0.001  
Diuretics 103 (21%) 10 (7%) 0.001  
Statins 185 (37%) 25 (17%) 0.001  
ICS 295 (59%) - - 
LAMA 293 (59%) - - 
SABA 305 (61%) - - 
LABA 31 (6%) - - 
Abbreviations: ICS= Inhaled Corticosteroid; LAMA= Long-Acting Muscarinic Antagonists 
SABA= Short Acting Bronchodilator Agonists; LABA= Long Acting Bronchodilator Agonists; - 
= not reported. 
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Initial Haemodynamics Data 
The 500 patients with COPD had a greater mean peripheral and central systolic BP 
than comparators, both p<0.01, but both groups had similar peripheral and central 
diastolic blood pressure (Table 5.3). Peripheral and central MAP were greater in 
patients with COPD than their individual counterparts, p<0.05 (Table 5.3). Mean 
peripheral and central pulse pressure were greater in the patients than the 
comparators, p<0.05. Heart rate of patients with COPD was 74 (11) and greater than 
comparator subjects 67 (10), p<0.001. Mean aortic PWV was greater in the patients 
9.9 (2.4) compared with non-COPD individuals 8.3 (1.7), p<0.001. The difference 
remained after adjustment for age, sex, waist circumference, peripheral MAP, 
smoking status and log10 CRP (Adjusted R
2= 0.38, F=21.8, p<0.001). Aortic PWV was 
associated with age in both groups, p<0.001. Aortic stiffness differed across age 
categories between patients with COPD and comparator subjects, all p<0.001 (Figure 
5.1).  
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Table 5.3: Differences in haemodynamics between patients with COPD and comparators 
at initial visit 
Data presented as mean (SD). 
Abbreviations: SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= pulse 
pressure; MAP= mean arterial pressure; PWV= pulse wave velocity; CO= cardiac output. 
  
  COPD (n=500) Comparator (n=150) p value 
Peripheral SBP (mmHg) 146 (18) 140 (18) 0.001 
Peripheral DBP (mmHg) 82 (10) 81 (8) 0.283 
Peripheral PP (mmHg) 64 (15) 59 (15) 0.001 
Peripheral MAP (mmHg) 103 (11) 100 (10) 0.011 
Central SBP (mmHg) 133 (18) 128 (19) 0.003 
Central DBP (mmHg) 83 (10) 83 (11) 0.886 
Central PP (mmHg) 50 (14) 45 (22) 0.001 
Central MAP (mmHg) 106 (42) 102 (11) 0.039 
Heart Rate (bpm) 74 (11) 67 (10) 0.001 
Aortic PWV (m/s) 9.9 (2.40) 8.3 (1.66) 0.001 
CO (L/min) 5.84 (1.21) 5.95 (1.03) 0.324 
Stroke Volume (ml) 86 (20) 96 (20) 0.001 
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Figure 5.1: Bar chart of aortic stiffness in patients with COPD and comparator subjects 
by age categories at initial visit 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc, p<0.001.   
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Relationship between Aortic Stiffness and Blood Pressure 
In the patients, aortic stiffness was related to peripheral MAP (r=0.41), peripheral PP 
(r=0.41), central MAP (0.27) and central PP (r=0.30), all p<0.01 (Table 5.4). Similarly, 
aortic stiffness of the comparators was associated with peripheral and central blood 
pressure indices (Table 5.4). Increased heart rate was associated with increased 
aortic PWV in patients with COPD (r=0.24, p<0.001) and comparator subjects (r=0.21, 
p=0.012). Greater aortic PWV was associated with lower peripheral (r=0.12, p=0.006) 
and central (r=0.13, p=0.005) diastolic blood pressure. However, neither of these 
relationships was evident in the comparator group (Table 5.4).  
Aortic stiffness did not relate to cardiac output in either group (Table 5.4). Aortic 
stiffness was related to stroke volume in the comparators (r=-0.25, p=0.003), but was 
not in the patients (Table 5.4). 
To examine the relationship of kidney function with aortic stiffness, the serum 
creatinine level and estimated glomerular filtration rate (eGFR) were measured in 
patients with COPD and comparator individuals. Aortic stiffness was associated eGFR 
in patients with COPD (r=-0.13, p=0.005) and comparator subjects (r=-0.17, p=0.044), 
but was only related to serum creatinine (r=0.20, p<0.001) in the patients (Table 5.4).  
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Table 5.4: Relationships between aortic PWV and physiological characteristics in 
patients with COPD and comparators at initial visit 
Pearson’s correlation COPD (n=500) p value  Comparator (n=150)  p value 
Peripheral SBP (mmHg) 0.411 0.001 0.517 0.001 
Peripheral DBP (mmHg) 0.124 0.006 0.136 0.099 
Peripheral MAP (mmHg) 0.294 0.001 0.370 0.001 
Peripheral PP (mmHg) 0.407 0.001 0.555 0.001 
Central SBP (mmHg) 0.313 0.001 .438 0.001 
Central DBP (mmHg) 0.127 0.005 0.056 0.496 
Central MAP (mmHg) 0.269 0.001 0.335 0.001 
Central PP (mmHg) 0.296 0.001 0.366 0.001 
Heart rate (bpm) 0.240 0.001 0.209 0.012 
Cardiac output (L/min) 0.080 0.083 0.046 0.584 
Stroke Volume (ml) -0.068 0.143 0.248 0.003 
Resting O2 saturation (%) -0.146 0.002 -0.160 0.149 
Serum Creatinine (µmol/l) 0.195 0.001 0.077 0.363 
eGFR (mls/min/1.73m
2
) -0.128 0.005 -0.169 0.044 
log10 Fibrinogen (g/L) 0.033 0.476 -0.033 0.697 
log10 CRP (mg/L) 0.131 0.005 0.193 0.022 
Number of Comorbidities 0.199 0.001 0.421 0.001 
Abbreviations: SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= pulse 
pressure; MAP= mean arterial pressure; eGFR= estimated glomerular filtration rate; CRP= C-
reactive protein. 
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Relationship between Aortic Stiffness and Gender  
Within the patients, aortic PWV was greater in males with COPD 10.2 (2.7) than their 
female counterparts 9.5 (2.0), p=0.003. The difference remained after controlling for 
age and peripheral MAP (Adjusted R2=26%, F=6.15, p=0.014). However, the 
difference was not significant after adding waist circumference to the model (Adjusted 
R2=30%, F=0.16, p=0.693). In contrast, gender had no effect on aortic stiffness in 
comparator group. 
Across gender comparison, after adjustment for waist circumference, peripheral MAP, 
smoking exposure and log10 CRP, male patients 9.9 m/s (95%CI: 9.6 to 10.2) had 
greater aortic PWV than male comparators 9.1 m/s (95%CI: 8.5 to 9.6), (adjusted 
R2=22%, F=6.3 and p=0.012). Similarly, the aortic PWV of females with COPD 9.4 
m/s (95%CI: 9.1 to 9.6) was greater than females without COPD 8.7 m/s (95%CI: 8.3 
to 9.2), adjusted R2=25%, F=5.13 and p=0.024 (Figure 5.2).   
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Figure 5.2: Bar chart comparing aortic stiffness by gender in patients with COPD and 
comparators at initial visit 
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Data presented as mean with SD. 
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Relationship between Aortic Stiffness and Lung Function 
In the patients, aortic stiffness was related to the severity of airway obstruction (r=-
0.10, p=0.037), however, in the comparators, aortic stiffness was not related to FEV1, 
p>0.05 (Table 5.5). Aortic stiffness did not differ across the GOLD categories. Patients 
with COPD in all GOLD categories had greater aortic PWV compared with non-COPD 
subjects, all p<0.001 (Figure 5.3). 
Patients with an FEV1>50% predicted had lower aortic PWV 9.6 m/s (2.2) than 
patients with an FEV1<50% predicted 10.70 m/s (2.6), p<0.001, and patients in both 
categories had greater aortic PWV compared with non-COPD subjects 8.3 m/s (1.7), 
all p<0.001 (Figure 5.4).  
In the patients, aortic stiffness was associated with oxygen saturation (r=-0.15, 
p=0.002), but was not in the comparators (Table 5.5). 
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Figure 5.3: Bar chart of aortic PWV in comparators and patients with COPD across 
GOLD category at initial visit 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc, p<0.001. 
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Figure 5.4: Bar chart of aortic PWV in comparators, patients with an FEV1>50% 
predicted and patients with an FEV1<50% at initial visit 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc, p<0.001. 
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Relationship between Aortic Stiffness and Body Composition 
In the patients, aortic PWV was related to BMI (r=0.18) waist circumference (r=0.26), 
waist: hip ratio (r=0.24), fat mass (r=0.17) and FFMI (r=0.14), all p<0.01. However, 
these relationships were not evident in comparator group (Table 5.5). Aortic stiffness 
did not differ across BMI categories in patients with COPD, p>0.05. 
Relationship between Aortic Stiffness and Smoking 
In patients with COPD, increased aortic PWV was associated with the number of 
smoking pack-years (r=0.13, p=0.005), but this relationship was not found in 
comparator subjects (Table 5.4). Within the patients, there was no difference in pack-
years between previous smokers mean (SD) 35 (2) and current smokers 35 (2), but 
current smokers were younger 63 (8) than previous smokers 67 (6), p<0.001. The 
aortic PWV was similar between current smokers and previous smokers after 
correcting for age (F=1.26, p>0.05). Within the comparators, there was a difference in 
the number of pack-years smoked between current smokers mean (SD) 22 (2) and 
previous smokers 15 (2), but they had a similar aortic PWV, 7.8 (1.4) and 8.4 (1.7), 
p>0.05, respectively. 
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Table 5.5: Relationships between aortic PWV and physical characteristics in patients 
with COPD and comparator subjects at initial visit 
Pearson’s correlation COPD (n=500) 
(n=500) 
p value Comparator (n=150) 
(n=150) 
p value 
Age (years) 0.405 0.001 0.518 0.001 
FEV1 (%) -0.095 0.037 -0.079 0.339 
FEV1/FVC (L) -0.110 0.016 -0.071 0.393 
Smoking (pack-years) 0.129 0.005 -0.002 0.984 
No. Exacerbations/year -0.023 0.620 - - 
BMI (kg/m
2
) 0.177 0.001 0.037 0.653 
Waist circumference (cm) 0.263 0.001 0.008 0.923 
Waist:Hip ratio 0.239 0.001 0.155 0.062 
FFM (kg) 0.143 0.002 0.037 0.655 
FFMI (kg/m
2
) 0.141 0.002 0.002 0.984 
Fat Mass (kg) 0.172 0.001 0.083 0.312 
Abbreviations: FEV1= forced expiratory volume in 1 second; FEV1/FVC= forced expiratory 
volume in 1 second to forced expiratory volume ratio; BMI= body mass index; FFM= fat free 
mass; FFMI= fat free mass index. 
  
 164 
 
Relationship between Aortic Stiffness and Circulating Inflammatory Biomarkers 
Circulating log10CRP was related to aortic stiffness in patients with COPD (r=0.13, 
p=0.005) and comparator subjects (r=0.19, p=0.022). However, the fibrinogen level 
was not associated with aortic stiffness in either group, p>0.05 (Table 5.5).  
To determine the effect of exacerbations on aortic stiffness, frequent exacerbators 
and infrequent exacerbators were compared. There was no difference in aortic 
stiffness between frequent exacerbators 9.9 (2.6) and infrequent exacerbators 9.9 
(2.3), p>0.05. However, both groups had greater aortic PWV than comparator 
subjects 8.3 (1.7), p<0.001 (Figure 5.5). 
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Figure 5.5: Bar chart of aortic stiffness in comparators and patients with frequent and 
infrequent exacerbation 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc, p<0.001. 
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Determinants of initial aortic PWV 
A hierarchical regression analysis was used to determine predictors of aortic PWV at 
the initial visit. The first model included gender to examine the behaviour of aortic 
PWV across gender. The second model was based on the most known influential 
factors on aortic PWV including age and peripheral MAP. In the third model, the 
potential factors were included: FEV1% predicted, waist circumference, heart rate, 
smoking history, eGFR, log10CRP. For body composition, waist circumference was 
chosen because abdominal obesity exerts an adverse effect on the arterial system 
and increases aortic stiffness. Estimated GFR rather than serum creatinine was 
chosen to delineate kidney function because it is more robust and takes into account 
age and gender as well as the level of serum creatinine. In the patients, in the first 
model, gender explained 2% of variation in aortic stiffness (F=7.31, p<0.01). Adding 
age and peripheral MAP to the regression model explained another 26% with a 
significant change in R (R=28%, F=73.20, p<0.001). However, including potential 
factors in the model revealed that gender was no longer a predictor and among the 
potential factors only waist circumference and heart rate which could explain an 
additional 12% of variation in aortic PWV (R=38%, F=10.01, p<0.001). The predictors 
of aortic PWV in COPD were age, peripheral MAP, waist circumference and heart 
rate, and explained 38% of variation in aortic PWV (Table 5.6). In the comparator 
group, similarly to COPD group, age and peripheral MAP explained 36% of the 
variability in aortic stiffness (R2= 0.33, F=22.89, p<0.001) (Table 5.7). However, none 
of the potential factors added any additional information to the model and the change 
in R was non-significant (R=0.05, F=1.49, p=0.177). 
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Table 5.6: Predictors of aortic stiffness in patients at initial visit 
  B SE Beta p value  Adjusted R
2 
Model 1     0.02 
Gender -.594 .220 -.131 0.007  
Model 2     0.28 
Gender -.396 .190 -.087 0.038  
Age (years) .137 .013 .435 0.001 
Peripheral MAP (mmHg) .057 .008 .282 0.001 
Model 3     0.38 
Age (years) .135 .013 .428 0.001  
Peripheral MAP (mmHg) .043 .008 .214 0.001 
Waist circumference (cm) .063 .016 .409 0.001 
Heart rate (bpm) .045 .008 .226 0.001 
Abbreviations: MAP= mean arterial pressure. 
 
 
 
 
 
Table 5.7: Predictors of aortic stiffness in comparator subjects at their initial visit 
 B SE Beta p value  Adjusted R
2 
Model 3  0.33 
Age (years) .090 .015 .434 0.001 
Peripheral MAP (mmHg) .045 .012 .276 0.001 
Abbreviation: MAP= mean arterial pressure.  
 168 
 
Part II: 
Characteristics of Returning Patients 
Of the 500 patients who were assessed at the initial visit, 143 consecutive patients 
completed a two-year follow-up visit by end of December 2013 and were included in 
the analysis. In this longitudinal study, there was no comparator group due to time 
constraint of the three-year PhD study period, which it did not allow for follow-up the 
comparators.  
To ensure that the 143 consecutive patients included in the analysis represented the 
whole patient group who will have been reassessed, a comparison analysis was 
carried out between returning patients (n=143) and the rest of the patients (n=357). 
The returning patients were similar to the rest of 500 patients in body composition, 
peripheral and central blood pressure indices, aortic stiffness, cardiac hemodynamic 
indices and inflammatory biomarkers, all p>0.05. However, the returning patients were 
older, and had lower FEV1 and eGFR, p<0.05 (Table 5.8). 
Of the returning patients, 9 patients had developed hypertension, 4 had developed 
high cholesterol, 3 had angina and 3 had developed osteoporosis (Figure 5.7). Among 
the returning patients, 16 out of 30 patients were still smokers. 
The severity of airflow obstruction by GOLD stratification was: GOLD I n=12, GOLD II 
n=72, GOLD III n=42 and GOLD IV n=17. Patients were further stratified into above 
and below 50% predicted of an FEV1: patients with an FEV1>50% predicted, n=94, 
and patients with an FEV1<50% predicted, n=59. On the follow-up visit, the patients 
had a reduction in FEV1% predicted and FVC%. The change in FEV1 across the 
GOLD categories was significant only in GOLD I&II (Table 5.9).  
Following the classification used by Landbo et al. (1999), of the 143 patients, 7% had 
a low BMI (<19.9 kg/m2), 37% had an elevated BMI (25-29.9 kg/m2) and 34% were 
classified as obese (BMI>30 kg/m2), while 21% were within the normal limit for BMI 
(20-24.9 kg/m2).  
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Table 5.8: Comparison between initial visit data in patients assessed at 2 years and 
patients yet to be assessed 
 To be assessed (n=357) Reassessed (n=143) p value 
Age (years) 65 (8) 68 (7) 0.001 
FEV1 (L) 1.7 (0.8) 1.3 (0.5) 0.001 
FVC (L) 2.4 (0.9) 2.4 (0.8) 0.753 
FEV1/FVC 53 (10) 51 (12) 0.033 
FVC% 86 (21) 83 (20) 0.226 
FEV1% 58 (18) 54 (20) 0.031 
BMI (kg/m
2
) 27.9 (6) 28.0 (6) 0.800 
Waist circumference (cm) 99 (15) 99 (15) 0.755 
Waist:Hip ratio 0.96 (0.10) 0.94 (0.12) 0.303 
FM (kg) 26.8 (11.4) 26.7 (10.5) 0.949 
FFM (kg) 49.5 (10.9) 48.6 (10.8) 0.446 
FFM:FM ratio 2.2 (1) 2.2 (1.3) 0.845 
FFMI (kg/m
2
) 18 (2.7) 18 (2.6) 0.669 
Peripheral SBP (mmHg) 145 (19) 148 (17) 0.287 
Peripheral DBP (mmHg) 82 (10) 82 (11) 0.921 
Peripheral MAP (mmHg) 103 (12) 103 (11) 0.358 
Peripheral PP (mmHg) 64 (16) 65 (15) 0.232 
Central SBP (mmHg) 133 (19) 135 (17) 0.461 
Central DBP (mmHg) 83 (10) 83 (11) 0.879 
Central MAP (mmHg) 104 (12) 104 (12) 0.529 
Central PP (mmHg) 50 (14) 52 (15) 0.728 
Heart rate (bpm) 74 (11) 76 (11) 0.068 
Aortic PWV (m/s) 9.7 (2.3) 10.2 (2.7) 0.102 
CO (L/min) 5.9 (1.3) 5.7 (1.1) 0.051 
SV (ml) 87 (20) 83 (19) 0.072 
O2 saturation 96 (2) 96 (2) 0.658 
Smoking (packs/year) 40 (23) 42 (30) 0.384 
No. Exacerbations 2.2 (2) 2.5 (1.9) 0.072 
Fibrinogen (g/L) 3.4 (1.3) 3.7 (1.1) 0.179 
CRP (mg/L)# 3.6 (2.9) 3.0 (2.8) 0.164 
eGFR (mls/min/1.73m
2
) 95 (20) 89 (20) 0.001 
Data presented as mean (SD) unless otherwise indicated, # Geometric mean. 
Abbreviations: FEV1= forced expiratory volume in one second; FVC= forced vital capacity; 
BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= 
pulse pressure; PWV= pulse wave velocity; CO= cardiac output; SV= stroke volume; 6MWD= 
six minute walking distance; CRP= C- reactive protein; eGFR= estimated glomerular filtration 
rate. 
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Table 5.9: Change in FEV1 (ml) across GOLD categories in patients with COPD at follow-
up visit 
  Mean 95% Confidence Interval for Mean 
  
P value 
GOLD I -166 278 54 0.006 
GOLD II -178 -256 -100 0.001 
GOLD III -65 -120 -10 0.192 
GOLD IV 47 -102 196 0.300 
  
 
 
 
 
Figure 5.6: Distribution of comorbidities in patients at initial visit and two years follow-
up
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Changes in Cardiovascular Parameters at Two Years Follow-up 
 
Peripheral and central blood pressure indices had decreased significantly over two 
years in the patients, p<0.05 (Table 5.10). The aortic PWV of the patients had 
increased after two years from the initial assessment by mean (95%CI) 0.7 m/s (0.35 
to 0.95), p<0.001 (Table 5.10). Males and females patients showed a similar change 
in aortic PWV. The heart rate remained stable on both visits, but there was a 
reduction in stroke volume and cardiac output after two years from the initial 
assessment, p<0.05 (Table 5.10). However, the change in aortic PWV was not 
associated with cardiac output or stroke volume, p>0.05. 
Relationship between Blood Pressure and Change in Aortic Stiffness 
Change in aortic PWV did not relate to the changes in systolic, diastolic or mean 
arterial pressures.  
Relationship between Lung Function and Aortic Stiffness 
There was no difference in aortic stiffness across the GOLD categories. This analysis 
was further expanded and compared the change in aortic PWV between patients with 
an FEV1>50% predicted (n=84) and patients with an FEV1 <50% predicted (n=59). 
The results also showed no difference between patients with mild to moderate airway 
obstruction compared with severe and very severe airflow obstruction, p>0.05. 
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Table 5.10: Changes in patients with COPD after two years from the initial assessment 
  Initial visit 
(n=143) 
Follow-up visit 
(n=143) 
Mean Change 
(95%CI) 
p value 
Gender (Male:Female) 65:78 65:78  
Age (years) 68 (7) 70 (7) 2 1.86 2.04 0.001 
FEV1 (L) 1.3 (0.5) 1.1 (0.5) -0.12 -0.16 -0.07 0.001 
FVC (L) 2.4 (0.08 2.3 (0.8) -0.16 -0.23 -0.08 0.001 
FVC% predicted 83 (19) 79 (22) -4 -7 -2 0.001 
FEV1%predicted 54 (19) 51 (16 -3 -4 -1 0.001 
Smoking (pack-years) 42 (30) 43 (28) 1.25 -3 5 0.519 
BMI (kg/m
2
) 28 (6) 27.8 (6)  -0.20 -0.59 0.21 0.356 
Waist (cm) 99 (15) 99 (15) -0.16 -1.30 0.99 0.786 
Waist:Hip ratio 0.94 (0.10) 095 (0.12 0.01 0.01 0.02 0.120 
Fat Mass (kg) 26.7 (11) 26.2 (10.5) -0.55 -1.44 0.34 0.224 
FFM (kg) 48.6 (10.8) 48.1 (10.8) -0.53 -1.05 -0.01 0.048 
Peripheral SBP (mmHg) 148 (17) 144 (17) -4 -7 -1 0.008 
Peripheral DBP (mmHg) 82 (11) 79 (11) -3 -4 -1 0.001 
Peripheral PP (mmHg) 66 (15) 65 (15) -1 -4 1 0.207 
Peripheral MAP 103 (11) 100 (11) -3 -5 -1 0.001 
Central SBP (mmHg) 135 (17) 130 (16) -5 -7 -1 0.006 
Central DBP (mmHg) 83 (11) 81 (11) -2 -4 -1 0.003 
Central PP (mmHg) 52 (15) 50 (14) -2 -4 1 0.138 
Central MAP (mmHg) 104 (12) 102 (12) -2 -4 -1 0.012 
Heart Rate (bpm) 76 (11) 76 (12) 0 -1 2 0.700 
Aortic PWV (m/s) 10.2 (2.7) 10.9 (2.6) 0.70 0.37 0.95 0.001 
CO (L/min) 5.7 (1.1) 5.5 (1.2) -0.20 -0.30 -0.02 0.024 
Stroke Volume (ml) 83 (19) 79 (20) -4 -7 -2 0.001 
Resting O2 (%) 96 (2) 96 (2) 0 -0.08 0.63 0.128 
CRP (mg/L)# 3.0 (2.8) 3.1 (2.6) 0.1 0.9 1.2 0.953 
Fibrinogen (g/L) 3.7 (1.1) 3.3 (0.9) -0.40 -0.56 -0.20 0.001 
Serum creatinine(µmol/L) 72 (16) 76 (16) 3.43 1.76 5.11 0.001 
eGFR (mls/min/1.73m
2
) 89 (20) 81 (17) -8 -2 -7 0.001 
Data presented as mean (SD) unless otherwise indicated, #=Geometric mean, mean (95%CI). 
Abbreviations: FEV1= forced expiratory volume in one second; FVC= forced vital capacity; 
BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= 
pulse pressure; MAP= mean arterial pressure; PWV= pulse wave velocity; CO= cardiac 
output; SV= stroke volume; CRP= C- reactive protein; eGFR= estimated glomerular filtration 
rate 
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Relationship between Body Composition and Change in Aortic Stiffness 
Previously in the cross-sectional analysis, aortic PWV was related to global and 
regional obesity indices. Therefore, in this section, the effect of body composition was 
examined. Body composition did not change significantly in the patients apart from a 
significant loss of FFM (Table 5.10). The change in aortic PWV did not differ across 
BMI categories, p>0.05. This analysis was further extended by dividing patients into 
two groups: underweight and normal weight in one group, and overweight and obese 
in another group. Similar to whole group analysis, there was no statistical difference 
between the groups, p>0.05. 
Relationship between Change in Aortic Stiffness and Changes in Inflammatory 
Biomarkers 
After two years from the initial visit, the fibrinogen level decreased significantly, while 
CRP level remained statistically unchanged and a third of the patients remained 
inflammation free during the study period, <3 mg/L (Figure 5.8). In contrast, the 
number of exacerbations of the patients had increased (Table 5.10). 
Although the level of fibrinogen decreased, aortic PWV had increased. There was no 
association between change in aortic PWV and the reduction in plasma fibrinogen or 
increase in the number of exacerbations.  
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Figure 5.7A: The pie chart showing the distribution of patients according to the change 
in the fibrinogen level during the follow-up period 
 
Figure 5.7B: The pie chart showing the distribution of patients according to the change 
in the CRP level during the follow-up period
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Subgroup Analysis 
After two years from the initial assessment, a subset of patients was identified to have 
greater progression in aortic stiffness. This group (progressor) was defined as any 
patients who demonstrated an increase in aortic PWV by more than 0.20 m/s from the 
baseline measurement (Cecelja and Chowienczyk, 2012). The progressors showed a 
rapid increase in aortic PWV than the rest of the group (non-progressor). Therefore, a 
further analysis was performed to explore the characteristics of this group and the 
factors associated with accelerated aortic stiffness. 
Out of 143 patients with COPD, 93 patients (progressors) had greater increase in 
aortic PWV, 1.6 (95%CI: 1.3 to 1.9) m/s, p<0.001 whereas 50 patients (non-
progressor) had a significant reduction in aortic PWV -1.0 (95%CI:-1.3 to -0.7) m/s, 
p<0.001. Out of 50 non-progressor patients, 32 (64%) were previously diagnosed with 
isolated systolic hypertension and on the second visit three patients had developed 
hypertension. Non-progressors also experienced a significant reduction in peripheral 
and central blood pressure indices, p<0.001 (Table 5.11). However, there were no 
changes in peripheral and central pulse pressure. Cardiac hemodynamic indices of 
the non-progressor did not change during the follow-up period, p>0.05, but eGFR 
significantly decreased by mean (95%CI) -11 (-18 to -8), p<0.001 (Table 5.11). In the 
non-progressors, lung function as measured by FVC was reduced significantly over a 
period of the two years follow-up, p<0.001 (Table 5.11). Non-progressors also 
demonstrated a reduction in the fibrinogen level while CRP remained unchanged 
(Table 5.11). In the non-progressor patients, improvement of aortic stiffness was not 
associated with the reduction in blood pressure indices.  
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Table 5.11: Characteristics of non-progressor patients at initial visit and 2 years follow-
up 
  Initial visit 
(n=50) 
 
2 year-visit 
(n=50) 
 
Mean change 95%CI p value 
Age (years) 68 (7) 70 (7)   
FEV1 (L) 1.3 (0.5) 1.2 (0.5) -0.08 -0.15 -0.01 0.035 
FVC (L) 2.5 (0.7) 2.3 (0.7) -0.13 -0.25 -0.02 0.026 
FVC% predicted 84 (20) 79 (22) -5 -7 -2 0.001 
FEV1%predicted 56 (24) 54 (22) -2 -5 1 0.170 
Smoking (pack-years) 44 (4) 42 (4) -2 -9 4 0.463 
BMI (kg/m
2
) 28.8 (5.9) 28.8 (5.8) -0.07 -0.68 0.53 0.810 
Waist (cm) 103 (14) 102 (14) -1 -3 1 0.244 
Waist:Hip ratio 0.95 (0.10) 096 (0.10) -0.34 -1.44 0.76 0.536 
Fat Mass (kg) 28.7 (10.2) 28.3 (10.5)2 -0.55 -1.44 0.34 0.224 
FFM (kg) 49.6 (1.3) 48.8 (1.4) -0.69 -1.53 0.15 0.105 
Peripheral SBP (mmHg) 152 (19) 143 (18) -9 -15 -3 0.002 
Peripheral DBP (mmHg) 84 (10) 78 (9) -6 -9 -4 0.001 
Peripheral PP (mmHg) 68 (19) 65 (16) -23 -7 1 0.164 
Peripheral MAP 106 (11) 99 (10) -7 -11 -4 0.001 
Central SBP (mmHg) 138 (17) 129 (16) -9 -15 -4 0.001 
Central DBP (mmHg) 86 (10) 79 (9) -7 -9 -4 0.001 
Central PP (mmHg) 53 (15) 50 (14) -3 -7 1 0.103 
Central MAP (mmHg) 107 (11) 100 (11) -7 -11 -3 0.001 
Heart Rate (bpm) 78 (12) 78 (13) 0 -2 3 0.736 
Aortic PWV (m/s) 11.0 (2.2) 10.0 (2.1) -1.00 -1.3 -0.7 0.001 
CO (L/min) 5.8 (1.2) 5.6 (1.2) -0.20 -0.45 0.05 0.115 
Stroke Volume (ml) 84 (20) 80 (20) -4 -8 1 0.108 
Resting O2 (%) 96 (2) 96 (2) 0 -1 1 0.128 
CRP (mg/L)# 3.0 (2.9) 3.1 (2.8) 0.1 0.8 1.4 0.711 
Fibrinogen (g/L) 3.7 (0.9) 3.3 (0.7) -0.40 -0.67 -0.14 0.004 
Serum creatinine (µmol/L) 72 (16) 79 (18) 7 4 9 0.001 
eGFR (mls/min/1.73m
2
) 90 (20) 79 (22) -11 -18 -8 0.001 
Data presented as mean (SD) unless otherwise indicated, #=geometric mean, mean (95%CI). 
Abbreviations: FEV1= forced expiratory volume in one second; FVC= forced vital capacity; 
BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= 
pulse pressure; MAP= mean arterial pressure; PWV= pulse wave velocity; CO= cardiac 
output; SV= stroke volume; CRP= C- reactive protein; eGFR= estimated glomerular filtration 
rate.
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In the progressors, 43 (64%) had a previous diagnosis of isolated systolic 
hypertension on the initial visit and six new patients were diagnosed with hypertension 
on the second visit. Unlike non-progressors, peripheral and central blood pressure 
indices remained unchanged, p>0.05, while stroke volume significantly decreased, 
p<0.001 (Table 5.12). In the progressors, lung function indices had declined during 
the two years follow-up period, p<0.001 (Table 5.12). Similar to non-progressors, 
progressors‘ kidney function index as measured by eGFR demonstrated a significant 
reduction in its level, p<0.001 (Table 5.12). The level of inflammatory biomarkers 
behaved similarly as in the non-progressors, and plasma fibrinogen returned to its 
normal level, p<0.001, while circulating CRP maintained its level as it was at the initial 
visit, p> 0.05 (Table 5.12). The progression of aortic PWV was only related to baseline 
age of the progressors (r=0.23, p=0.029). The impact of comorbidities on aortic 
stiffness progression was further explored and showed no association between the 
number of comorbidities and the progression of aortic PWV. A quarter of the 
progressors had no previous history of diagnosed comorbidities and nearly a third of 
them had just one comorbidity (Figure 5.9). 
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   Table 5.12: Clinical characteristics of progressors at initial visit and 2 years follow-up 
Data presented as mean (SD) unless otherwise indicated, #=geometric mean, mean (95%CI). 
Abbreviations: FEV1= forced expiratory volume in one second; FVC= forced vital capacity;       
BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= 
pulse pressure; MAP= mean arterial pressure; PWV= pulse wave velocity; CO= cardiac 
output; SV= stroke volume; CRP= C- reactive protein. 
  
  Initial visit 
(n=93) 
 
2 year-visit 
(n=93) 
Mean change 95%CI p value 
Age (years) 67 (7) 69 (7)   
FEV1 (L) 1.25 (0.5) 1.10 (0.5) -0.14 -0.20 -0.08 0.001 
FVC (L) 2.4 (0.8) 2.2 (0.9) -0.17 -0.27 -0.07 0.001 
FVC% predicted 83 (19) 77 (20) -6 -9 -3 0.001 
FEV1%predicted 52 (16) 49 (17) -3 -5 -1 0.001 
Smoking (pack/year) 41 (29) 44 (30) 3 -1 8 0.176 
BMI (kg/m
2
) 27.5 (5.4) 27.3 (5.7) -0.25 -0.78 0.28 0.353 
Waist (cm) 98 (15) 99 (16) 0.37 -1.07 1.82 0.610 
Waist:Hip ratio 0.94 (0.10) 0.95 (0.10) 0.01 -0.01 0.02 0.212 
Fat Mass (kg) 25.5 (11.3) 24.9 (10.6) -0.67 -1.92 0.59 0.295 
FFM (kg) 48.0 (10.6) 47.6 (10.6) -0.44 -1.12 0.24 0.200 
Peripheral SBP (mmHg) 145 (17) 145 (17) -1 -4 2 0.505 
Peripheral DBP (mmHg) 80 (11) 80 (12) 0 -2 1 0.600 
Peripheral PP (mmHg) 65 (16) 64 (15) -1 -3 2 0.658 
Peripheral MAP 101 (11) 100 (11) -1 -3 1 0.505 
Central SBP (mmHg) 133 (17) 132 (16) -1 -4 2 0.481 
Central DBP (mmHg) 82 (12) 81 (12) -1 -2 2 0.679 
Central PP (mmHg) 51 (15) 51 (13) 0 -3 2 0.574 
Central MAP (mmHg) 102 (11) 102 (11) 0 -2 2 0.938 
Heart Rate (bpm) 74 (11) 75 (12) 1 -2 2 0.816 
Aortic PWV (m/s) 9.8 (2.3) 11.4 (2.7) 1.6 1.3 1.9 0.001 
CO (L/min) 5.6 (1.1) 5.4 (1.1) -0.20 -0.31 0.03 0.107 
Stroke Volume (ml) 83 (18) 78 (19) -5 -8 -2 0.001 
Resting O2 saturation (%) 96 (2) 96 (2) 0 -1 1 0.425 
CRP (mg/L)# 3.0 (2.5) 3.1 (2.8) 0.1 0.8 1.2 0.706 
Fibrinogen (g/L) 3.7 (1.1) 3.3 (0.9) -0.40 -0.61 -0.12 0.004 
Serum creatinine (µmol/l) 72 (16) 74  (13) 2 1 4 0.122 
eGFR (mls/min/1.73m
2
) 89 (18) 81 (16) -8 -11 -4 0.001 
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Figure 5.8: Distribution of comorbidities in progressor patients at two years visit
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In contrast, the non-progressors had improvement in peripheral and central blood 
pressure indices, p<0.01 (Table 5.13). Although, there was a significant difference in 
the change of aortic stiffness between the progressors and non-progressors, 
peripheral and central pulse pressure remained similar between both groups, p>0.05 
(Table 5.13). Comparing progressor patients with non-progressor patients revealed 
that the progressors experienced more rapid decline in lung function indices than the 
non-progressors, p<0.001 (Table 5.13). Both groups had similar reduction in plasma 
fibrinogen on the follow-up visit, p<0.01, while circulating CRP remained unchanged in 
both groups during the two years follow-up period (Table 5.13).  
The progressors demonstrated a substantial increase in aortic PWV than the non-
progressors after correcting for the difference in peripheral MAP (Adjusted R2=51%, 
F=121, p<0.001). The same finding was found when the change in peripheral MAP 
was replaced by the change in central MAP. The model was further expanded and 
included baseline age, sex, the difference in FEV1% predicted, difference in peripheral 
MAP, smoking status and showed that increased aortic PWV remained significant in 
the progressors (adjusted R2=51%, F=119.8, p<0.001).  
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Table 5.13: Differences between progressor and non-progressor patients after two 
years 
 
 Non-progressors 
(n=50) 
 
Progressors 
(n=93) 
p value 
Change in FEV1 (ml) -80 (-150 to -100) -140 (-200 to -80) 0.001 
Change in FEV1% predicted -2 (-5 to 1) -3 (-5 to -1) 0.594 
Change in FVC % predicted -5 (-7 to -2) -6 (-9 to -3) 0.001 
Smoking history (packs/year) -2 (-9 to 4) 3 (-1 to 8) 0.334 
Change in peripheral SBP (mmHg) -9 (-15 to -3) -1 (-4 to 2) 0.007 
Change in peripheral DBP (mmHg) -6 (-9 to –4) 0 (-2 to 1) 0.001 
Change in peripheral PP (mmHg) -2 ( -7 to -1) -1(-3 to 2) 0.304 
Change in peripheral MAP (mmHg) -7 (-11 to -4) -1 (-3 to 1) 0.001 
Change in central SBP (mmHg) -9 (-15 to -4) -1 (-4 to 2) 0.006 
Change in central DBP (mmHg) -7 (-9 to -4) -1 (-2 to 2) 0.001 
Change in central PP (mmHg) -3 (-11 to -3) 0 (-3 to 2) 0.267 
Change in central MAP (mmHg) -7 (-11 to -3) 0 (-2 to 2) 0.001 
Change in heart rate (bpm) 0 (-2 to 3) 1 (-2 to 2) 0.902 
Change in aortic PWV (m/s) -1 (-1.3 to 0.7) 1.6 (1.3 to 1.9) 0.001 
Change in fibrinogen (g/l) -0.40 (-.67 to -0.14) -0.40 (-0.61 to -0.12) 0.936 
Change in CRP (mg/l)# 0.10 (0.8 to 1.4) 0.1 (0.8 to 1.2) 0.941 
Data presented as mean (95%CI) unless otherwise indicated, #=geometric mean. 
Abbreviations: FEV1= forced expiratory volume in one second; FVC= forced vital capacity; 
SBP= systolic blood pressure; DBP= diastolic blood pressure; PP= pulse pressure; MAP= 
mean arterial pressure; PWV= pulse wave velocity; CRP= C- reactive protein. 
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5.4 Discussion 
Cross-sectional study: Baseline Findings 
The cross-sectional results of this study showed that patients with COPD have greater 
aortic stiffness than comparators similar in age and gender proportion. The greater 
aortic PWV in the patients than the comparators and the association with central pulse 
pressure support the theory of that increased aortic stiffness is a systemic 
manifestation associated with COPD.  
Increased aortic stiffness in patients with COPD has also been confirmed in other 
studies that used the same index and different indices (Maclay et al., 2009, Maclay et 
al., 2012, Mills et al., 2008, Patel et al., 2013). In the study by Sabit and colleagues 
(2007), they failed to adjust for other confounding factors in patients with COPD that 
may have a bearing on aortic stiffness including blood pressure and smoking, which 
are believed to play a role in increased aortic stiffness and may have inflated the 
difference. In the present study, to avoid the residual confounding factor from smoking 
and blood pressure, the association between aortic stiffness and COPD remained 
after correcting for peripheral mean arterial pressure and smoking. Other studies have 
used augmentation index or radial PWV as measures of arterial stiffness. Mills and 
co-worker (2007) used AIx as a measure of arterial stiffness. However, AIx is not the 
optimal measure for arterial stiffness, and is gender and heart rate dependent. A 
further limitation of this study was the failure to control for blood pressure, which they 
thought, was a determinant of arterial stiffness. The other study by McAllister and co-
authors (2008) used radial PWV, which is less robust than aortic PWV as the brachial 
artery contains more collagen and less elastin than the aorta and, therefore, it does 
not reflect physiological changes associated with blood pressure and the work 
imposed on the heart. In contrast, Janner et al. (2012) have recently reported a 
conflicting result to this study and found no significant association between COPD and 
arterial stiffness after adjustment for cardiovascular risk factors including blood 
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pressure, CRP, socioeconomic and physical activity. However, the researchers in this 
study used the AIx as an outcome measure for arterial stiffness, which is not the gold 
standard for arterial stiffness measurement, in addition to other disadvantages 
mentioned above. Additionally, the diagnosis of COPD was based on pre-
bronchodilator spirometry, which is not the gold standard for confirming COPD and 
may have led to inclusion of patients with other obstructive airway diseases including 
asthma (GOLD, 2014). Although, the authors stated that the difference was corrected 
for physical activity, assessment of physical activity was subjectively recorded which 
depends upon patients recall.  
Subendocardial manifestations present in patients with COPD at an early stage of the 
disease even in those without overt cardiovascular problems (Sabit et al., 2010a). 
Aortic stiffness improves the Framingham cardiovascular risk prediction, independent 
of conventional risk factors (Mitchell et al., 2010).  The increase in both central systolic 
and pulse pressure in parallel with increased aortic stiffness implicate the amount of 
load being exerted on the heart as well as alteration of aortic vasculature properties 
(Mitchell et al., 2004). Central haemodynamics may be more relevant to reflect the 
pathogenesis of cardiovascular disease and damage to the sensitive organs such as 
the kidney (Roman et al., 2007). The earlier return of the reflected arterial wave during 
late systole increases left ventricle afterload and consequently reduces coronary 
perfusion in diastole leading to sub-endocardial ischaemia (Laurent et al., 2006). In 
COPD, aortic stiffness is the best predictor of left ventricle dysfunction in patients 
without overt CVD and associated with myocardial injury (Patel et al., 2013, Sabit et 
al., 2010a). These findings may partly explain the underlying mechanism linking CVD 
in COPD and possibly the relationship between aortic stiffness and lung function in 
healthy individuals. 
The association of aortic stiffness with heart rate may indicate a predominant role of 
sympathetic overactivity in aortic stiffness and subsequently increased risk of CVD. 
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Similar to the current study, in treated hypertensive patients, Benetos and colleagues 
(2002) found the increased heart rate was a significant predictor of aortic stiffness. 
Elevated resting heart rate, a marker of sympathetic overactivity, is associated with 
CVD and all cause of mortality in COPD (Jensen et al., 2013). Autonomic nervous 
system dysfunction has been recognised in patients with COPD and could be a 
potential mechanism linking COPD to CVD (Van Gestel et al., 2012). Chronic elevated 
heart rate may alter mechanical wall properties of the aorta through decreased 
compliance and increased the aortic wall stress. A cyclic increased heart rate exposes 
aortic wall to greater strain, and subsequently leading to elastin degradation, which is 
a marker of aortic stiffness and a systemic feature of COPD (Maclay et al., 2012, 
Mitchell et al., 2004, Whelton et al., 2013). Elevated aortic stiffness in parallel with a 
greater heart rate may implicate a poor cardiac function as a consequence of 
myocardial damage (Sabit et al., 2010a). 
The association between aortic stiffness and renal function biomarkers (i.e. serum 
creatinine and eGFR) supports the notion that increased aortic stiffness could be 
related to the glomerular damage happening at the microvascular level. Recently, the 
GOLD guideline has emphasised the need for early detection and management of 
comorbidities in COPD (GOLD, 2014). One of the most common comorbidities 
associated with COPD is CVD.  Cardiovascular morbidity and mortality is inversely 
and independently associated with kidney function (Anavekar et al., 2004, Gibson et 
al., 2003). Alteration of small vessels function of a vital organ such as the kidney and 
its haemodynamics could be another horizon to explore the link between 
cardiovascular disease and COPD. Both patients with COPD and renal dysfunction 
share a common risk factor for CVD, which is increased arterial stiffness. The 
interplay of microvascular changes and the macrovascular function in COPD could be 
a triggering factor for causing arterial stiffness. Casanova et al. (2010) measured 
urinary albumin/creatinine ratio in 129 stable patients with COPD and 51 smoking 
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controls, and showed higher level of microalbuminuria in the patients compared with 
smoking controls, independent of traditional cardiovascular risk factors. This suggests 
that patients with COPD have some degree of kidney vascular damage, which is a 
risk factor for cardiovascular events and may precipitate the development of aortic 
stiffness. A study by John et al. (2013) revealed that aortic stiffness in patients with 
COPD is related to glomerular damage as measured by urine albumin/creatinine ratio. 
However, John and colleagues (2013) included patients with known renal impairment 
and therefore, glomerular damage cannot be exclusively related to COPD and 
increased aortic stiffness. In contrast, in the current study, patients with COPD were 
free of known kidney dysfunction, which may, indicate that elevated aortic stiffness 
could cause subclinical damage to the kidney before its clinical manifestations. 
Age is the major determinant of aortic stiffness (McEniery et al., 2005). This is not 
surprising, as with age, there are structural and functional changes to the vascular 
system, which could be accelerated by the presence of a systemic disease such as 
COPD. A similar finding has been recently reported in healthy and diseased 
populations (Alghatrif et al., 2013, Cecelja and Chowienczyk, 2009, McEniery et al., 
2005, McEniery et al., 2010, Teoh et al., 2013). Interestingly, in the review by Cecelja 
and Chowienczyk (2009) found that age and blood pressure are the only predictors of 
the variability in aortic stiffness, and accounted for approximately 50% of that change. 
Hypertension is common in patients with COPD and is estimated between 40% and 
60% (Curkendall et al., 2006, Mannino et al., 2008). The relationship between 
hypertension and COPD is unclear; however, increased arterial stiffness may play a 
role. Elastin degradation, a systemic feature of COPD, is also involved in the 
development of hypertension (Maclay et al., 2012, Te Velde et al., 2004). Therefore, 
increased aortic stiffness in COPD could be predisposing risk factor for hypertension 
development in the COPD population. Indeed, a recent longitudinal study from the 
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Framingham Offspring cohort showed that aortic stiffness is an independent predictor 
of the incident of hypertension in non-cardiovascular participants (Kaess et al., 2012). 
In the present study, aortic stiffness was more pronounced in males with COPD than 
the females and was independent of conventional cardiovascular risk factors including 
age, blood pressure and airway severity. This is recently supported in the London 
COPD Cohort study and the Baltimore Longitudinal Study of Ageing (Alghatrif et al., 
2013, Patel et al., 2013). Conversely, a conflicting result has been reported by other 
studies (Duprez et al., 2009, Russo et al., 2012). In the Multi-Ethnic Study of 
Atherosclerosis study, women demonstrated lower large and small arteries elasticity 
than men, which was dependent on height and body size (Duprez et al., 2009).  A 
similar finding has also been reported in the Cardiovascular Abnormalities and Brain 
Lesions cohort study, which demonstrated that women had higher arterial stiffness 
than men measured by AIx, independent of body size and heart rate (Russo et al., 
2012). However, this relationship disappeared after adjustment for other cardiac risk 
factors. This controversy is attributed to the fact that these studies have used AIx as a 
measure of arterial stiffness, which is not the gold standard and is age and female 
dependent (Laurent et al., 2006). The supposition that women have greater arterial 
stiffness than men, because of their body size and shorter aortic path length would 
assume or lead to the conclusion that children would have greater aortic stiffness than 
adults. However, this is not the case in reality as arterial stiffness increases with age.  
In the present study, males with COPD had greater aortic PWV than the females, 
independent of age and blood pressure, which clearly shows the high risk of 
premature cardiovascular events in the males is independent of the effect of age and 
blood pressure. Although males and females with COPD were similar in physiological 
measures, males had more visceral obesity than the females, which increases the risk 
of CVD, and may partially explain the relationship. Obesity increases aortic stiffness 
and both are independent risk factors for cardiovascular events (Recio-Rodriguez et 
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al., 2012, Sutton-Tyrrell et al., 2005, Sutton-Tyrrell et al., 2001). The combined effect 
of obesity and aortic stiffness in men in conjunction with COPD culminate in 
worsening cardiovascular morbidity. Recently, aortic stiffness was found to be 
associated with subclinical left ventricle dysfunction in a group of patients with COPD 
and free of overt cardiovascular disease when compared with age and sex matched 
controls (Sabit et al., 2010a). Another potential explanation of why males with COPD 
can have a stiffened aorta is probably testosterone deficiency (Atlantis et al., 2013). 
Males with COPD have lower testosterone level than disease free males (Laghi et al., 
2005). Low testosterone level is associated with increased aortic stiffness in the 
elderly and enhances the risk for cardiovascular morbidity and mortality (Araujo et al., 
2011, Dockery et al., 2003, Jones, 2010). The association between increased aortic 
stiffness and low levels of testosterone has been found in several populations and yet 
is to be explored in COPD (Fukui et al., 2007, Kyriazis et al., 2011). Nevertheless, 
increased aortic stiffness is well established in COPD, which is an independent 
predictor for cardiovascular morbidity and mortality in several populations including 
the healthy elderly. As males age, the level of testosterone progressively decreases 
and increases the incidence of fatal and non-fatal cardiac events (Herring et al., 2013, 
Jones, 2010).  
In the current study, patients with mild to moderate airflow obstruction had increased 
aortic stiffness compared with non-COPD subjects. There was also a significant 
difference in aortic stiffness between patients with an FEV1>50% and patients with an 
FEV1<50%. These findings could be interpreted as showing that aortic stiffening 
occurs at early stage of the disease and progresses as the function of airway 
declines. The relationship between the degree of aortic stiffness and severity of 
airway obstruction in patients with COPD may explain the increased risk for coronary 
heart disease and stroke in COPD. The result of this study is supported by findings 
from Sabit et al. (2007) study and other research (Cinarka et al., 2013, Janner et al., 
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2012, McAllister et al., 2007, Mills et al., 2008). Although, these studies used different 
indices to assess aortic stiffness, they agreed that there is a relationship between 
aortic stiffness and pulmonary function.  
The relationship between pulmonary function and aortic stiffness in the general 
population is contentious in the literature. In this study and others, there was a 
negative association between lung function and aortic stiffness in non-COPD subjects 
(Bolton et al., 2009, Janner et al., 2012, Sabit et al., 2007). In contrast, a study in 678 
Japanese American adult subjects found no significant relationship (Taneda et al., 
2004). This could be due to the type of the statistical analysis they used to identify the 
relationship. They treated their variables as dichotomous, which may have 
underestimated the association.  
The association between inflammatory biomarkers and arterial stiffness in COPD is 
contradictory. In the current study, increased aortic stiffness was associated with high 
levels of circulating CRP. A similar relationship between increased CRP and aortic 
PWV was found in a population from the same community and in others (Patel et al., 
2013, Sabit et al., 2007). In contrast, Cinarka et al. (2013) reported a conflicting result. 
This could be related to the fact that their study was underpowered and 96% of their 
population were male, therefore, the relationship was underestimated. Association 
between aortic stiffness and frequency of exacerbation in parallel with elevated CRP 
may suggest the possibility of a systemic elastin degradation and acceleration of 
atherosclerotic features (Maclay et al., 2012, Patel et al., 2013). 
COPD is a persistent inflammatory disease with elevated CRP level, which is a 
predictor of adverse outcomes in this population (Thomsen et al., 2012). Increased 
circulating CRP may be responsible for accelerating atherosclerosis leading to aortic 
stiffening. CRP is also involved in inducing endothelial dysfunction, which will 
consequently increase vascular fibrosis and subsequently lead to elevated aortic 
stiffness (Barr et al., 2007, Ives et al., 2013). 
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Another mechanism may explain the association between aortic stiffness and COPD 
is hypoxia. In the current research, aortic PWV was inversely related to resting oxygen 
saturation. A similar finding has been found in two cross-sectional studies (Cinarka et 
al., 2013, Sabit et al., 2007). In contrast, although McAllister and colleagues (2007) 
used the same method as in the current study (i.e. pulse oximeter) to measure oxygen 
saturation, they found no association between oxygen saturation and radial PWV. 
This may be due to the method they used to measure arterial stiffness (radial PWV) 
which is not the gold standard and unlikely to reflect physiological changes in the 
aorta (Laurent et al., 2006). The effect of hypoxia on arterial stiffness is still unknown. 
Nevertheless, hypoxia may alter arterial smooth muscle structure and function and 
increase its predisposition to rigidity (Lattimore et al., 2005). To support this 
hypothesis, a study by Bartels and co-authors (2004) demonstrated that supplemental 
oxygen resulted in reduced arterial stiffness in a population of patients with airflow 
obstruction. Hypoxia may also influence arterial stiffness by its effect on systemic 
inflammation (Takabatake et al., 2000). Repetitive hypoxia that is usually seen in 
patients with COPD either sustained as in the late stage of the disease or intermittent 
as during an exacerbation or exercise, which induces cardiac stress (i.e. an increase 
in heart rate) and renal stress (i.e. a decrease in renal blood flow) (Skwarski et al., 
1998).  
Tobacco exposure has a causal effect in COPD and CVD, therefore, it was 
considered in the analysis. In this study, although the smoking history between the 
patients and comparators was different, this is unlikely to account for the increased 
aortic stiffness observed in patients with COPD, as increased aortic stiffness  was 
independent of pack-years of smoking. Within the comparator group, current smokers 
with a higher pack-years history did not have greater aortic PWV. Within the patients, 
there was a difference in aortic PWV between patients in GOLD I&II and patients in 
GOLD III&IV, who were similar in terms of current smokers and the number of pack 
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years smoked. A similar finding was found by Sabit et al. (2007) study, who reported 
that increased aortic stiffness in patients with COPD was independent of the number 
of pack-years smoked. Consistent with previous findings, in 157 emphysematous 
patients, McAllister and colleagues (2007) reported no difference in PWV between 
active smokers and ex-smokers. In the general population, Zureik and co-authors 
(2001) found similar aortic PWV in never smokers, current smokers and ex-smokers. 
To the best knowledge of the researcher, this is the largest cross-sectional study to 
date, which has confirmed previous findings of the association between COPD and 
elevated aortic stiffness. In this study, aortic stiffness was greater in the patients than 
the comparators similar in age and gender, and it was independent of traditional 
cardiovascular risk factors. The present study added to previous studies that male 
patients had greater aortic stiffness than their female counterparts and this difference 
remained after controlling for age and blood pressure. Additionally, the present study 
found waist circumference and heart rate as well as age and blood pressure are 
predictors of increased aortic stiffness in COPD.  
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Longitudinal study: Two-year Findings 
This is the first longitudinal study evaluating the change in aortic stiffness over time in 
COPD and showed that there was a significant increase in aortic stiffness, 
independent of age, airway severity, body composition, mean blood pressure and 
inflammation. In this study, a subset of patients was also identified to have an 
accelerated progression in aortic stiffness. The accelerated progression of aortic 
stiffness seen in patients with COPD was three-fold greater than expected with normal 
ageing, independent of the traditional risk factors, which suggests that COPD is an 
independent risk factor for increased aortic stiffness and premature vascular ageing, 
which subsequently enhance the risk of CVD. 
A few studies have examined the progression of aortic stiffness over time. Similar to 
the current study, in treated hypertensives, Benetos et al. (2002) reported an annual 
increase in aortic PWV by 0.17 m/s, and was independent of mean arterial pressure. 
In a longitudinal prospective study in patients with renal failure and on chronic 
haemodialysis, Utescu and colleagues (2013) showed that the progression of 0.84 
m/s in aortic stiffness over fourteen months was independent of age, atherosclerosis, 
CVD, diabetes and inflammation. In contrast, Briet et al. (2011) evaluated annual 
progression of aortic stiffness in 180 patients with chronic kidney disease for four 
years. The researchers failed to find a significant change in aortic stiffness. In this 
study, the researchers lost 30% of their population during the follow-up and this may 
explain why the rate of aortic stiffness progression was underestimated. In addition, 
majority of the patients in this study had been prescribed renin-angiotensin system 
blocker, which may have anti-progression effect on aortic vascular properties. 
The link between aortic stiffness and elevated blood pressure is complex and not well 
understood. In this study, the rate of aortic progression was not associated with mean 
arterial pressure, indeed, there was a significant reduction in peripheral and central 
MAP after two years, while aortic stiffness had substantially increased. Similar to the 
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current study, Benetos et al. (2002) reported that the adjusted annual rate of aortic 
stiffness progression was independent of MAP. In another population, Utescu and 
colleagues (2013) found an increase in blood pressure after a period of over one year 
in chronic haemodialysis patients, however, the change in aortic stiffness was not 
dependent on blood pressure. This proposes that the accelerated increase in aortic 
stiffness is independent of blood pressure. Recently, aortic stiffness was found to 
predict the incidence of hypertension (Kaess et al., 2012). Indeed, this is interesting 
as it is in contrast to current understanding and may infer that aortic stiffness develops 
before increases in blood pressure takes place, which implies that there are other 
contributing factors involved in initiating aortic stiffness and its progression. 
Depletion of FFM is a common problem in patients with COPD and increases with low 
BMI and the disease severity (Bolton et al., 2004, Vestbo et al., 2006). However, it is 
not limited to cachectic patients or those at late stage disease, as it exists in normal 
BMI patients with mild to moderate airway obstruction (Vestbo et al., 2006). Studies 
have shown that in patients with COPD, FFMI is inversely related to survival 
independent of BMI and other covariates such as sex, smoking and lung function 
(Schols et al., 2005, Slinde et al., 2005, Vestbo et al., 2006). In patients with COPD, 
free of overt heart disease, Sabit et al. (2010) found that left ventricle mass, FFM and 
cellular protein breakdown were all interrelated suggesting that alterations in cardiac 
and skeletal muscle may occur as part of a global protein catabolic process. 
Reduction of cardiac haemodynamics indices in parallel with loss of FFM may reflect 
the left ventricle dysfunction and its inability to deliver adequate amounts of blood to 
perfuse skeletal muscle leading to tissue deprivation and consequently increased 
protein turnover. Impaired oxygen delivery to skeletal and cardiac muscle as a result 
of reduced blood supply is a further explanation for loss of normal haemodynamics 
and reduced reserve capacity of the cardiovascular system in COPD.  
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Alteration of vascular wall properties may occur via endothelial dysfunction that alter 
collagen and elastin structure and result in arterial stiffness (Zieman et al., 2005). The 
role of endothelial dysfunction in promoting arterial stiffness in COPD is controversial 
and this is largely related to variations of methodological approaches to study 
endothelial function (Barr et al., 2007, Ives et al., 2013, Maclay et al., 2009). However, 
this does not preclude the interaction between endothelium and increased elastin 
degradation, which promotes calcification and atherosclerosis (Zieman et al., 2005). 
Aortic stiffness reflects the pathological state of the central arteries and accumulated 
atherosclerotic changes. Hence, aortic stiffness is elevated in COPD and has 
previously been shown to be associated with aortic calcification, a feature of 
atherosclerosis, left ventricle dysfunction and myocardial injury; suggesting that rapid 
progression of aortic stiffness mirrors the atherosclerotic changes in the aortic wall 
(Bolton et al., 2011, Patel et al., 2013, Sabit et al., 2010a). A recent exploratory study 
in patients with COPD, free from CVD, type 2 DM and inflammatory disease showed 
that deposition of aortic calcification was influenced by vascular inflammation 
measured by F18-Fluorodeoxyglucose positron emission tomography (FDG-PET) 
compared with ex-smoker control subjects (Coulson et al., 2010). Vascular 
inflammation may be implicated in cardiovascular events (Hansson, 2005). This has 
recently been supported from a large retrospective study on 513 non-cancer patients 
who underwent FDG-PET for suspected malignancy (Figueroa et al., 2013). In this 
study, the researchers found vascular inflammation, measured by FDG-PET, is an 
independent predictor of cardiovascular events during a four-year follow-up. Aortic 
atherosclerotic change is usually preceded by activation of endothelium where there is 
elastin breakdown caused by high sheer stress, which subsequently may lead to 
initiation of local inflammatory response (Hansson, 2005). 
Patients with COPD have evidence of both pulmonary and extrapulmonary elastin 
breakdown (Black et al., 2008, Maclay et al., 2012). In the lung, degradation of elastin 
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results in loss of lung compliance and airway patency, while an altered ratio of elastin 
to collagen in the vasculature results in arterial stiffening (Maclay et al., 2012). 
Patients with emphysema experienced greater skin elastin degradation and increased 
expression of MMP-9 compared with non-COPD smoking controls, which were 
associated with increased aortic stiffness. Increased elastin breakdown is involved in 
vascular calcification, which promotes atherosclerotic features and stiffness (Bolton et 
al., 2011, Maclay et al., 2012, Zieman et al., 2005). Such alterations may be 
genetically predetermined or secondary to increased elastolytic compounds such as 
MMP– 9 (Maclay et al., 2012). In healthy subjects as well as patients with COPD, 
MMP-9 is associated with increased aortic stiffness (Maclay et al., 2012, Yasmin et 
al., 2006). This infers that patients with COPD may be genetically predisposed to have 
enhanced aortic stiffness, which could be mediated via several stimuli including 
connective tissue degradation. This increases the susceptibility of autoimmune 
involvement and may explain the failure of the immune system to suppress persistent 
inflammation associated with COPD (Agusti et al., 2003).  
Persistent systemic inflammation in COPD may play a role in the development of 
aortic stiffness and increase the risk for cardiovascular disease. Several cross-
sectional studies have found an association between arterial stiffness and 
inflammation while others did not (Cinarka et al., 2013, Maclay et al., 2009, Mills et al., 
2008). Yet, the nature of these studies limits their findings as COPD is a 
heterogeneous disease and drawing a conclusion based on a single visit 
measurement is inconclusive. Controlling for other confounding factors such as 
tobacco exposure and blood pressure is also lacking in some studies. Therefore, the 
relevance of this relationship cannot be established based on this design. The current 
longitudinal study overcomes these limitations and found no association between 
progression of aortic stiffness and inflammatory biomarkers. Interestingly, in this 
study, although aortic stiffness increased over two years, the CRP level remained 
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unchanged over the period of follow-up while a third of the patients remained 
inflammation free (i.e. CRP within the normal limit). Similar findings have also been 
reported in another group of patients with chronic kidney disease and on long term 
haemodialysis (Utescu et al., 2013). The investigators in this study observed that the 
level of CRP remained stable during the follow-up period of fourteen months, and was 
not related to the progression of aortic stiffness.   
The role of systemic inflammation in the pathogenesis of aortic stiffness cannot be 
excluded, but it may not be responsible for the initiation of aortic stiffness in COPD or 
the inflammatory biomarkers used in the current study may not reflect local 
inflammation in the aorta. Indeed, the recent investigative work by Coulson and 
colleagues (2010) who supported this assumption and showed that aortic 
inflammation and calcification, measured by FDG-PET, was independent of systemic 
inflammation. This is not extraordinary in COPD as the systemic inflammation is not a 
constant feature in all patients with COPD (Agusti et al., 2012). Recently, in the 
ECLIPSE cohort study, Agusti and colleagues (2012) found that systemic 
inflammation behaved differently in COPD, as about a third of their patients were free 
from abnormal systemic inflammation, while another third expressed no changes in 
their inflammatory biomarkers after a year of follow-up (Agusti et al., 2012). 
Moreover, a subset of patients was identified to have a rapid increase in aortic 
stiffness progression, independent of blood pressure, lung severity and inflammation.  
The association of aortic stiffness progression in COPD with age suggests that age 
related vascular changes occur prematurely in COPD. Similarly, Benetos and 
colleagues (2002) reported that progression of aortic stiffness in patients with 
hypertension was age dependent. The increase of 1.6 m/s means that the estimated 
biological aortic age for this group of patients is 16 years greater than their 
chronological age, which increases the cardiovascular risk by more than 22% 
(Vlachopoulos et al., 2010). The theory of premature ageing has recently been 
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appreciated in COPD and numbers of studies have been increasing to understand 
cellular and molecular mechanisms of biological ageing.  From the same community 
population, Sabit and colleagues (2007) were the first to suggest that COPD causes 
premature vascular ageing characterised by increased aortic stiffness. COPD 
provokes elastin degradation either inside the lung by destruction of the lung 
parenchyma or externally via vascular elastin and collagen deposition (Black et al., 
2008, Maclay et al., 2012). In the current study, the mean rate of decline in FEV1 in 
the progressors was 140 ml. Rapid decline in the lung function could be responsible 
directly or indirectly for elastin breakdown, which subsequently increases aortic 
ageing. A similar finding was reported in a cross-sectional study by Zureik et al. 
(2001) in 194 middle-age men free from overt cardiovascular disease. They found that 
for every 93 ml reduction in FEV1, aortic stiffness increased by 2.5 m/s. Patel et al. 
(2006) found an association between COPD and skin wrinkling, indicative of elastin 
degradation, and was age dependent. This finding was also extended by Maclay and 
co-authors (2012) who showed a relationship between skin elastin breakdown and 
MMP-9 and both were associated with increased aortic stiffness. Circulating MMP-9 
has been implicated in the pathogenesis of atherosclerosis and predisposing factor to 
aortic stiffness (Yasmin et al., 2006).  
Atherosclerosis and COPD are both chronic inflammatory states that may cause 
premature vascular ageing and certainly share common risk factors such as smoking, 
inflammation, endothelial dysfunction and protease/antiprotease imbalance such as 
circulating MMP-9. In COPD, the severity of airways disease is associated with 
increased carotid intima-media thickness, and this atherosclerotic change can occur 
during the early stage of the disease, independent of smoking. Subclinical 
atherosclerosis occurs early in COPD because of endothelial dysfunction and 
microvascular alteration and progresses with the decline in lung function (Barr et al., 
2012). Endothelial dysfunction has recently been implicated in the pathogenesis of 
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arterial stiffness in COPD, which interestingly could be reversed by ingestion of an 
antioxidant cocktail (Ives et al., 2013). A study by Bolton et al. (2011) in patients with 
COPD showed that aortic stiffness is associated with aortic calcification and it was 
independent of MAP. In the light of current results and previous findings mentioned 
above, COPD may cause premature vascular ageing, which is characterised by 
increased aortic stiffness independent of conventional cardiovascular risk factors. 
Aortic stiffness could reflect a vascular insult occurring in its early stage and 
underlying hidden or sub-clinical cardiovascular disease.  
Study limitations 
The major limitation of this longitudinal study is lack of a non-COPD group to compare 
the extent of aortic stiffness progression and factors influencing it. A second limitation 
was no cardiac scan had been done to confirm subclinical damage to the heart as well 
as there was no measure performed to ascertain the presence of atherosclerosis. 
Conclusion 
COPD is an independent risk factor for progression of aortic stiffness. Accelerated 
increase in aortic stiffness occurs in a sub-group of patients with COPD, which is 
independent of traditional risk factors. This may enhance the risk of cardiovascular 
events and promote more research on the causes and mechanisms. Accelerated 
aortic stiffness progression may reflect cumulative, subclinical target organ damage 
with decline in functional reserve that is manifested as frailty.  Given the simplicity and 
rapidity of aortic stiffness measurement, its use in primary care practice could be 
beneficial to identify people with COPD who are at increased risk of cardiovascular 
disease and administer appropriate preventive strategy. Future interventional studies 
are required to slow the progression of aortic stiffness and reduce the risk of CVD in 
COPD.  
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6 Chapter Six 
Cross-sectional and Longitudinal 
Evaluation of Frailty in COPD 
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Introduction 
This chapter of the thesis evaluated frailty in patients with COPD and was subdivided 
into two parts: 
The first part was a cross-sectional study including all the participants recruited into 
the ARCADE study at initial visit to establish the concept of frailty. 
The second part of this chapter was a longitudinal study of patients who had been 
reviewed after their completion of two years from their participation at the initial visit. 
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6.1 Background 
Frailty is a progressive clinical syndrome in parallel with COPD and ageing. Frailty 
and COPD are both associated with increased comorbidities and reduced functional 
activity and physical capacity (Fried et al., 2004, Rockwood, 2005, Savva et al., 2013, 
Thomsen et al., 2012, Waschki et al., 2011). The latter is a risk factor for many 
comorbid conditions including cardiovascular disease, osteoporosis, metabolic 
disorders and sarcopenia (Barnes and Celli, 2009, Watz et al., 2008). Frailty is a 
complex phenomenon and its relation with ageing makes the distinction between the 
two difficult. However, in COPD, these signs appear early and may represent 
premature ageing and consequently lead to frailty, which are gender dependent 
(Agusti et al., 2010, Aryal et al., 2013, Cesari et al., 2004, Gale et al., 2013). In 
parallel with the proposed theory of frailty, which implies that failure of physiological 
systems to respond to further stressors, leading to an interruption of homeostasis 
status and appearance of frailty (Walston et al., 2006). Several underlying 
physiological mechanisms have been proposed to cause frailty including 
inflammation, immunosenescence, obesity and lack of activity (Abbatecola and 
Paolisso, 2008, Clegg et al., 2013, Fulop et al., 2010). COPD is accompanied by 
various extra-pulmonary comorbidities, which increases morbidity and risk of death 
(Divo et al., 2012, Vanfleteren et al., 2013). Most assessments of disease status, 
particularly in routine clinical settings, do not include comorbidities, though recently a 
scoring system based on the BODE index and comorbidities predictive of non-survival 
was described, and was predictive of the mortality risk over a four year period (Divo et 
al., 2012).   
Comorbidities represent deficits in individual physiological systems and are often 
multiply present in a single patient (Vanfleteren et al., 2013). The presence of multiple 
comorbidities in COPD resembles the accumulation of deficits in physiological 
systems seen in natural ageing (Fried et al., 2001, Rockwood and Mitnitski, 2011). 
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Frailty better predicts adverse outcomes than age independent of co-existing medical 
conditions and is associated with an increased risk of falls, hospitalisation, residential 
care and reduced HRQoL, and progression to disability and increased mortality (Fried 
et al., 2001, Jones et al., 2005, Rockwood and Mitnitski, 2007, Fried et al., 2009, 
Rockwood and Mitnitski, 2011, Rockwood et al., 2005, Romero-Ortuno and Kenny, 
2012). The similarities between the accumulation of deficits in ageing and multiple 
comorbidities in COPD, suggests that frailty is likely to be common in COPD, and be 
related to comorbidities and increased morbidity.  
However, the frailty concept in COPD needs to be established using a validated 
measure of frailty and subsequently confirm this finding in a longitudinal study to 
target future understanding and management of frailty in COPD, as there is no study 
so far which has examined the rate of frailty progression in either health or disease. 
Only a few longitudinal studies are available on frailty and these studies looked at the 
incidence of frailty (Barzilay et al., 2007, Baylis et al., 2013, Gale et al., 2013, Puts et 
al., 2005b). 
Hypothesis 
Patients with COPD would be more frail and have more impairments compared with 
similar age and sex comparator subjects. Additionally, the patients would have an 
increase in the frailty index after two years from the initial assessment. 
Aim 
The aim of this study was to examine the frailty concept in patients with COPD 
compared with similar age and gender non-COPD subjects. Secondly, this study 
aimed to evaluate the change in frailty in patients with COPD over time. 
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6.2 Method 
This was a cross-sectional study of patients with stable COPD confirmed, with 
spirometry and comparators from the Assessment of Risk in Chronic Airways Disease 
Evaluation (ARCADE) study. Comparators were current or ex-smokers free from 
respiratory disease. All subjects were clinically stable and free of inflammatory 
disease such as rheumatoid arthritis, oral maintenance corticosteroids and long-term 
oxygen therapy (full inclusion and exclusion criteria in Chapter 2: Table 2.1, p 65). All 
subjects gave written informed consent and the study had approval from the South 
East Wales Research Ethics Committee. 
Lung Function 
All subjects performed spirometry (Vitalograph), to measure forced expiratory volume 
in one second (FEV1), forced vital capacity (FVC) and the FEV1/FVC ratio (Chapter 
2:2.3.5, p 80). The number of exacerbations per year was recorded. 
Body Composition  
Weight and body composition were measured barefoot in lightweight indoor clothing, 
fat free mass (FFM), fat mass (FM) and the percentage fat were determined using a 
Bioelectrical impedance device (Tanita BC-418). The FFMI was expressed as a 
height-squared ratio and the body mass index (BMI kg/m2) was calculated (Chapter 
2:2.3.1, p 68). A stretch resistant tape measure was used to measure waist and hip 
circumference.  
Physical Performance   
All subjects performed the Timed Up and Go test (Chapter 2:2.3.6, p 79). The 
subjects also undertook the six minute walking distance (6MWD) test. Prior to the test, 
resting heart rate and oxygen saturation was recorded by pulse oximetry with the 
subjects breathing air (Chapter 2:2.3.7, p 81).  
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Handgrip Measurement 
Maximal right and left handgrip strength (HGS) was determined twice in each hand 
using a hand dynamometer (T.K.K. 5401 grip-D, Takei, Japan) (Chapter 2:2.3.8, p 
84). 
Measurement of Pulse Wave Velocity 
Aortic PWV was assessed non-invasively using the SphygmoCor device connected to 
a laptop computer (Chapter 2:2.3.3, p 72).  
Cardiac Haemodynamics Measurement 
Cardiac haemodynamics were measured non-invasively using a new bioreactance 
technology (NICOM, Cheetah, Medical Inc., Indianapolis, IN) (Chapter 2:2.3.4, p 77).  
Inflammatory Biomarkers 
High sensitivity C-reactive protein (CRP) and fibrinogen were determined from a blood 
sample according to standard procedures (University Hospital of Wales, 
Biochemistry). 
Frailty  
A modified version of the comprehensive geriatric assessment specific to community 
dwelling individuals was administered to all participants (Chapter 2:2.3.10, p 85). A 
Frailty Index was calculated by dividing the total number of CGA deficits by the 
maximum, 61. 
Health Related Quality of Life 
The patients completed the St. George‘s Respiratory Questionnaire (SGRQ) and the 
COPD Assessment Test (CAT) that were previously detailed (Chapter 2:2.3.9, p 85). 
The number of reported diagnosed comorbidities in patients and comparators were 
also recorded. 
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Data Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences 
(SPSS, Chicago, IL), version 18.0. Results are presented as arithmetic or median 
(range) (for non-normally distributed), log10 transformed mean and standard deviation 
(SD). Analyses included One-way or Two-way Analysis of Variance (ANOVA) as 
appropriate, Pearson‘s correlations and hierarchical multiple regression analysis. 
Difference between visits was performed using paired t- test. Categorical data was 
analysed using the Chi-square test. The p<0.05 was considered significant. Subjects 
aged less than 50 years were added to the 50-59 age category. 
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6.3 Result 
Subject Characteristics 
The patients (n=500) and comparators (n=150) were similar in age, gender and BMI, 
but the patients had a greater tobacco exposure and a lower FEV1 and FVC 
compared with comparators, all p<0.001 (Table 6.1). The severity of airflow 
obstruction in the patients was GOLD 1 n=73, GOLD 2 n=251, GOLD 3 n=144 and 
GOLD 4 n=32. Of the 500 patients, 207 reported infrequent exacerbations, less than 
two per year, while 293 patients reported two or more per year.  
Body composition was classified according to Landbo et al. (1999), of the 500 
patients, (26) 5% had a low BMI (<19.9 kg/m2), (196) 39% had an elevated BMI (>25 
kg/m2), (163) 33% were classified as obese (BMI>30 kg/m2), while (115) 23% were 
within the normal limit for BMI (20-25 kg/m2). Among comparator subjects, (34) 23% 
had an optimal BMI and (116) 77% had an elevated BMI, 28% of these subjects were 
obese (BMI >30 kg/m2). Patients had greater waist circumference and waist: hip ratio, 
and lower fat free mass and oxygen saturation, all p<0.001. However, both groups 
had similar fat mass (Table 6.1). The proportion of subjects with a prior diagnosis of 
comorbidities was greater in the patients (Table 6.2). Details of reported comorbidities 
and medications in both groups were previously mentioned (Chapter 5, Table 5.2). 
Most of the patients (64%) and comparators (82%) were ex-smokers and had a 
different pack year exposure.  
The TUG test of patients with COPD 11.1 (3.7) s was greater than the comparators, 
8.2 (1.2) s, while the 6MWD of the patients 320 (126) m was less compared with non-
COPD subjects 501 (86) m, all p<0.001. Likewise, the HGS of the patients, 25.6 (9.8) 
was weaker than the comparators, 31.1 (10.4) kg, p<0.001. 
Circulating CRP and fibrinogen were greater in patients with COPD compared to non-
COPD subjects, all p<0.001 (Table 6.1). 
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Table 6.1: Physical and clinical characteristics of patients with COPD and comparators 
at initial visit 
 COPD (n=500) 
(n= 500) 
Comparator (150) 
(n= 150) 
p value 
Gender Male:Female 255:245 75:75 0.451 
Age (years) 66 (7.3) 65 (8.0) 0.125 
Smoking (pack-years) 41 (25.5) 21 (17.9) 0.001 
FEV1 (L) 1.64 (0.84) 2.73 (0.67) 0.001 
FVC (L) 2.50 (0.98) 3.50 (0.90) 0.001 
FEV1/FVC (L) 0.53 (0.11) 0.78 (0.05) 0.001 
FEV1 (%) 59 (21) 105 (13) 0.001 
FVC (%) 87 (21) 110 (15) 0.001 
BMI (kg/m
2
) 28.1 (5.5) 28.3 (4.2) 0.664 
Waist circumference (cm) 100 (15) 95 (13) 0.001 
Hip circumference (cm) 104 (11) 105 (12) 0.891 
Waist:Hip ratio 1.0 (0.1) 0.9 (0.1) 0.001 
HGS (kg) 27.1 (9.9) 31.0 (10.2) 0.001 
FFM (kg) 49.6 (11.0) 52.2 (9.5) 0.011 
FFMI (kg/m
2
) 18.1 (2.6) 18.5 (2.3) 0.088 
Fat mass (kg) 26.9 (11.1) 26.9 (8.6) 0.985 
Aortic PWV (m/s) 9.9 (2.40) 8.3 (1.66) 0.001 
CO (L/min) 5.84 (1.21) 5.95 (1.03) 0.324 
Stroke Volume (ml) 86 (20) 96 (20) 0.001 
6MWD (m) 324 (124) 502 (86) 0.001 
TUG (s) 11.1 (3.7) 8.2 (1.2) 0.001 
Resting O2 saturation (%) 97 (2) 98 (1) 0.001 
Fibrinogen (g/L)# 3.51 (1.31) 3.08 (1.25) 0.001 
CRP (mg/L)# 3.49 (2.89) 1.76 (3.18) 0.001 
All data mean (SD) unless otherwise indicated, # Geometric mean  
Abbreviations: FEV1= forced expiratory volume in 1 second; FVC= forced vital capacity;  
BMI= body mass index; HGS= handgrip strength; FFM= fat free Mass; FFMI= fat free mass 
index; 6MWD= six minute walk distance; TUG= Timed Up and Go; CRP= C-reactive protein. 
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Frailty 
The total CGA score and the FI were greater in patients than comparators (Table 6.2). 
The possibility that comorbidities might unduly weigh the FI in COPD was addressed 
by comparing the scores after exclusion of the medical comorbidity scores, the CGA 
score remained greater in the patients than in non-COPD subjects, p<0.001 (Table 
6.2). The FI was not related to age in either group and did not differ across age 
categories, p>0.05. However, patients with COPD had a greater FI than comparator 
subjects across age categories (Figure 6.1). The total FI was related to the number of 
previously diagnosed comorbidities, which included hypertension, angina, atrial 
fibrillation, hypercholesterolaemia, diabetes and osteoporosis, in patients (r =0.456) 
and comparators (r =0.421), all p<0.001 (Table 6.3).  
Using the upper 95%CI of the FI for the comparator group (0.05), as an upper limit for 
non-frail status in non-COPD subjects, 446 (92%) of the 500 patients were frail, and 
56 (37%) of the comparators were frail.  
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Table 6.2: Questionnaire scores in patients with COPD and comparators 
 COPD (n= 500) Comparator (n= 150) p value 
CGA Total 8.3 (0.25-28.5) 2.25 (0.0-11.25) 0.001 
CGA without medical 2.8 (0.0-14.0) 0.25 (0.0-5.25) 0.001 
Frailty Index 0.15 (0.08) 0.05 (0.04) 0.001 
SGRQ Symptom 66 (20) - - 
SGRQ Activity 66 (26) - - 
SGRQ Impact 38 (21) - - 
SGRQ Total 51 (20) - - 
Total CAT Score 21 (9) - - 
Data are Median (range) or Mean (SD), - = not assessed 
Abbreviations: CGA= Comprehensive Geriatric Assessment; SGRQ= St George‘s 
Respiratory Questionnaire; CAT= COPD Assessment Test. 
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Table 6.3: Relationships of FI with physical and clinical characteristics in patients with 
COPD and comparator subjects at initial visit 
Pearson’s correlation COPD 
(n=500) 
p value Comparator 
(n=150) 
p value 
Age (years) -0.004 0.937 0.122 0.138 
FEV1 (%) -0.193 0.001 -0.201 0.014 
FEV1/FVC  -0.035 0.439 0.097 0.238 
Smoking (pack-years) 0.037 0.409 -0.002 0.977 
No. Exacerbations/year 0.262 0.001 - - 
BMI (kg/m
2
) 0.173 0.001 0.281 0.001 
Waist circumference (cm) 0.157 0.001 0.177 0.035 
Hip circumference (cm) 0.130 0.005 0.202 0.014 
Waist:Hip ratio 0.089 0.050 0.014 0.869 
FFM (kg) -0.057 0.206 -0.084 0.307 
FFMI (kg/m
2
) 0.043 0.341 -0.005 0.947 
Fat Mass (kg) 0.148 0.001 0.325 0.001 
HGS (kg) -0.353 0.001 -0.182 0.026 
Aortic PWV 0.088 0.052 0.192 0.019 
CO (L/min) 0.004 0.930 -0.015 0.857 
SV (ml) -0.140 0.003 -0.112 0.184 
6MWD (m) -0.581 0.001 -0.371 0.001 
TUG (s) 0.516 0.001 0.082 0.324 
Resting O2 saturation (%) -0.155 0.001 -0.206 0.012 
log10Fibrinogen (g/L) 0.162 0.001 0.191 0.023 
log10 CRP (mg/L) 0.156 0.001 0.271 0.001 
Number of Comorbidities 0.456 0.001 0.421 0.001 
All data mean (SD) unless otherwise indicated. 
Abbreviations: FEV1= forced expiratory volume in 1 second; BMI= body mass index; FFM=   
fat free Mass; FFMI= fat free mass Index; HGS= handgrip strength; CO= cardiac output; SV= 
stroke volume; 6MWD= six minute walk distance; TUG= Timed Up and Go; CRP= C-reactive 
protein. 
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Figure 6.1: Bar chart illustrating the difference in FI between patients with COPD and 
comparators across age categories at initial visit 
Data presented as mean with SD. 
ANOVA, p<0.001. 
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Relationship between Frailty and Physical Performance  
The FI was related to the 6MWD (r=-0.58) and TUG (r=0.52) in patients with COPD, 
all p<0.001, but was only related to the 6MWD (r=-0.37) in the comparators, p<0.001 
(Table 6.3).  
Relationship between Frailty and Body Composition 
The patients and comparators had similar BMI, p>0.05 (Table 6.1), but patients with 
COPD had greater FI than the comparator group across the BMI category, p<0.001 
(Figure 6.2). In the patients, the FI was greater at the extremes of BMI (Figure 6.2). 
However, in the comparator group, the FI increased with BMI, p<0.01. The FI was 
related to the FM and waist circumference in both patients and comparators, all 
p<0.01, but not the FFM (Table 6.3).  
Relationship between Frailty and Gender 
 
The FI of female patients 0.17 (0.08) was greater than their male counterparts 0.14 
(0.09), p<0.001. Similarly for the comparators, females 0.05 (0.04) were more frail 
than males 0.04 (0.03), p<0.001. The difference remained after controlling for age, 
waist: hip ratio and log10 CRP in the patients (Adjusted R
2= 7%, F=23.80, p<0.001) 
and the comparators (Adjusted R2= 12%, F=9.27, p=0.003). A Two-way ANOVA 
showed that female patients with COPD had a greater FI after the age of 60 than the 
male patients, F= 2.51, p=0.040. 
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Figure 6.2: Bar chart illustrating the difference in frailty index between patients with 
COPD and comparator subjects across BMI categories at initial visit 
 Data presented as mean with SD. 
 
ANOVA, Bonferonni post-hoc, p<0.001. 
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Relationship between Frailty Index and Lung Function 
The FI was related to FEV1% predicted in the patients (r=-0.19, p<0.001) and the 
comparators (r=-0.20, p=0.019). In the patients, there was a significant difference in FI 
across GOLD categories, p<0.01. Post hoc analysis showed the only difference 
existed across the GOLD categories was between GOLD1 and GOLD3, p<0.001. 
However, the FI of the comparators was lower than the patients across all GOLD 
categories, p<0.001 (Figure 6.3). 
Relationship between Frailty and Cardiac Function 
In the patients, the FI was related to stroke volume (r=-0.14, p=0.003), but was not in 
the comparators. The stroke volume of the patients was also associated with FFM 
(r=0.58, p<0.001) and FFMI (r=0.46, p<0.001). The FI was not associated with cardiac 
output in either group, p>0.05 (Table 6.3). There was no relationship between FI and 
aortic stiffness in the patients, but it was evident in the comparators (r=0.19, p=0.019). 
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Figure 6.3: Bar chart representing FI in patients with COPD across GOLD categories 
and comparator subjects at initial visit 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc. 
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Relationship between Frailty and Inflammatory Biomarkers 
Both circulating CRP and fibrinogen were related to the FI in the patients and 
comparators, all p<0.05 (Table 6.4). The frailty score in the patients was also related 
to the number of exacerbations per year, (r=0.262, p<0.001). The FI of frequent 
exacerbators, 0.17 (0.08), was greater than infrequent exacerbators, 0.13 (0.08), and 
both were greater than that of the comparators, 0.05 (0.04), p<0.001 (Figure 6.4). 
Based on the FI upper 95%CI of the comparators, 165 of 204 (81%) infrequent 
exacerbators and 277 of 296 (94%) frequent exacerbators were frail. 
Relationship between Frailty and Health Related Quality of Life 
The FI score of the patients was related to SGRQ (r=0.60) and its sub-domains; 
activity (r=0.57), symptom (r=0.42) and impact (r=0.57), all p<0.001. Similarly, the 
health status as measured by the total score of the CAT was related to the FI score of 
the patients (r=0.54, p<0.001). 
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Figure 6.4: Comparison between comparators and patients with infrequent and frequent 
exacerbation at initial visit 
Data presented as mean with SD. 
ANOVA, Bonferonni post-hoc. 
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Disease status and frailty 
Based on the upper 95%CI of the FI for the comparator group (0.05), to define an 
upper limit for non-frail status in all subjects, patients and comparators were classified 
as frail or non-frail. The differences between non-frail and frail comparators were a 
shorter 6MWD, p=0.003, and CRP, p=0.029. Similarly, comparison between non-frail 
comparators and non-frail patients revealed a shorter 6MWD in the patients, p=0.002, 
a greater level of CRP, p=0.023, apart from spirometric indices. Comparison between 
frail comparators and non-frail patients only showed differences for spirometry 
measures, all p<0.001. Comparisons between frail comparators and frail patients 
demonstrated a lesser 6MWD, with greater number of co-morbidities and 
exacerbations per year in the patients, all p<0.001. Comparing the non-frail and frail 
patients revealed that frail patients had a lesser stroke volume, 6MWD and HGS with 
a greater aortic PWV, TUG test, waist circumference, number of diagnosed co-
morbidities and exacerbations than non-frail, all p<0.001 (Table 6.4). The COPD 
specific measures of the total SGRQ and CAT score were greater in the frail patients, 
p<0.01. 
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Table 6.4: Comparison between frail and non-frail patients with COPD at initial visit 
 Frail (n=446) Non-Frail (n=54) p value 
Age (years) 66 (7) 65 (7) 0.380 
FEV1% predicted 58 (20) 66 (21) 0.011 
SGRQ 53.1 (19.1) 21.6 (13.6) 0.001 
BMI (kg/m
2
) 28.2 (5.6) 26.4 (3.2) 0.049 
Waist circumference (cm) 100 (15) 94 (10) 0.025 
Waist:Hip ratio 0.96 (0.10) 0.93 (0.06) 0.054 
Fat Mass (kg) 27.2 (11.4) 23.5 (7.2) 0.227 
FFM (kg) 49.6 (11) 50.3 (11.2) 0.704 
HGS (kg) 26.6 (9.7) 32.5 (10.1) 0.001 
Aortic PWV (m/s) 10.0 (2.4) 9.0 (1.9) 0.012 
CO (L/min) 5.8 (1.2) 5.8 (1.0) 0.482 
SV (ml) 85 (20) 92 (23) 0.042 
6MWD (m) 313 (121) 450 (72) 0.001 
TUG (s) 11.3 (3.8) 8.7 (1.4) 0.001 
Smoking (packs/year) 41 (25) 36 (23) 0.229 
No. Exacerbations/ year 2.3 (1) 1.0 (1) 0.001 
CAT 21.4 (8.3) 11.3 (6.9) 0.001 
CRP (mg/L)# 3.6 (2.9) 2.80 (2.2) 0.174 
Fibrinogen (g/L)# 3.6 (1.3) 3.1 (1.2) 0.006 
   All data mean (SD) unless otherwise indicated, # Geometric mean  
  Abbreviations: FEV1= forced expiratory volume in 1 second; BMI= body mass index; FFM=    
fat free mass; HGS= handgrip strength; PWV= pulse wave velocity; CO= cardiac output; SV= 
stroke volume; 6MWD= six minute walk distance; TUG= Timed Up and Go; SGRQ = St 
George‘s Respiratory Questionnaire; CAT= COPD Assessment Test; CRP = C-reactive 
protein. 
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Predictive Factors for Frailty  
A hierarchical multiple regression was conducted with the FI as a dependent variable. 
Gender was entered at stage one to control for gender. The TUG, HGS, waist 
circumference, 6MWD, FEV1% predicted, MRC and SGRQ Activity score were 
entered at stage two because these variables are commonly associated with frailty. 
Third stage included potential variable including stroke volume, CRP, fibrinogen and 
number of exacerbations. 
In the patients, the hierarchical multiple regression revealed that gender contributed 
2% to variation in frailty (F=10.59, p=0.001). Introducing HGS, 6MWD, TUG and 
SGRQ Activity score to the model explained an additional 43% of variation in frailty 
and this change in R2 was significant (R2=45, F=48.6, p<0.001). However, adding 
potential variables to the regression model demonstrated no additional variation in 
frailty (R2=0.001, F=0.438.6, p=0.646). The most important predictors of frailty were 
SGRQ Activity score, TUG, HGS and 6MWD, and these four predictors explained 
45% of variation in frailty (Table 6.5).  
Similar to the patients, gender explained 4% of variation in frailty in comparator group 
(F=6.75, p<0.001). Introducing 6MWD to the model added an additional 13% of 
variation in frailty with significant change in R2  (R2=17%, F=5.05, p<0.001). However, 
adding potential variables to the regression model revealed no significant change in 
the model (R2=0.005, F=0.437, p=0.647). The only predictor of frailty in the 
comparators was 6MWD, which explained 17% of variation in frailty (Table 6.6). 
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Table 6.5: Hierarchical multiple regression for variables predicting frailty in patients 
with COPD at initial visit 
  B SE Beta p value  Adjusted R
2
 
Stage 1 .02 
Gender .024 .007 .144 .001 
Stage 2  .45 
HGS (kg) -.002 .000 -.201 .000 
6MWD (m) .000 .000 -.148 .004 
TUG (s) .006 .001 .251 .000 
SGRQ Activity score .001 .000 .303 .000 
Stage 3 .45 
HGS (kg) -.002 .000 -.200 .000 
6MWD (m) .000 .000 -.144 .005 
TUG (s) .006 .001 .252 .000 
SGRQ Activity score .001 .000 .303 .000 
Abbreviations: HGS= handgrip strength; 6MWD= six minute walk distance; TUG= Timed Up 
and Go; SGRQ= St George‘s Respiratory Questionnaire.  
 
Table 6.6: Hierarchical multiple regression for variables predicting frailty in comparator 
subjects at initial visit 
 B Std. Error Beta p value Adjusted R
2 
Stage 1 0.04 
Gender .015 .006 .210 0.010  
Stage 2 0.17 
6MWD (m) .001 .001 -.288 0.001  
Stage 3 0.17 
6MWD (m) .001 .001 -.274 0.003  
Abbreviation: 6MWD= six minute walk distance 
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Frailty Longitudinal Results 
The frailty index of the 143 patients who completed the two years follow-up had 
increased (Table 6.7). Using the predetermined frailty index of 0.05 as an acceptable 
upper limit for non-frail patients with COPD (page. 197), 133/143 patients were frail at 
the baseline and continued to be frail at the follow-up visit, five patients had 
progressed from non-frail status at baseline to be frail at two years follow-up, while 
two patients remained non-frail during the study period. The frailty status of three 
patients reduced and patients became non-frail at the two years follow-up 
assessment. The severity of airflow obstruction by GOLD stratification was mentioned 
previously (Chapter 5, page. 158). The distribution of the modified MRC 
breathlessness score was: mMRC 0 n= 14, mMRC 1 n= 42, mMRC 2 n=34, mMRC 3 
n=48 and mMRC 4 n=5. 
After two years, 10% had lost some weight while 8% had gained weight. Following the 
classification used by Landbo et al. (1999), of the 143 patients, 7% had a low BMI 
(<19.9 kg/m2), 37% had an elevated BMI (25-29.9 kg/m2) and 34% were classified as 
obese (BMI>30 kg/m2), while 21% were within the normal limit for BMI (20-24.9 
kg/m2). Based on previous published data on patients with COPD from this 
geographical region (South Wales), Bolton et al. (2004) classified a low FFMI for men 
as <16.89 kg/m2 and <13.28 kg/m2 for women. Using these cut-off values, 9 patients 
had a low FFMI. Four of these had a low BMI, therefore 5 had a hidden loss of FFM.  
The patients demonstrated significant loss of FFM and HGS after two years from their 
initial visit, while there was no change in BMI and other body composition indices, 
p>0.05 (Table 6.7).  
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Table 6.7: Physical and physiological changes in the patients after two years from the 
initial assessment 
  Initial visit 
(n=143) 
Follow-up visit 
(n=143) 
Mean change 95%CI  p value 
Age (years) 68 (7) 70 (7)     
Gender (Male:Female) 65:78 65:78    - 
FI 0.16 (0.08) 0.18 (0.09) 0.02 0.01 0.03 0.001 
FEV1 (L) 1.3 (0.5) 1.1 (0.5) -0.12 -0.16 -0.07 0.001 
FVC (L) 2.4 (0.08) 2.3 (0.8) -0.16 -0.23 -0.08 0.001 
FVC% predicted 83 (19) 79 (22) -4 -7 -2 0.001 
FEV1%predicted 54 (19) 51 (16 -3 -4 -1 0.001 
Smoking (pack-years) 42 (30) 43 (28) 1.25 -3 5 0.519 
BMI (kg/m
2
) 28 (6) 27.8 (6)  -0.20 -0.59 0.21 0.356 
Waist (cm) 99 (15) 99 (15) -0.16 -1.30 0.99 0.786 
Waist:Hip ratio 0.94 (0.10) 095 (0.12) 0.01 0.01 0.02 0.120 
Fat Mass (kg) 26.7 (11) 26.2 (10.5) -0.55 -1.44 0.34 0.224 
FFM (kg) 48.6 (10.8) 48.1 (10.8) -0.53 -1.05 -0.01 0.048 
FFF:FM 2.2 (1.3) 2.2 (1.2) 0.01 -0.15 0.18 0.932 
HGS (kg) 26.2 (9.8) 24.6 (9.9) -1.6 -3.63 -0.87 0.002 
CO (L/min) 5.7 (1.1) 5.5 (1.2) -0.20 -0.30 -0.02 0.024 
Stroke Volume (ml) 83 (19) 79 (20) -4 -7 -2 0.001 
6MWD (m) 307 (83) 328 (145) 21 3 39 0.003 
TUG (s) 11.4 (3.9) 13.2 (8.3) 1.8 0.7 2.8 0.001 
No. Exacerbation/ year 2.5 (1.95) 2.9 (2.2) 0.4 0.03 0.70 0.034 
mMRC  1.95 (1.1) 2.24 (1.22) 0.31 0.08 0.50 0.008 
SGRQ Symptom 67 (19) 68 (20) -1 -2 -4 0.486 
SGRQ Impact 42 (19) 40 (18) -2 -3 -5 0.087 
SGRQ Activity 72 (22) 73 (23) -1 -2 -4 0.499 
Resting O2 saturation (%) 96 (2) 96 (2) 0 -0.08 0.63 0.128 
CRP (mg/L)# 3.0 (2.8) 3.1 (2.6) 0.1 0.9 1.2 0.953 
Fibrinogen (g/L) 3.7 (1.1) 3.3 (0.9) -0.40 -0.56 -0.20 0.001 
Data presented as mean (SD), # Geometric mean and mean (95%CI). 
Abbreviations: FI= frailty index; FEV1= forced expiratory volume in one second; FVC= forced 
vital capacity; BMI= body mass index; FM= fat mass; FFM = fat free mass; FFM:FM= fat free 
mass to fat mass; HGS= handgrip strength; CO=  cardiac output; SV=  stroke volume; 6MWD= 
six minute walk distance; TUG= Timed Up and Go; mMRC= modified Medical Research 
Council; SGRQ= St George‘s Respiratory Questionnaire; CRP= C-Reactive protein. 
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The Relationship between Physical Performance and Increased Frailty 
Increased frailty was associated with reduced physical performance as assessed by 
TUG test (r=0.39, p<0.001) and 6MWD (r=-0.19, p=0.034). The change in the TUG 
score was associated with the change in the 6MWD (r=-0.25, p=0.006). 
The relationship between Body Composition and Increased Frailty 
In the patients, increased frailty index was associated with loss of fat free mass (r=-
0.19, p=0.023) and handgrip strength (r=-0.25, p=0.004). Patients continued to follow 
a U-shaped pattern that was seen in the cross-sectional analysis. Frailty was higher 
on the extreme than who were considered to be normal or overweight (p<0.05).  
The Relationship between Gender and Increased Frailty 
In the cross-sectional analysis, female patients were more frail than the males. The 
gender variation persisted at the follow-up assessment with female patients 
demonstrating a greater change in the frailty index compared to their male 
counterparts (Figure 6.5). The difference remained after correcting for age (R2= 2%, 
F=5.16, p=0.025). The TUG time of the female patients had increased by mean 
(95%CI) 2.7 (0.9 to 4.5) s while the males had no change in the TUG test. In contrast, 
the 6MWD of the female patients remained as it was at the initial assessment, 2 (-20 
to 24) m, p>0.05, while the males had increased by mean (95%CI) 43 (15 to 72) m, 
p<0.01. The change in the 6MWD did not relate to the change in FI in the male 
patients.  
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Figure 6.5: Gender difference of frailty index in the patients at 2 years 
     Female                              Male 
Data presented as mean with SD. 
 
  
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Baseline 2-year Follow up
F
ra
ilt
y 
In
d
e
x
 
Time of Assessment 
p<0.05 
 225 
 
The Relationship between Cardiac Function and Increased Frailty 
The increase in frailty index was associated with a decline of cardiac hemodynamic 
indices as measured by stroke volume (r=-0.22, p=0.009) and cardiac output (r=-0.19, 
p=0.029). The decline in stroke volume and cardiac output in the patients was also 
related to the loss of fat free mass (r=0.23, p=0.008), (r=0.19, p=0.030), respectively. 
There was no association between the change in frailty index and the change in aortic 
PWV and its subcategories (progressors and non-progressors). 
The Relationship between Lung Function and Increased Frailty 
There was no association between the change in frailty index and the change in 
FEV1% predicted. The analysis was further expanded and no change in frailty across 
the GOLD categories was found. 
Relationship between Inflammatory Biomarkers and Increased Frailty 
Neither circulating CRP nor fibrinogen level was related to the change in frailty index 
of the patients, though the fibrinogen level had significantly decreased over the period 
of follow-up.  
There was no association between the change in frailty index and the change in the 
number of exacerbations, p>0.05. 
Relationship between the Number of Comorbidities and Increased Frailty 
In this longitudinal study, the change in frailty index did not relate the number of 
comorbidities, p>0.05. Interestingly, based on the upper limit of 95%CI of the frailty 
index for the comparator group (0.05), a group of patients without reported 
comorbidities was identified to be frail. 
Health Related Questionnaires. 
Although, in this study, there was an increase in the frailty index over the two years 
follow-up, the health-related quality of life measured by the SGRQ and CAT 
questionnaires did not change.  
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Predictive factors for Increased Frailty Index 
A hierarchical multiple regression was conducted with the FI change as a dependent 
variable. Gender was entered at stage one to control for gender. The change in FFM 
and HGS were entered at stage two to examine the effect of loss of musculoskeletal 
mass and strength on increased frailty. The third stage included the change in 
physical performance as measured by the TUG and 6MWD. Finally, the level of 
dyspnoea was entered at stage four. 
The hierarchical multiple regression revealed that gender could explain 2% of 
variation in the change of frailty (F=4.49, p=0.036). Introducing loss of fat free mass 
and HGS to the model added an additional 6% to the variation in the change of frailty 
information and the change in R2 was significant (R2=8%, F=5.50, p=0.021). Adding 
the change in the TUG time to the regression model explained an additional 11% of 
variation in the change of frailty and this change in R2 was significant (R2=19%, 
F=19.66, p<0.001). However, gender was no longer a predictor of the change in frailty 
as was the 6MWD. Adding breathlessness score to the regression model 
demonstrated no additional variation in the change of frailty (R2=0.013, F=2.26, 
p=0.136). The most important predictors of the change in frailty index were loss of fat 
free mass, loss of HGS and increased TUG time and these predictors explained 19% 
of variation in the change of frailty (Table 6.8).  
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Table 6.8: Hierarchical multiple regression for variables predicting the change in frailty 
in the patients at 2-year follow-up visit 
  B SE Beta p value  Adjusted R
2 
Stage 1 0.02 
Gender -0.02 0.01 -0.18 0.036 
Stage 2 0.08 
Gender -0.019 0.009 -0.16 0.047 
Loss of FFM -0.003 0.001 -0.17 0.036 
HGS -0.003 0.001 -0.19 0.022 
Stage 3 0.19 
Loss of FFM -0.003 0.001 -0.16 0.039 
HGS -0.002 0.001 -0.16 0.036 
Increased TUG time  0.002 0.001 0.35 0.001 
Abbreviations: FFM= fat free mass; HGS= handgrip strength; TUG=Timed Up and Go. 
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6.4 Discussion 
Cross-sectional study: Baseline Findings 
The results of this chapter demonstrated that patients with COPD were more frail than 
the comparator group, free from respiratory disease, as demonstrated by their greater 
CGA deficits and higher frailty index score. More patients, 92% were frail compared 
with the 57.8% previously reported by Park et al. (2013). Comparisons between this 
study and that of Park et al. (2013) and Galizia et al. (2011) are difficult due to 
different assessments of frailty and smaller study populations. Park and colleagues 
(2013) included 70 patients with physician diagnosed COPD without an objective 
measure of airflow limitation, lacked a specific comparator group, or previous 
validation of the frailty questionnaire used. However, the current research used the 
widely validated CGA assessment tool, which allowed to compare subject‘s FI with 
other populations where the FI has been widely used. The FI is a better predictor of 
outcome than chronological age or disability and the need for healthcare support 
(Rockwood et al., 2005, Romero-Ortuno and Kenny, 2012). In the current study, 
female patients and comparators had greater FI than males. A similar relationship was 
reported in the general population, and was similar to the mean FI of 0.15 reported for 
women over 65 years of age (Hubbard et al., 2010, Hubbard and Rockwood, 2011, 
Rossi et al., 2011a). 
In the general population, frailty is associated non-linearly with increasing age and 
with female gender, functional dependence, systemic inflammation and chronic 
disease (Fried et al., 2009, Hubbard et al., 2010, Jones et al., 2005, Rockwood et al., 
2005). Strong associations have been reported between frailty and cardiovascular and 
respiratory disorders, while there are few specific studies in individual chronic 
diseases, such as reported here in patients with COPD (Vaz Fragoso et al., 2012, 
Woods et al., 2005). In the Women‘s Health and Ageing Studies, the risk of frailty 
increased with inflammatory comorbidities, e.g., the combination of pulmonary 
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disease with anaemia carried a risk ratio of 5.57 compared with control subjects who 
had fewer comorbidities (Chang et al., 2010). A further study in this female cohort 
demonstrated that frailty was related non-linearly to the number of abnormal 
physiological systems, which was more predictive than the degree of abnormality in 
any one system and resembles the impact of multiple comorbidities in COPD (Fried et 
al., 2009). Physiological deficits in COPD include loss of skeletal muscle mass 
(sarcopenia) and function with progressive decline in physical activity, loss of bone 
mineral density, systemic inflammation, reduction in HRQoL and increasing 
cardiovascular morbidity and mortality (Bolton et al., 2004, Rossi et al., 2011a, Van 
Eeden et al., 2012). In the present study, the number of comorbidities was related to 
frailty in the COPD group. Hence, there are clear parallels with COPD where the 
number of comorbidities was related to frailty in the patients. Frailty was largely 
independent of age in the patients, indicating that an assessment of frailty was an 
additional measure of impairments over and above chronological age in COPD and 
may represent premature ageing. 
Increased numbers of comorbidities associated with COPD clearly could add to the 
degree of frailty, however, after removing these elements from the total score of CGA, 
frailty remained ten-fold different from the comparators, indicating that other features 
of COPD contributed to the presence of frailty. In the patients, the best predictors of 
frailty were the SGRQ activity score, TUG, HGS and 6MWD, which suggests loss of 
physical function and capacity, and muscle strength are key factors in frailty in COPD. 
The predictive association between reduced muscle strength and physical activity and 
frailty could explain why chronic lung inflammation and comorbidities could lead to 
premature ageing and frailty in COPD, and is supported by the association between 
frailty and exacerbation frequency. Hence, frailty in COPD is a multifactorial function 
of reduced quality of life, muscle strength and physical function. However, 
comorbidities and multisystem deficits in COPD are an important factor in the overall 
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morbidity and mortality, and their association with frailty suggest the latter may be 
used to predict a poor outcome (Divo et al., 2012). Loss of muscle strength and 
impairment of physical activity are an important factor of COPD and in the aetiology 
frailty pathway. The TUG test is a simple measure of physical performance and has 
been widely used as a measure of frailty. Although frailty has not been well studied in 
the COPD population, the presence of a multisystem disease such as COPD could 
accelerate ageing process by developing several manifestations including loss of 
muscle mass, weakness, decreased walking speed and comorbidities. Comparing 
patients with COPD to their comparators using this integrated test showed that 
patients with COPD were slower to perform this task which may be due to the 
contribution of several factors including loss of lower extremity strength as part of the 
nature of the disease that involve musculoskeletal system. Finding a relationship 
between TUG and frailty measure in patients with COPD but not in the comparators 
may suggest that these patients are experiencing accelerated ageing than 
comparators of the same age. This supports previous research that suggests that 
TUG is a useful measure for screening and identifying people with frailty (Viccaro et 
al., 2011). Using the TUG test in this population appears to come in parallel with what 
has been published in the literature in a frail elderly population and may allow 
clinicians to capture different aspects of frailty, which include weakness of the lower 
extremity, slow walking speed and impaired balance. 
This study also showed that frailty was associated with components of body 
composition, including BMI, FM, FFM, their ratio and hip and waist circumference, all 
changes that occur in both COPD and ageing (Angleman et al., 2006, Cesari et al., 
2006, Eisner et al., 2007, Rossi et al., 2011a, Walston et al., 2002). The U-shaped 
relationship between frailty and accepted categories of the BMI seen in the patients is 
similar to the U-shaped distribution in both males and females reported in the English 
Longitudinal Study of Ageing (Rossi et al., 2011). In the comparator group, although 
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frailty increased with BMI, the lack of individuals with a low BMI in this group limited 
finding a U shaped distribution. In the patients, the FFM was less than in the 
comparator group, but when expressed as the FFMI, there was no difference. Loss of 
muscle mass as in sarcopenia in the elderly has been considered to be a major factor 
leading to frailty, particularly in the phenotypic characterisation (Fried et al., 2001). 
However, in both COPD and natural ageing, increases in the FM and abdominal 
obesity have been closely linked to impaired physical function (Eisner et al., 2007, 
Cesari et al., 2006). In both groups, FM was directly related to the FI, as were the 
waist and hip circumferences in the patients and hip circumference in the 
comparators, which parallels the importance of the FM as a factor in frailty in the 
general population (Cesari et al., 2006). Increased FM and frailty in the elderly has 
also been linked to increased levels of circulating biomarkers of inflammation 
(Hubbard and Woodhouse, 2010, Walston et al., 2002). Circulating CRP an indicator 
of IL-6 activity increases with age and has been linked to frailty and abdominal 
obesity, independent of BMI, which may reflect the negative impact of chronic low 
grade systemic inflammation on physical function and wellbeing (Angleman et al., 
2005). These reported associations with frailty and ageing, in many ways parallels 
findings in COPD, where systemic inflammation may be causal, compensatory or an 
epi-phenomenon, but is associated with an increased risk of major comorbidities and 
is a predictor of mortality (Celli et al., 2012, Hubbard and Woodhouse, 2010, Thomsen 
et al., 2012). 
Frailty is a risk factor for the incident and development of CVD (Fried et al., 2001, 
Newman et al., 2001, Khan et al., 2013). The relationship between frailty and stroke 
volume in the patients suggests reduced normal physiological reserve of the heart or 
a subclinical abnormality such as myocardial ischaemia and left ventricle dysfunction. 
In COPD, asymptomatic left ventricle systolic and diastolic dysfunction, a feature of 
impaired cardiac capacity, was associated with loss of FFM (Sabit et al., 2010a). In 
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agreement with the results from Sabit et al. (2010), Barr and colleagues (2010) 
provided an evidence of decreased left ventricle volume and SV in a large population 
with COPD without a history of CVD and was related to the degree of airway severity. 
Although, the interaction between COPD and left-sided heart disease is complex and 
is not fully understood, it is known that lower SV will lead to impaired oxygen delivery 
to the tissue, which subsequently results in loss of left ventricle muscle mass and left 
ventricle dysfunction (Collis et al., 2001). This is supported by the data from the 
Cardiovascular Health Study, which showed that frail patients had reduced left 
ventricle function and poor myocardial function (Newman et al., 2001). 
In the elderly, frailty independently predicts the risk of falls, worsening mobility, loss of 
activities of daily living, increased risk of hospitalisation and death over short term 
periods (Fried et al., 2001). The CGA quantifies the number of deficits, and as a 
generic tool, it is useful to compare frailty in different populations, and as a prognostic 
indicator of their health outcomes. The comparison of frail and non-frail status within 
the patients based on a reference range derived from the same population source 
clearly identified patients with major disease related deficits giving a potential global 
assessment tool that might predict adverse outcomes, including the risk of death or 
the need for institutional care, based on the impact of accumulating deficits, and be 
useful for planning interventions.  
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Discussion  
Longitudinal study: Two-year Findings 
This is the first longitudinal study exploring the progression of frailty in COPD. Patients 
with COPD had an increase in their frailty index over the two years follow-up period 
with progressive decline in physical performance and loss of muscle mass and 
strength. This supports the findings of the cross-sectional analysis that COPD is an 
independent risk factor for frailty. As there is no previous study that has assessed the 
frailty longitudinally in COPD, comparisons are difficult. 
In the patients, loss of FFM and handgrip strength was associated with the 
progression of frailty. Concomitant loss of FFM and skeletal muscle mass and 
strength (sarcopenia) is one of the comorbidities associated with COPD and similarly 
a hallmark of frailty. An increased FI in parallel with sarcopenia in patients with COPD 
suggests that COPD precipitates features of premature ageing.  The cause of 
sarcopenia in COPD is not fully understood and likely to be multifactorial. In this 
cohort study, though, the level of plasma fibrinogen decreased while circulating CRP 
remained stable; there was no association between systemic inflammation and 
sarcopenia in the patients. The association between loss of FFM and systemic 
inflammation is still debated, as the studies in this topic are cross-sectional in design, 
which limits their findings. Loss of muscle mass in COPD does not just reduce 
patient's mobility, but it also impairs glucose metabolism and increases insulin 
resistance (Barnes and Celli, 2009). Insulin plays a potent role in maintaining muscle 
mass by balancing between muscle protein synthesis and breakdown,  up-regulating 
glucose uptake and inhibiting fat tissue degradation (Magkos et al., 2010). In COPD, 
abdominal obesity acts as an active endocrine gland producing abundant of 
inflammatory cytokines that induce insulin resistance in skeletal muscle (Rutten et al., 
2010, Gosker et al., 2007). Increased insulin resistance predisposes to intramuscular 
fat gain, which enhances fatty acid delivery and subsequently reduces fat oxidative 
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capacity of skeletal muscle. In type 2 diabetes, the patients experience a high rate of 
muscle mass loss compared with non-diabetic individuals due to increased insulin 
resistance (Park et al., 2009). Given the high prevalence of type 2 diabetes in patients 
with COPD, this enhances insulin resistance and may accelerate musculoskeletal 
mass wasting. A similar relationship has been evident in natural ageing and in the 
elderly with sarcopenia and frailty (Abbatecola and Paolisso, 2008).  
The association between loss of handgrip strength and frailty in patients with COPD 
independent of chronological age is more likely to reflect the accelerated ageing 
process that COPD imposes on the musculoskeletal system as manifested by 
sarcopenia and loss of muscle strength. Loss of muscle mass and strength have been 
linked in COPD to serious consequences including exercise intolerance, poor health 
related quality of life and increased mortality (Bolton et al., 2004, Schols et al., 2005, 
Rutten et al., 2013). In COPD, reduced handgrip strength is associated with reduced 
muscle mass and physical activity (Engelen et al., 2000b, Pitta et al., 2006). Likewise, 
in healthy elderly, handgrip is associated with reduced lower extremity strength and 
daily activity, and predicts future disability and mortality (Al Snih et al., 2004, Ling et 
al., 2010). Furthermore, handgrip strength, a measure of frailty, was found to predict 
future frailty in 717 elderly men and women, independent of age (Syddall et al., 2003). 
The cause of sarcopenia in COPD and frailty is multifactorial, including inflammation, 
endocrine changes and most importantly physical inactivity (Watz et al., 2009, Cesari 
et al., 2004). Patients with COPD often avoid involvement in moderate to high 
intensity activities due to their breathlessness and subsequently and unconsciously 
adopt sedentary lifestyles. Compelling evidence supports the role of physical inactivity 
in skeletal muscle loss and sarcopenia, which are cardinal features of frailty.  
Following the patients for two years allowed for further exploration of the features of 
frailty in COPD and the interaction between them and defined the best predictor of the 
progression of frailty in COPD. The only predictor of the progression of frailty in 
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patients with COPD was the change in TUG test. Reduced physical performance over 
a short period of time (i.e. two years) reflects the impact of COPD on frailty and 
strengthens the notion of an accelerated ageing process, which is supported by loss 
of muscle mass, handgrip weakness and physical inactivity and parallels the same 
factors associated with natural ageing.  
The TUG is a strong predictor of frailty and mortality in the elderly and has been used 
to assess the risk of falls in patients with COPD (Savva et al., 2013, Beauchamp et 
al., 2009). The predictive relationship of the TUG test of the progression of frailty in 
COPD parallels what is published in the literature on frailty in the elderly population. In 
a cohort study of 417 elderly subjects living in the community, the TUG test was a 
good predictor of one year decline in functional and physical activities, which are the 
hallmark of physical frailty (Viccaro et al., 2011). Furthermore, in the Irish longitudinal 
study of ageing, the TUG test was discretely able to discriminate between frail and 
nonfrail individuals (Savva et al., 2013). Poor physical performance is an accepted 
criterion for frailty and a feature of COPD. Frailty is a dynamic clinical syndrome and 
its transition from one stage to another can be missed. Similarly, in COPD, a patient‘s 
level of activity is not routinely assessed in clinical practice. Therefore, the TUG test 
could be a useful screening test to reflect the level of impairment in patients with 
COPD. The TUG test incorporates muscle function, strength, balance and gait speed, 
which capture age-related changes and physiological deterioration (Podsiadlo and 
Richardson, 1991). These symptoms are commonly associated with COPD and 
features of the frailty phenotype (Fried et al., 2001). Physical inactivity could be the 
first step in the development of musculoskeletal dysfunction and trigger the frailty 
down spiral phase. Therefore, clinicians should be alert to different aspects of frailty in 
patients with COPD especially physical inactivity. 
In this study, there was no relationship between the 6MWD and the progression of 
frailty. Although the 6MWD is a measure of exercise capacity, its improvement did not 
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reflect on the frailty status of the patients as frailty progressed. The concept of 
exercise capacity is totally different from physical activity. It has been suggested that 
an improvement in exercise capacity will subsequently lead to an improvement in the 
level of physical activity. Daily physical activity is a life style habit that requires 
continuous motivation and repetitive activity while exercise capacity is a maximum 
tolerability the patients could sustain. Unlike the TUG test, the 6MWD did not reflect 
patient‘s physical activity and musculoskeletal strength. Although, the 6MWD is a 
good outcome measure of submaximal exercise capacity than lung function, it does 
not reflect the level of daily activity that involves repetitive movement and 
subsequently stimulating the musculoskeletal system. In addition to that, the 6MWD 
cannot capture associated impairments in COPD including loss of muscle mass and 
strength (Spruit et al., 2010). 
Frailty and COPD are both progressive and multifactorial based on the interplay of 
genetic, physiological and physical factors. The response and behaviour of the human 
body to these changes is gender dependent (Hubbard and Rockwood, 2011, Aryal et 
al., 2013). The number of females with COPD has recently been increasing especially 
among non-smokers or those with less than 20 pack-years of smoking (Salvi and 
Barnes, 2009). Increased level of frailty in female patients with COPD is not 
surprisingly limited to this group of patients and in agreement with previous research 
from the general population (Fried et al., 2001, Hubbard et al., 2010).  Similarly, in the 
Cardiovascular Health Study, females were more frail and had more physiological 
impairments than males during the three years of follow-up (Fried et al., 2001). 
Contrary to this, in a cohort study of 2962 elderly subjects, followed up for nearly five 
years, Klein and colleagues (2005) reported that frailty was higher in males than 
females. This controversy is due to different frailty assessment and classification. The 
gender difference has not been studied extensively in COPD and likewise in frailty is 
still not known why females are more prone to frailty than males.  In this study, 
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although females with COPD had better lung function than males, they were more 
symptomatic and had reduced handgrip strength and prolonged that impacted on their 
health related quality of life, which resemble the physiological characteristics of frailty. 
Therefore, reduced physical performance and loss of muscle strength could induce 
inflammation that may be possibly causally related to the frailty in COPD.  Thus, 
physical inactivity and inflammation could be a unifying physio-biological process 
leading to clinical frailty that is more prevalent in females than males with COPD.  
Another explanation of why females with COPD are more frail than their male 
counterparts is the type of comorbidity. Males with COPD are at a higher risk of fatal 
diseases without a prior event of impaired health such as cardiovascular disease and 
rapidly progressive cancer while women with COPD present with a different pattern of 
comorbidities such as osteoporosis and depression (Agusti et al., 2010). Females with 
COPD in this study presented with better lung function than males, but they had 
worse symptoms and poor quality of life, which are frequently associated with anxiety 
disorder.  Recently, in the ECLIPSE cohort study, depression and anxiety were most 
frequently seen in females with COPD, which were mainly determined by disease 
symptoms and health status (Hanania et al., 2011).  
This is the first longitudinal study in COPD, which links the progression of frailty to 
reduced cardiac haemodynamics. The progression of frailty and its association with 
reduced cardiac haemodynamics over a short period suggests a subclinical damage 
to the heart prior to the appearance of its clinical manifestations. Cardiovascular 
disease is often underdiagnosed in patients with COPD and, therefore, the presence 
of frailty in parallel with a reduction in the heart reserve may implicate reduced 
physiological reserve of the heart to respond to further challenges, such as chest 
infection. Disintegration of normal harmony between body organs leads to a decline in 
their functional reserve and subsequently intolerance to further insult that is defined as 
frailty (Rockwood and Mitnitski, 2007). Since COPD is a multisystem disease, patients 
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with COPD may have accumulated subclinical organ damage related to vasculature 
abnormality including left ventricle dysfunction, aortic calcification and kidney 
impairment (Sabit et al., 2010, Bolton et al., 2007, John et al., 2013). Sabit and 
colleagues (2010) have shown that patients with COPD, free of CVD, had a 
symptomatic left ventricle dysfunction, which was associated with loss of muscle 
mass, independent of airway severity. Decreased blood supply to the skeletal muscle 
causes muscle mass loss and in a consequence produces abundant amino acids that 
subsequently cause further damage to other muscles including cardiac muscle, 
leading to left ventricle dysfunction (Rasmussen et al., 2006, Sabit et al., 2010a). 
Skeletal muscle is highly metabolic and consequently requires an enhanced metabolic 
demand, FFM may govern the required adequate blood supply for a given heart rate 
(Collis et al., 2001). Impaired oxygen delivery to skeletal and cardiac muscle as a 
result of reduced blood supply may be a further explanation for this relationship 
between frailty and reduced cardiac haemodynamics in COPD. In the Cardiovascular 
Health Study, frail patients with CVD had reduced left ventricle function and poor 
myocardium performance (Newman et al., 2001). In line with Newman et al. (2001) 
findings, the Health Ageing and Body Composition study showed that frailty was an 
independent risk factor for the incidence of heart failure after the adjustment for other 
confounding factors (Khan et al., 2013). In COPD, depletion of FFM, a feature of 
frailty, is believed to be secondary, in part, to a protein catabolic state as consequent 
of an imbalance in protein synthesis and breakdown (Eid et al., 2001, Engelen et al., 
2000a). It has been previously shown in patients with COPD that cellular protein 
breakdown as measured by urinary pseudouridine (PSU) was inversely related to fat 
free mass (Bolton et al., 2004). Recently, Sabit et al. (2010a) took this a step further 
and showed that cellular protein breakdown and FFM were related to left ventricle 
mass. In the present study, reduced cardiac haemodynamics may further suggest 
another global feature of frailty in COPD, which may occur in parallel with loss of 
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musculoskeletal mass as part of the global catabolic process in COPD. Decreased 
cardiac haemodynamics may explain the cause of muscle mass loss and therefore 
cardiac dysfunction.  
The role of inflammation in COPD is well established and may play a role in the frailty 
(Thomsen et al., 2012, Walston et al., 2002). The reason for not finding any 
association between inflammatory biomarkers in COPD and frailty progression could 
be related to various reasons. Firstly, most of the inflammatory biomarkers studied in 
frailty are not just specific to frailty syndrome as no study has examined the 
relationship between inflammatory biomarkers and frailty in absence of other 
comorbidities. Therefore, the presence of multimorbidity in these studies could inflate 
the association between frailty and inflammation. The majority of the studies 
investigating the relationship between frailty and inflammation are cross-sectional in 
design, which their results cannot be used to draw a definite conclusion on the 
predictive role of inflammation on frailty and its development. There has been no 
longitudinal study so far which examined the relationship between the progression of 
frailty and the change in inflammatory biomarkers. The cohort studies on frailty 
coming from the Cardiovascular Health Study, Longitudinal Ageing Study Amsterdam, 
Hertfordshire Ageing Study and the English longitudinal Study of Ageing have 
examined the incidence of frailty-related inflammation, and the results are sparse and 
inconsistent (Barzilay et al., 2007, Baylis et al., 2013, Gale et al., 2013, Puts et al., 
2005b).  
Secondly, before proceeding to the second explanation, it is still unknown if frailty is a 
cause or consequence of a specific disease or combination of multimorbid conditions. 
COPD is a multisystem disease including neuroendocrine, cardiovascular and 
musculoskeletal disorders (Barnes and Celli, 2009).  The most frequently cited 
inflammatory biomarkers are CRP, IL-6 and fibrinogen. However, these biomarkers 
lack reproducibility and specificity (Cazzola et al., 2008). Furthermore, none of the 
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biomarkers has been found viable to predict or monitor COPD progression (Tzortzaki 
et al., 2006). Recently, a one-year follow-up from the ECLIPSE cohort study showed 
that 16% of the patients did not have high inflammatory biomarkers while 30% of the 
patients had no change in the inflammatory biomarkers (Agusti et al., 2012). A three-
year cohort study in 218 stable patients with moderate to very severe COPD failed to 
show that CRP can discriminate between survivors and deceased patients (De Torres 
et al., 2008). An interventional study to determine the effect of fluticasone and 
fluticasone plus salmeterol on CRP or IL-6 in 289 patients with COPD showed neither 
fluticasone nor the combination therapy had a significant effect on serum CRP or IL-6 
(Sin et al., 2008). Absence of the relationship between the progression of frailty and 
inflammation in COPD does not preclude the possible role of inflammation, but 
probably the chosen biomarkers in this study may not have been specific and 
sensitive enough to explain this kind of relationship. 
This is first cohort study to explore the relation between COPD and frailty, which 
stimulates several questions. The debate on frailty has been ongoing for two decades 
and recently frailty is accepted as a clinical syndrome (Morley et al., 2013). Frailty is a 
multisystem deficit in parallel with COPD and requires a trigger to develop and 
exhaust the reserve of the body system. COPD is a systemic disease that precipitates 
the physiological reserve of other systems.  Frailty does not exist until the body 
system is unable to respond to further stressors (Fried et al., 2001). COPD causes 
multiple impairment and functional limitations, which are fundamental features of 
frailty. At this stage, the reserve function of the body system has already begun to 
decline and eventually become unresponsive to further stressors. Thus, frailty could 
be a clinical manifestation of COPD. For example, in this cohort study, patients had 
loss of muscle mass and strength, which influenced their physical performance and 
increased their level of frailty.  
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Frailty is an important aspect in COPD and patients with COPD should be examined 
for frailty in routine clinical practice to implement early identification and management.  
Applying a simple questionnaire can capture different aspects of comorbidities and 
avoid possible consequences associated with COPD such as physical inactivity, loss 
of FFM, musculoskeletal mass and strength and reduced cardiac haemodynamics, 
healthcare utilization and health related quality of life.  
Study Limitations 
It is acknowledged that this cohort study lacked a comparator group as with many 
published studies. However, due to the time constraint of the PhD, it was not possible 
to follow-up the comparator group. Another limitation was this study was not powered 
to identify the progression of frailty in COPD. However, this is a community study, 
which represented patients with stable COPD. In this study, there was no measure to 
ascertain left ventricle dysfunction or the protein turnover. 
Conclusion 
Patients with COPD were more frail than the comparator group of current or ex-
smokers, independent of age. Frailty in COPD was related to reduced physical 
performance and health status. In each age category, FI was greater in patients than 
comparators, which supports the possibility that COPD is associated with premature 
ageing.  
In the follow-up study, frailty progressed in the patients and predominantly in the 
females. The progression of frailty in COPD was dependent on the decreased 
physical performance in conjunction with loss of muscle mass and strength. The CGA 
is a potential quick, simple and inexpensive questionnaire that provides a global 
assessment of COPD. It is an assessment that highlights multisystem deficits, which 
could guide interventions and monitor disease progress.  
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7  
Chapter Seven 
Conclusions and Future Research 
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7.1 Conclusions 
7.1.1 A Simple and Rapid Measure of Physical Performance in COPD 
Physical inactivity is one of the common comorbidities associated with COPD and 
increased cardiovascular risk, loss of muscle mass and mortality. However, the 
assessment of physical performance is not routinely examined in clinical practice due 
to limited resources. Timed Up and Go is a rapid and simple test that has been widely 
used in the elderly to assess physical performance and frailty. 
The cross-sectional results showed that patients with COPD had longer TUG time 
compared with non-COPD subjects. The TUG test was related and a predictor of the 
most common test of submaximal exercise capacity, the 6MWD. The TUG test had 
shown the potential to be a useful clinical test in primary care to capture different 
aspects of physical performance. 
7.1.2 Aortic Stiffness in Patients with COPD 
Cardiovascular disease is the most common comorbidity associated with COPD.  
Aortic stiffness is an independent predictor of CVD morbidity and mortality is several 
populations including healthy elderly and undoubtedly plays a pivotal role in the 
increased risk of CVD in COPD. 
The cross-sectional results revealed that patients with COPD had greater aortic 
stiffness than similar age and gender comparators, independent of blood pressure, 
heart rate, airway severity, tobacco exposure and inflammation.  Aortic stiffness was 
greater in males with COPD than their female counterparts and was dependent on 
waist circumference. 
The results of this longitudinal study clearly showed that COPD is an independent risk 
factor for aortic stiffness progression and premature vascular ageing.  Patients with 
COPD showed a rapid aortic stiffness progression by six-fold compared with 
estimated normal aortic ageing. A subset of patients demonstrated an accelerated 
aortic biological ageing by 16 years over a two-year follow-up, independent of 
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conventional risk factors and consequently their CVD morbidity and mortality 
increased by more than 22%.  Aortic PWV is a simple, reliable and non-invasive 
measure that can be used in clinical practice to identify patients who are at high risk of 
cardiovascular events and provide proper management. 
7.1.3 Frailty in COPD 
Presence of the multimorbidity in patients with COPD resembles the multideficit 
associated with frailty. 
The results of the cross-sectional study demonstrated that patients with COPD were 
more frail compared with similar age and gender non-COPD individuals, independent 
of airway severity and inflammation. Females were more frail than males in both 
groups.  Frailty in COPD was dependent on physical performance and function and 
musculoskeletal strength. 
The longitudinal results showed that the progression of frailty in COPD was related to 
the reduced physical performance and loss of muscle mass and strength. The 
progression of frailty in COPD clearly supports the hypothesis of premature ageing in 
COPD and reduced homeostasis capacity of patient‘s physiological system to sustain 
further internal or external insult. Since frailty is an independent predictor of adverse 
outcomes and mortality in non-COPD populations, implementing frailty assessment in 
parallel with a simple test such as the TUG test would optimise management for 
patients with COPD. 
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7.2 Future Research 
7.2.1 A Simple and Rapid Measure of Physical Performance in COPD 
 Since TUG test is related to the 6MWD, a measure of exercise capacity, a field 
study is needed to examine the applicability of the TUG test in primary and 
secondary care as a routine assessment of physical performance. 
 As the TUG test is a predictor of physical performance, it is useful to examine 
body composition and bone mineral density using the DEXA scan and this will 
give insight about the impact of fat mass and fat free mass and their ratio on 
functional status. 
 Since the TUG test is related to handgrip strength, body composition and 
exercise capacity, future studies are needed to incorporate lower extremity 
function, body composition, exercise capacity and daily physical activity, and 
this will give more insight about the physical impairment. 
7.2.2 Aortic Stiffness in Patients with COPD 
 Future longitudinal studies investigating progression of arterial stiffness in 
patients with COPD should include comparator subjects with similar smoking 
history to provide a realistic comparison between these groups. 
 Future longitudinal studies of arterial stiffness in COPD should quantify 
anatomical emphysema using high resolution computed tomography. This may 
determine whether an emphysematous phenotype or a chronic bronchitis 
phenotype patients are at particular risk of aortic stiffness progression.  
 Since loss of FFM correlates with cardiac haemodynamics, future longitudinal 
studies investigating the progression of aortic stiffness should include 
measurement of left and right ventricular function and their relationship with 
aortic stiffness progression and changes in body composition. Such longitudinal 
studies may also be able to indicate whether sub-clinical left and right 
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ventricular dysfunction exists in parallel with loss of FFM and progression of 
aortic stiffness. 
 Since this longitudinal study showed a subset of patients who had a rapid 
progression of aortic stiffness independent of blood pressure and inflammation, 
future longitudinal studies are needed to investigate vascular properties and 
include both endothelia and oxidative mechanism. 
 Osteoprotegerin (OPG) is a marker of bone attenuation as well as vascular 
remodelling and aortic stiffness has been previously shown to be elevated in 
patients with COPD and osteoporosis, therefore, including OPG measurement if 
future longitudinal studies would provide another horizon of increased CVD in 
COPD. 
 Future longitudinal studies should include newly diagnosed patients with COPD 
at different stages and assess the effects on inhaled bronchodilators on aortic 
stiffness progression and incident of CVD. This should include measurement of 
aortic stiffness, airways obstruction, cardiac haemodynamics and systemic 
inflammation at baseline and repeated annually. This will give an insight of 
which treatment has a substantial effect on aortic stiffness progression and 
increased risk for CVD. 
7.2.3 Frailty in COPD 
 Since this research has shown that frailty is another manifestation of COPD, 
frailty assessment should be included as part of patient‘s general assessment to 
capture other comorbidities beyond lung function. 
 Future longitudinal studies should include comparator subjects to determine the 
rate of frailty progression compared with a COPD population. 
 Future studies should include patients with COPD without comorbidities and 
monitor the development of physiological deficits in comparison with a 
comparator group. 
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 Since this study has shown that frailty progression was related to loss of muscle 
mass and strength independent of inflammation, future longitudinal studies are 
needed to investigate the cause of sarcopenia. 
 Future longitudinal studies of frailty in COPD should include lower extremity 
strength and function, and daily physical activity in parallel with simple tests 
such TUG, HGS and mMRC and body composition to determine if physical 
inactivity is the main trigger of frailty phenotype. 
 Since reduced functional reserve of the heart was related to frailty progression, 
future studies of frailty in COPD should assess cardiac function to provide early 
detection of cardiovascular abnormalities. 
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Appendix A: Participant Information Sheet for Patients 
                                                                                                                                                                                                                                                              
                                                                                                                            
“Assessment of Risk in Chronic Airways Disease Evaluation - ARCADE‖   
You are invited to take part in a research study.  Before you decide whether to take 
part, it is important for you to understand why the research is being done and what it 
will involve. One of our research team members will go through this sheet with you 
and answer any questions you have. Please take time to read the following 
information carefully and discuss it with relatives, friends and your GP if you wish. We 
feel that this would take about 15 minutes to go through. Please ask us if there is 
anything that is not clear or if you would like more information. This study is funded for 
the first three years by a research grant from GlaxoSmithKline. 
Why are we doing this study? 
As we get older, our arteries generally stiffen over a period of time. This leads to an 
increase in blood pressure and may place us at a greater risk of strokes and heart 
attacks. A similar process occurs in patients with chronic obstructive pulmonary 
disease (COPD) causing premature arterial stiffening. However, we are not sure how 
quickly their arteries stiffen, and whether this is related to the severity of COPD. Also, 
the reasons for arterial stiffening in COPD are not well understood. We now have the 
means to assess arterial stiffness and the aim of this study is to measure how quickly 
arteries stiffen over time in COPD, and what factors are associated with this. 
Dennis J Shale MD  
Professor of Respiratory Medicine 
J R Cockroft 
Professor of Cardiology 
 Nichola S Gale PhD 
Research Associate  
 
Department of Respiratory Medicine 
Cardiff University School of Medicine 
Level 1, Wales Heart Research Institute 
Heath park 
Cardiff 
CF14 4XN 
 290 
 
Why have I been asked to participate? 
You have been asked to participate because you fall into the following group: 
 Between 35-80 years 
 Have a diagnosis of Chronic Obstructive Pulmonary Disease 
 
Individuals who fall in this categories have been similarly approached by a letter and 
we are looking to recruit 1500 patients with COPD. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be asked to sign a consent form. However, you are free to withdraw from the 
study at any time without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
Visit 0: 
If you agree to take part, you will be asked to attend an initial visit lasting 
approximately 1 hour at a clinic at the University Hospital of Wales, Cardiff or your 
General Practitioner‘s surgery if it is one of the participating research sites. Here we 
will go through the information sheet, consent form and obtain a detailed lifestyle and 
medical history from you in addition to a medical examination.  
You will then be requested to make 3 visits to the Wales Heart Research Institute at 
University Hospital of Wales, Cardiff, spaced over the next 5 years. All measurements 
made at these visits will be the same and each visit will last approximately 2 hours. 
Visit 1 will be baseline, visit 2 will be 2 years and visit 3 will be 5 years following your 
baseline visit.  
Visit 1: 
It would be preferable if you could refrain from smoking for at least 6 hours prior to 
attending. The following measurements will be made: 
 We will check your height, weight and hip and waist circumference (using a 
tape).  
 Blood pressure: After lying down for 15 minutes, you will have your blood 
pressure taken, just like at your General Practitioner‘s surgery.  
 Arterial stiffness measurements: A small, pencil-like probe will be placed on 
the artery (blood vessel) at your wrist, neck and upper leg to calculate how stiff 
your arteries are. We will also record an electrocardiogram (ECG) with stickers 
on your chest to track small changes in your heart rate.  
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 Cardiac output: We will place some stickers on your chest and neck and 
measure how much  blood is being pumped around with each heart beat.  
 Lung function tests: You will then be asked to blow out as hard as you can into 
a tube after inhaling salbutamol (a safe drug using an inhaler with a spacer 
device) unless contraindicated to measure your lung function (the size of your 
lungs and how quickly you can empty them).  
 Measurement of body composition: At this point we will check the proportion of 
muscle and fat tissue in your body by asking you to stand barefoot on a 
machine with hand grips. A tiny electric current which is not painful or harmful 
in any way is then passed and the measurements recorded. None of these 
measurements are painful.  
 Hand-grip strength: This will be measured using a spring device. 
 Bone density scan: We will then measure the bone density in your heels by 
using an ultrasound device which has no radiation. 
 Blood sample: We will then ask you to give a blood sample of approximately 
50 mls (5 tablespoons of blood) from your arm. This sample is used to 
measure various levels of naturally occurring substances in the blood, (ex: 
cholesterol, glucose and inflammatory molecules). This blood sample will be 
disposed after the study is completed in 5 years.  
 Timed up and go (TUG) test: You will be requested to get up from a chair, walk 
to a distance of 3 metres, turn around, walk back and sit down again while we 
measure the time taken to do so. 
 6-minute walking test: You will then be requested to walk for 6 minutes on a 
flat surface at your own pace with breaks if necessary while we also check 
your oxygen levels in the blood using a non-invasive probe on your finger.  
 Urine sample: Finally we will ask you for a urine sample (20ml or equivalent of 
4 teaspoons) in a container to test for certain molecules.  
 
A small proportion of participants will be invited to attend repeat assessments within 2 
weeks of the assessment visit 1. They will be given activity monitors to get an idea of 
their exercise levels in real life. 
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Visits 2 and 3: 
The data collected on subsequent visits (2 years & 5 years later) will be compared 
with the baseline to demonstrate any changes in blood vessel stiffening, inflammatory 
molecules in blood and evolution of cardiovascular risk factors. Data generated from 
the study will be stored at the WHRI for a period of 10 years in the safe custody of 
Professor D J Shale. 
Will there be any side-effects? 
Taking blood may lead to minor discomfort, but only experienced people will take 
blood samples. 
Are there any risks involved in taking part? 
Apart from the blood sample, all of the measurements are non-invasive and we don‘t 
foresee any risks involved. 
Are there any possible benefits to taking part? 
You will have a detailed assessment of your blood pressure and other cardiovascular 
risk factors (eg glucose, cholesterol levels) and we will be happy to make your results 
available to your General Practitioner if you agree. 
Will my taking part in this study be confidential? 
By consenting to take part in this research, you will consent to the collection, 
processing, disclosure and transfer of your personal data for medical research 
purposes only. Named information will be sent to the NHS Central Register and you 
will be flagged by the NHS Information Centre (NHS IC) for the purpose of follow-ups. 
Any data that is sent will be encrypted and we will follow ethical and legal practice to 
ensure that all information about you is handled in confidence. This is done to identify 
any new health problems that you may develop in relation to the heart while you are 
enrolled in our study. Information held by the NHS and records maintained by the 
General Register Office may be used to keep in touch with you and follow your health 
status.  Your data will not be available to GSK as they are financially sponsoring this 
as an independent study. 
Will my GP be informed? 
The doctor in charge of the study will inform your GP of your participation in the study 
with your consent. In addition with your permission, they will be informed of any 
clinically relevant results that may become available during the study.   
What will happen to the study results? 
The results of the study may be published in scientific journals or presented at medical 
conferences, a few months after completing the study.  You will not be identified in any 
report or publication. An overall summary report (fully anonymised) will be sent to your 
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General practitioner at the end of the study. You will be able to access this through your 
GP upon the completion of the study. 
What happens if something goes wrong? 
The doctors involved in the study, and the Wales Heart Research Institute have 
suitable indemnity insurance if you are harmed due to someone‘s negligence. 
However, there are no special compensation arrangements for non-negligent harm. 
Regardless of this, if you wish to complain about any aspect of the way you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms will be available to you. 
What will happen if I withdraw from the study? 
If you withdraw from the study, this will in no way affect your future medical care. Data 
or tissue already collected up to the point of withdrawal will be anonymised and 
utilised for study purposes. 
The same would apply if capacity to consent is lost during the study. You will be 
withdrawn from the study and data or tissue already collected under consent will be 
anonymised and utilised for study purposes. 
Will I be reimbursed for any travel expenses? 
Travel expenses of up to £30 will be given as necessary for trips to hospital to cover bus, 
mileage and parking. Taxis can also be ordered from our department to pick you up or 
drop you off. 
Who is organising this study? 
This study is being organised by the Wales Heart Research Institute of the Cardiff 
University. The investigators in charge are Professor D J Shale and Professor J R 
Cockcroft. 
Who has reviewed this study? 
The South East Wales Research Ethics Committee has reviewed this study and given 
it a favourable opinion. 
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Contacts for research-related enquiries: 
If you require more information about the study, then please contact any of the 
research team members namely Dr M Irfan (Clinical Research Fellow), Dr Nichola 
Gale (Research Associate) or Mrs Margaret Munnery (Research Nurse) on Tel 
02920742352. Alternatively, you may wish to speak to the Principal Investigator: -    
Professor J R Cockcroft                       OR       Professor D J Shale 
Consultant Cardiologist                                        Professor in Respiratory  Medicine  
Level 1,                                                                Level 1 
Wales Heart Research Institute                           Wales Heart Research Institute 
University Hospital of Wales                                University Hospital of Wales  
Heath Park                                                           Heath park 
Cardiff                                                                   Cardiff 
C14 4XN                                                               CF14 4 XN 
0292074 3489                                                      0292074 3489 
 
Thank you for reading this information sheet.                                              
Remember - You are under no obligation to participate in this study. If you wish to leave 
the study at any point you may do so for any reason. Please take as much time to read 
this leaflet as require; do not feel that you have to make a decision quickly. Researchers 
will be available to answer any questions you may have. All the data collected will be 
confidential and is only for the purposes of research. 
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Appendix B: Participant Information Sheet for Comparator Subjects 
                                                                                                                                                                                                                           
                                                 
 
                                                                                                                        
                                                                                                                            
PARTICIPANT INFORMATION SHEET FOR COMPARATOR SUBJECTS                                                                  
“Assessment of Risk in Chronic Airways Disease Evaluation - ARCADE‖   
You are invited to take part in a research study.  Before you decide whether to take 
part, it is important for you to understand why the research is being done and what it 
will involve. One of our research team members will go through this sheet with you 
and answer any questions you have. Please take time to read the following 
information carefully and discuss it with relatives, friends and your GP if you wish. We 
feel that this would take about 15 minutes to go through. Please ask us if there is 
anything that is not clear or if you would like more information. This study is funded for 
the first three years by a research grant from GlaxoSmithKline. 
Why are we doing this study? 
As we get older, our arteries generally stiffen over a period of time. This leads to an 
increase in blood pressure and may place us at a greater risk of strokes and heart 
attacks. A similar process occurs in patients with chronic obstructive pulmonary 
disease (COPD) causing premature arterial stiffening. However, we are not sure how 
quickly their arteries stiffen, and whether this is related to the severity of COPD. Also, 
the reasons for arterial stiffening in COPD are not well understood. We now have the 
means to assess arterial stiffness and the aim of this study is to measure how quickly 
arteries stiffen over time in COPD, and what factors are associated with this. 
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We are comparing these measurements in patients with COPD against those in 
subjects free of COPD who have a history of smoking.  
Why have I been asked to participate? 
You have been asked to participate because you fall into the following group: 
Between 35-80 years 
Have a history of smoking 
Other individuals in this group have been similarly approached by a letter and we are 
looking to recruit 300 such subjects in this study to act as comparators for the 1500 
patients with COPD. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be asked to sign a consent form. However, you are free to withdraw from the 
study at any time without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
Visit 0: 
If you agree to take part, you will be asked to attend an initial visit lasting 
approximately 1 hour at a clinic at the University Hospital of Wales, Cardiff or your 
General Practitioner‘s surgery if it is one of the participating research sites. Here we 
will go through the information sheet, consent form and obtain a detailed lifestyle and 
medical history from you in addition to a medical examination.  
You will then be requested to make 3 visits to the Wales Heart Research Institute at 
University Hospital of Wales, Cardiff, spaced over the next 5 years. All measurements 
made at these visits will be the same and each visit will last approximately 2 hours 
(please see figure 1 on page 5). Visit 1 will be baseline, visit 2 will be 2 years and visit 
3 will be 5 years following your baseline visit.  
Visit 1: 
It would be preferable if you could refrain from smoking for at least 6 hours prior to 
attending. The following measurements will be made: 
 We will check your height, weight and hip and waist circumference (using a 
tape).  
 Blood pressure: After lying down for 15 minutes, you will have your blood 
pressure taken, just like at your General Practitioner‘s surgery.  
 Arterial stiffness measurements: A small, pencil-like probe will be placed on the 
artery (blood vessel) at your wrist, neck and upper leg to calculate how stiff your 
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arteries are. We will also record an electrocardiogram (ECG) with stickers on 
your chest to track small changes in your heart rate.  
 Cardiac output: We will place some stickers on your chest and neck and 
measure how much  blood is being pumped around with each heart beat.  
 Lung function tests: You will then be asked to blow out as hard as you can into a 
tube after inhaling salbutamol (a safe drug using an inhaler with a spacer 
device) unless contraindicated to measure your lung function (the size of your 
lungs and how quickly you can empty them).  
 Measurement of body composition: At this point we will check the proportion of 
muscle and fat tissue in your body by asking you to stand barefoot on a 
machine with hand grips. A tiny electric current which is not painful or harmful in 
any way is then passed and the measurements recorded. None of these 
measurements are painful.  
 Hand-grip strength: This will be measured using a spring device. 
 Bone density scan: We will then measure the bone density in your heels by 
using an ultrasound device which has no radiation. 
 Blood sample: We will then ask you to give a blood sample of approximately 50 
mls (5 tablespoons of blood) from your arm. This sample is used to measure 
various levels of naturally occurring substances in the blood, (ex: cholesterol, 
glucose and inflammatory molecules). This blood sample will be disposed after 
the study is completed in 5 years.  
With your permission some blood will also be taken and stored for future analyses, 
which will examine the genes which are known or likely to be important in determining 
how stiff or elastic your arteries are. This sample taken for genetic analysis will be 
stored for 10 years in the custody of Professor D J Shale and Professor J R Cockcroft 
at the Wales Heart Research Institute (WHRI), Cardiff. 
Further ethical approval will be sought if any genetic testing is required beyond 5 
years. As these genetic markers are mainly to establish a genetic link for the natural 
evolution of COPD it would not have any implications on inherited risk or insurance 
status. GlaxoSmithKline, the sponsors of the first three years of the study will have 
access to the genetic data, but you will not be identified individually to the sponsors or 
anyone else in respect of this data. 
 Timed up and go (TUG) test: You will be requested to get up from a chair, walk 
to a distance of 3 metres, turn around, walk back and sit down again while we 
measure the time taken to do so. 
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 6-minute walking test: You will then be requested to walk for 6 minutes on a flat 
surface at your own pace with breaks if necessary while we also check your 
oxygen levels in the blood using a non-invasive probe on your finger.  
 Urine sample: Finally we will ask you for a urine sample (20ml or equivalent of 4 
teaspoons) in a container to test for certain molecules.  
 
A small proportion of participants will be invited to attend repeat assessments within 2 
weeks of the assessment visit 1. They will be given activity monitors to get an idea of 
their exercise levels in real life. 
Visits 2 and 3: 
The data collected on subsequent visits (2 years & 5 years later) will be compared 
with the baseline to demonstrate any changes in blood vessel stiffening, inflammatory 
molecules in blood and evolution of cardiovascular risk factors. Data generated from 
the study will be stored at the WHRI for a period of 10 years in the safe custody of 
Professor D J Shale. 
Will there be any side-effects? 
Taking blood may lead to minor discomfort, but only experienced people will take 
blood samples. 
Are there any risks involved in taking part? 
Apart from the blood sample, all of the measurements are non-invasive and we don‘t 
foresee any risks involved. 
Are there any possible benefits to taking part? 
You will have a detailed assessment of your blood pressure and other cardiovascular 
risk factors (eg glucose, cholesterol levels) and we will be happy to make your results 
available to your General Practitioner if you agree. 
Will my taking part in this study be confidential? 
By consenting to take part in this research, you will consent to the collection, 
processing, disclosure and transfer of your personal data for medical research 
purposes only. Named information will be sent to the NHS Central Register and you 
will be flagged by the NHS Information Centre (NHS IC) for the purpose of follow-ups. 
Any data that is sent will be encrypted and we will follow ethical and legal practice to 
ensure that all information about you is handled in confidence. This is done to identify 
any new health problems that you may develop in relation to the heart while you are 
enrolled in our study. Information held by the NHS and records maintained by the 
General Register Office may be used to keep in touch with you and follow your health 
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status.  Your data will not be available to GSK as they are financially sponsoring this 
as an independent study. 
Will my GP be informed? 
The doctor in charge of the study will inform your GP of your participation in the study 
with your consent. In addition with your permission, they will be informed of any 
clinically relevant results that may become available during the study.   
What will happen to the study results? 
The results of the study may be published in scientific journals or presented at 
medical conferences, a few months after completing the study.  You will not be 
identified in any report or publication. An overall summary report (fully anonymised) 
will be sent to your General practitioner at the end of the study. You will be able to 
access this through your GP upon the completion of the study. 
What happens if something goes wrong? 
The doctors involved in the study, and the Wales Heart Research Institute have 
suitable indemnity insurance if you are harmed due to someone‘s negligence. 
However, there are no special compensation arrangements for non-negligent harm. 
Regardless of this, if you wish to complain about any aspect of the way you have 
been approached or treated during the course of this study, the normal National 
Health Service complaints mechanisms will be available to you. 
What will happen if I withdraw from the study? 
If you withdraw from the study, this will in no way affect your future medical care. Data 
or tissue already collected up to the point of withdrawal will be anonymised and 
utilised for study purposes. 
The same would apply if capacity to consent is lost during the study. You will be 
withdrawn from the study and data or tissue already collected under consent will be 
anonymised and utilised for study purposes. 
Will I be reimbursed for any travel expenses? 
Travel expenses of up to £30 will be given as necessary for trips to hospital to cover 
bus, mileage and parking. Taxis can also be ordered from our department to pick you 
up or drop you off. 
Who is organising this study? 
This study is being organised by the Wales Heart Research Institute of the Cardiff 
University. The investigators in charge are Professor D J Shale and Professor J R 
Cockroft. 
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Who has reviewed this study? 
The South East Wales Research Ethics Committee has reviewed this study and given 
it a favourable opinion. 
Contacts for research-related enquiries: 
If you require more information about the study, then please contact any of the 
research team members namely Dr M Irfan (Clinical Research Fellow),  Dr Nichola 
Gale (Research Associate) or Mrs Margaret Munnery (Research Nurse) on Tel 
02920742352. Alternatively, you may wish to speak to the Principal Investigator: -    
Professor J R Cockcroft                         OR            Professor D J Shale 
Consultant Cardiologist                                              Professor in Respiratory medicine 
Level 1,                                                                      Level 1 
Wales Heart Research Institute                                 Wales Heart Research Institute 
University Hospital of Wales                                      University Hospital of Wales  
Heath Park                                                                 Heath park 
Cardiff                                                                        Cardiff 
C14 4XN                                                                    CF14 4 XN 
0292074 3489                                                            0292074 3489 
Thank you for reading this information sheet.                                    
Remember - You are under no obligation to participate in this study. If you wish to 
leave the study at any point you may do so for any reason. Please take as much time 
to read this leaflet as require; do not feel that you have to make a decision quickly. 
Researchers will be available to answer any questions you may have. All the data 
collected will be confidential and is only for the purposes of research. 
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Appendix C: Participant Questionnaire 
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Appendix D: Consent Form 
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Appendix E: St. George’s Respiratory Questionnaire 
This questionnaire is designed to help us learn much more about how your breathing is 
troubling you and how it affects your life. We are using it to find out which aspects of your 
illness cause you the most problem. 
Please read the instructions carefully and ask if you do not understand something.  
Do not spend too long deciding about your answer. 
PART 1 
Please tick 1 of the following 
 Most days 
a week 
Several 
days  
a week 
A few 
days a 
month 
Only with 
chest 
infection 
Not at all 
1) Over the last year, I have 
coughed 
     
2) Over the last year, I have 
brought up phlegm (sputum): 
     
3) Over the last year, I have 
had shortness of breath: 
     
4) Over the last year, I have 
had attacks of wheezing: 
     
 
5) During the last year, how many severe or very bad unpleasant attacks of chest 
trouble have you had? Please tick 1 of the following  
More than three  
 
3 attacks  
 
2 attacks 
 
1 attack  
 
None  
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6) How long did the worst attack of chest trouble last? Please tick 1 of the following 
a week or more  
 
3 or more days   
 
1 or 2 days  
 
less than a day 
      
 
  
7) Over the last year, in an average week, how many good days (with little chest 
trouble) have you had? Please tick 1 of the following 
None   
 
1 or 2  
 
3 or 4 
 
nearly every day 1
  
 
 
8) If you have a wheeze, is it worse in the morning? Yes/No 
PART 2 
9)         How would you describe your chest condition?  Please tick 1 of the following 
The most important problem I have  
Causes me quite a lot of problems               
Causes me a few problems               
Causes no problem   
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10) If you have ever had paid employment?  Please tick 1 of the following 
My chest trouble made me stop work  
My chest trouble interferes with my work or made 
me change my work 
 
My chest trouble does not affect my work  
 
11) Questions about what activities usually make you feel breathless.         
Sitting or lying still      Yes/No 
Getting washed or dressed                      Yes/No 
Walking around the home                             Yes/No 
Walking outside on the level                           Yes/No 
Walking up a flight of stairs                               Yes/No 
Walking up hills Yes/No 
Playing sports or games   Yes/No 
 
 
12) More questions about your cough and breathlessness.         
My cough hurts  Yes/No 
My cough makes me tired Yes/No 
I get breathless when I talk Yes/No 
I get breathless when I bend over  Yes/No 
My cough or breathing disturbs my sleep  Yes/No 
I get exhausted easily  Yes/No 
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13) Questions about other effects your chest trouble may have on you. 
       My cough or breathing is embarrassing in public  Yes/No 
My chest trouble is a nuisance to my family, friends or neighbours  Yes/No 
I get afraid or panic when I cannot get my breath  Yes/No 
I feel that I am not in control of my chest problem Yes/No 
I do not expect my chest to get any better  Yes/No 
I have become frail or an invalid because of my chest Yes/No 
Exercise is not safe for me Yes/No 
Everything seems too much of an effort            Yes/No 
   
14) Questions about your medication.  
My medication does not help me very much  Yes/No 
I get embarrassed using my medication in public  Yes/No 
I have unpleasant side effects from my medication                 Yes/No 
My medication interferes with my life a lot Yes/No 
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15) Questions about how activities may be affected by your breathing.     
    I take a long time to get washed or dressed  Yes/No 
I cannot take a bath or shower, or I take a long time  Yes/No 
I walk more slowly than other people, or I stop for rests Yes/No 
Jobs such as housework take a long time, or I have to stop for 
rests  
Yes/No 
If I walk up one flight of stairs, I have to go slowly or stop  Yes/No 
If I hurry or walk fast, I have to stop or slow down  Yes/No 
My breathing makes it difficult to do things such as walk up hills, 
carry things up stairs, light gardening such as weeding, dance, 
play bowls or play golf  
Yes/No 
My breathing makes it difficult to do things such as carry heavy 
loads, dig the garden or shovel snow, jog or walk at 5 miles per 
hour, play tennis or swim  
Yes/No 
My breathing makes it difficult to do things such as very heavy 
manual work, run, cycle, swim fast or play competitive sports  
Yes/No 
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16) We would like to know how your chest trouble usually affects your daily life.  
Please tick which of the following apply to you 
I cannot play sports or games   
I cannot go out for entertainment or recreation   
I cannot go out of the house to do the shopping   
I cannot do housework  
I cannot move far from my bed or chair   
 
17) Tick the statement which you think best describes how your chest affects you.  
Please tick 1 of the following 
It does not stop me doing anything I would like to do  
It stops me doing one or two things I would like to do  
It stops me doing most of the things I would like to do  
It stops me doing everything I would like to do  
 
 
For Office use only 
Symptom ______  Activity ______ Impact ______ Total _______ 
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Appendix F: The COPD Assessment Test 
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Appendix G: Comprehensive Geriatric Assessment-Short Form 
